Studies on the development of a mouse model of Graves' disease by Barrett, Kerry
CENTRE FOR NEWFOUNDLAND STUDIES 
TOTAL OF 10 PAGES ONLY 
MAY BE XEROXED 
(Without Author's Pcnnission) 


1+1 National Library of Canada Bibliotheque nationale du Canada 
Acquisitions and 
Bibliographic Services 
Acquisisitons et 
services bibliographiques 
395 Wellington Street 
Ottawa ON K1A ON4 
Canada 
395, rue Wellington 
Ottawa ON K1A ON4 
Canada 
The author has granted a non-
exclusive licence allowing the 
National Library of Canada to 
reproduce, loan, distribute or sell 
copies of this thesis in microform, 
paper or electronic formats. 
The author retains ownership of the 
copyright in this thesis. Neither the 
thesis nor substantial extracts from it 
may be printed or otherwise 
reproduced without the author's 
permission. 
In compliance with the Canadian 
Privacy Act some supporting 
forms may have been removed 
from this dissertation. 
While these forms may be included 
in the document page count, 
their removal does not represent 
any loss of content from the 
dissertation. 
Canada 
Your file Votre reference 
ISBN: 0-612-89610-2 
Our file Notre reference 
ISBN: 0-612-89610-2 
L'auteur a accorde une licence non 
exclusive permettant a Ia 
Bibliotheque nationale du Canada de 
reproduire, preter, distribuer ou 
vendre des copies de cette these sous 
Ia forme de microfiche/film, de 
reproduction sur papier ou sur format 
electronique. 
L'auteur conserve Ia propriete du 
droit d'auteur qui protege cette these. 
Ni Ia these ni des extraits substantiels 
de celle-ci ne doivent etre imprimes 
ou aturement reproduits sans son 
autorisation. 
Conformement a Ia loi canadienne 
sur Ia protection de Ia vie privee, 
quelques formulaires secondaires 
ont ete enleves de ce manuscrit. 
Bien que ces formulaires 
aient inclus dans Ia pagination, 
il n'y aura aucun contenu manquant. 

St. John' s 
Studies on the development of a mouse model of Graves' disease 
by 
© Kerry Barrett 
A thesis submitted to the 
School of Graduate Studies 
in partial fulfillment of the 
requirements for the degree of 
Master of Science 
Division of Basic Sciences, Faculty of Medicine 
Memorial University of Newfoundland 
May 2003 
Newfoundland 
ABSTRACT 
Thyroid diseases are commonly caused by an autoimmune response to thyroid 
antigens. Hashimoto's thyroiditis (HT) is aT-cell mediated disease that ensues when the 
thyroid gland is destroyed by infiltrating lymphocytes specific antigens such as 
thyroglobulin (Tg) or thyroid peroxidase (TPO), leading to hypothyroidism. In Graves' 
disease (GD), autoantibodies against the thyroid-stimulating hormone receptor (TSHR) 
mimic the action of thyroid-stimulating hormone (TSH) and stimulate thyrocytes to 
overproduce thyroid hormones resulting in hyperthyroidism. Both spontaneous and 
experimentally induced animal models ofHT exist and have contributed considerably to 
our understanding of the disease process. In contrast, difficulties in inducing TSHR-
specific, stimulating antibodies have delayed the establishment of an animal model for 
GD. Recently, new strategies including immunization with TSHR-transfected fibroblasts 
and genetic immunization with eukaryotic expression vectors containing TSHR eDNA 
have provided promising results in mice, but further studies are required to optimize 
disease induction. 
The research described herein focuses on establishing a mouse model of GD 
through intradermal DNA immunization ofBALB/cJ and AKR/J mice with varying 
doses of plasmid vectors carrying the homologous (murine) or heterologous (human) 
TSHR eDNA (Chapter 3). By using an algorithm-based approach, we have also identified 
human TSHR peptides with A k-binding potential and tested their immunogenicity and 
pathogenicity in AKR/J mice (Chapter 4). Finally, an alternative method for identifying 
pathogenic Tg epitopes using DNA immunization was introduced and preliminary data 
are being presented (Chapter 5). 
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1.1 Graves' Disease 
CHAPTER ONE 
INTRODUCTION 
Graves' Disease (GD) is an autoimmune disorder characterized by lymphocytic 
infiltration of the thyroid gland and autoantibodies specific for the thyroid stimulating 
hormone receptor (TSHR) on the membrane ofthyroid follicular cells1• When these 
antibodies bind to the TSHR, they stimulate thyroid cells to grow and release thyroid 
hormones (thyroxine; T4 and triiodothyronine; T3) into the bloodstream. Unlike the 
natural receptor ligand (thyroid stimulating hormone; TSH), these thyroid-stimulating 
antibodies (TSAb ), are not regulated by a feedback mechanism, and consequently 
overstimulate the thyroid gland causing hyperthyroidism2. High levels of thyroid 
hormones in GD patients can result in acute weight loss, excessive sweating, a rapid, 
irregular heartbeat and anxiety. However, not all antibodies specific for the TSHR 
molecule act as agonists. Patients with primary myxoedema, for example, contain TSHR-
specific antibodies (TSBAb) that bind to different sites on the receptor, but block the 
binding of TSH and cause thyroid atrophy and hypothyroidism3• Evidence also exists for 
neutral TSHR-specific autoantibodies, which neither activate the thyrocyte nor block 
ligand action4. Several studies have shown that GD patients may have both TSAbs and 
TSBAbs suggesting that the relative amounts or affinities of these two types of 
autoantibodies determine the net biological effect on thyroid cell function5• Cell lines 
expressing recombinant TSHR have been used to detect the stimulating and blocking 
activity of these autoantibodies. While TSAbs enhance cAMP production in such cells, 
TSBAbs inhibit cAMP production mediated by TSH6. Another commonly used assay 
detects TSH-binding inhibitory immunoglobulins (TBII), comprising both the thyroid-
stimulating and TSH-blocking Abs, based on their ability to inhibit the binding of 1251-
labelled TSH to its receptor in thyroid membrane preparations6. 
1.2 Structure and Functional Domains of TSHR 
Molecular cloning and functional expression of the human TSHR led to rapid 
advances in understanding the structure and function of this molecule. The TSHR 
belongs to the guanine nucleotide regulatory (G)-protein-coupled receptor superfamily 
and is comprised of764 amino acids (a.a.) organized into a large (398 a.a.) N-terminal 
extracellular domain (ECD) responsible for interacting with the hormone ligand (TSH), 
and a C-terminal transmembrane/intracellular region (346 a.a.) responsible for signal 
transduction3;6-9. The protein contains a signal peptide of 20 amino acids which is cleaved 
during transport to the cell surface (~84.5 kDa)3;6-9. 
The 398 residues ofthe TSHR-ECD are loosely arranged into ~ 9leucine-rich 
motifs potentially forming amphipathic P-sheets3;6;8 with intramolecular disulphide bonds 
linking the cysteine residues located at theN- and C-termini of the ECD9. Compared to 
other related G-protein-coupled receptors such as luteinizing hormone (LH) and 
chorionic gonadotropin (CG) receptors, the ECD of the TSHR contains two unique 
insertion sites at positions 38-45 and 317-366, making it larger than LH and CG receptors 
by approximately 60 a.a3• Transfection of mammalian cells with various human TSHR 
deletion mutants or LH/CG receptor chimeras revealed that TSAb bind mainly to the N-
terminal region of the TSHR-ECD whereas TSBAb recognize mainly the C-terminal 
2 
region of the ECD7• Receptor glycosylation also appears to be a strict requirement for 
high affinity binding of pathogenic autoantibodies indicating that the 6 complex 
carbohydrate side chains on the TSHR protein may play a subtle role in the correct 
maintenance of the tertiary structure of the autoantigenic epitopes7;9. 
The 346 residues of the transmembrane region are organized into seven 
transmembrane segments, three extracellular loops, three intracellular loops, and a short 
(- 82 a.a.) carboxyl-terminal cytoplasmic tail8• While the importance of the TSHR-ECD 
for both TSH and TSHR-specific autoantibody binding is well recognized, it remains 
unclear whether the three extracellular loops linking the seven transmembrane-spanning 
regions contribute to the high-affinity binding of TSH, or to the binding of some or all the 
populations of TSHR -specific autoantibodies 7. 
1.3 Animal Models of Graves' Disease 
In many organ-specific autoimmune diseases, such as Hashimoto's thyroiditis 
(HT), animal models have contributed considerably to our understanding of the disease 
process. An animal model of GD must exhibit most of the clinical signs and symptoms of 
GD including (i) elevated thyroid hormone and/or reduced TSH levels; (ii) antibodies to 
the TSHR having biological activity (TSAb ); (iii) changes in thyroid architecture; and 
(iv) lymphocytic thyroiditis. Currently, an animal model developing spontaneous GD 
does not exist. So far, much of the research in this area has focused on experimentally 
inducing GD in mice. 
3 
1.3.1 Immunization with purified TSHR 
Initial attempts to immunize mice with purified TSHR were hindered by very low 
numbers ofTSHR expressed on thyrocytes (~103-104 TSHR molecules/cell)10, and the 
instability of the protein 11 . Slightly larger amounts of TSHR were obtained by detergent 
extraction from the human thyroid cell line (GEJ)12 followed by TSH-affinity column 
purification. Repeated immunization ofH-2-congenic mouse strains on BlO background 
with this receptor preparation emulsified in CF A (- 5 f.tg/immunization) induced low 
levels ofTBII, mild thyroiditis, and transient increase in free T3 levels in H-2s, H-2b, and 
H-2q mice13• Yet, even with the use of the GEJ cell line and an extensive purification 
process, limited quantities of antigen were acquired. 
1.3.2 Xenotransplantation of PBMCs or T cell lines plus autologous thyroid tissue 
into SCID mice 
An alternative approach to developing an animal model of GO involved 
transplanting thyroid tissue and immune cells from patients with autoimmune thyroid 
disease (AlTO) into mice with severe combined immunodeficiency disease (i.e. SCIO 
mice). Such mice accept xenografts of human tissue because they lack mature T and B 
cells14• Human lgG class autoantibodies to thyroglobulin (Tg) and thyroid peroxidase 
(TPO) developed in SCIO mice engrafted with suspensions of blood lymphocytes, 
thyroid lymphocytes, or even intact thyroid tissue from Graves' or Hashimoto patient 
donors15-19• More importantly, some mice xenografted with thyroid tissue from GD 
patients developed TSHR antibodies and transient hyperthyroxinemia19• In spite of the 
presence of TSHR antibodies, these mice did not show persistent hyperthyroxinemia, 
presumably because of the destructive thyroiditis observed shortly after tissue grafting. In 
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attempt to induce a more intense response, Soliman et al.20 engrafted SCID mice with 
thyroid tissue from a GD patient together with T cell clones reactive to recombinant 
hTSHR-ECD and observed low, but detectable levels ofTSAb in these mice. The 
occurrence of these TSAb, however, did not correlate with an increase in serum T3. 
Greater success was obtained following simultaneous xenotransplantation of tissue and 
autologous bone marrow cells from GD patients21 . Higher, but still variable, levels of 
thyroid autoantibodies, including TSAb, were detected in these mice as well as elevated 
T4levels for the 8-week period of the study. 
The difficulty and expense of maintaining SCID mice in a sterile environment, the 
variability between individual mice, as well as the difficulty in obtaining MHC-matched 
T cell clones, thyroid grafts, and autologous bone marrow cells are major limitations in 
the use of this approach to develop an animal model for GD. 
1.3.3 Immunization with recombinant TSHR 
Cloning of the human TSHR gene22"25 facilitated recombinant TSHR expression 
and purification from prokaryotic and eukaryotic cells. Several laboratories have stably 
expressed TSHR in Chinese hamster ovarian (CHOi5"30 or SP2/0 celllines31 for the 
purpose of generating large amounts of recombinant protein. Although these cells have 
been shown to transduce a signal after TSH25;30 and TSHR autoantibody30;32;33 
stimulation, and have been utilized in TSH-binding inhibition assays32, TSHR expression 
was still too low to make purification practical. Even with as many as 1 00, 000 TSHR 
molecules/CHO cell, only 1 J..tg of TSHR could be obtained from 6 confluent 1 0-cm 
dishes of cells; assuming 100% recovery6. 
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Numerous groups have reported on the prokaryotic expression of the TSHR 
ectodomain (TSHR-ECDi443. Costagliola and colleagues used E. coli to express human 
TSHR-ECD fused to the maltose binding protein (MBP)35• They immunized BALB/c (H-
2d) mice intraperitoneally (i.p.) with this fusion protein emulsified in alum and attenuated 
Bordetella pertussis toxin adjuvant and reported induction ofTSBAbs and TBII, as well 
as mild thyroiditis in this strain44. A very mild hypothyroxinemia, based on total T4 
values, was observed but it was also evident in control mice that received the MBP fusion 
partner alone, thus rendering these results inconclusive. Subsequently, the same group 
showed lack of similar responses in other strains of mice suggesting genetic control in the 
generation ofthese antibodies45 . Thyroiditis was also induced in BALB/c mice following 
multiple challenge with recombinant TSHR-ECD lacking theN and C-terminus (a.a. 43-
282)43. The authors suggested that removal of the serological immunodominant epitopes 
unmasked cryptic, disease-inducing T cell determinants. Despite thyroiditis induction, 
thyroid function remained unaffected in these mice. A major drawback using receptor 
produced in prokaryotic cells was the inability of bacteria to produce correctly folded and 
glycosylated protein46• In fact, recombinant protein produced in bacteria was usually 
denatured and not recognized by either TSH or autoantibodies whose binding critically 
depends on the correct conformational folding of the receptor polypeptide33;47• 
It was hoped that eukaryotic expression ofTSHR in insect cells, using 
baculovirus vectors, might offer a solution to this problem. Unlike other mammalian a-
protein-coupled receptors which have been expressed in high levels in insect cells48-50, 
the entire TSHR could not be expressed in insect cells for some unknown reason27;s t-sJ_ In 
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contrast, several research groups have expressed the ectodomain using this 
system36;4z;sJ;sz;s4-58• Indeed, glycosylated human ectodomain produced using this system 
is superior to the antigen from bacteria in terms of absorbing out TBII activity from GD 
patients' sera54;58, and in some cases, TSH binding54;57. Immunization of various strains 
of mice (H-2 b, d, k, s) with human TSHR-ECD produced by this method resulted in high 
titers of antibody against the TSHR protein which were capable of blocking the binding 
ofTSH to native TSHR, but lacked biological activitl9. Interestingly, elevated thyroxine 
levels were observed in BALB/c mice and, despite the absence of thyroiditis, there were 
morphological changes in the gland indicative of hyperactivity, such as focal scalloping 
of the colloid within isolated acini59. Another group showed that similarly challenged 
CBA/J mice also elicited TBII recognizing TSHR amino acids 22-41 as well as peptides 
clustered toward the carboxyl-terminus ofthe hTSHR-ECD (a.a. 322-415)60. However, 
unlike BALB/c mice, CBA/J mice remained euthyroid, and thyroid histology was normal. 
Carayanniotis, et al.61 reaffirmed the immunogenicity of insect-cell derived hTSHR-ECD 
in five different strains of mice (H-2b, d, q, k, s) by eliciting strong specific T cell responses 
and IgG responses in all strains following subcutaneous challenge with antigen 
emulsified in CF A. TBII were only detected in mice subjected to a hyperimmunization 
regime correlating with previous findings60• Unlike Wagle et al.59 who observed 
increased serum T4 levels and changes in thyroid histology of BALB/c mice, alterations 
in thyroid function as assessed by serum TSH, T4, iodine levels, or thyroid architecture 
were not detected in BALB/c mice or any other mouse strain. Suspecting that the 
inability to induce hyperthyroidism in mice was related to use of a heterologous rather 
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than homologous antigen, Davies' group expressed the biologically active homologous 
mTSHR-ECD in insect cells62• Indeed, sequencing of the mTSHR63 revealed potentially 
important differences from the hTSHR sequence, which could alter the tertiary structure 
of the receptor and prevent or diminish induction of agonist antibodies. The fact that only 
a minority ofhTSHR-specific antibodies that bind to the mTSHR, act as TSH agonists 
also agrees with this interpretation64-66• When BALB/c mice were challenged with murine 
TSHR-ECD in alum adjuvant containing pertussis toxin, TBII and TSBAb were induced, 
and mice had reduced levels of T3 accompanied by increased TSH, but no signs of 
thyroiditis or thyroid destruction were observed67• A later study compared the 
immunogenicity of extracellular domains of glycosylated mouse and human TSHR68• 
Mice immunized with either ectodomain developed high titers against their respective 
immunogens and comparable titers specific for TSHR peptides 1 (a.a. 22-41) and 23 (a.a. 
352-371). TBII reactivity was slightly higher in mice immunized with hwnan TSHR-
ECD than murine TSHR-ECD (52.2% vs. 34.5 %), while T4levels from murine TSHR-
ECD immunized mice were marginally higher than controls. Overall, the outcome of 
immunization with mouse TSHR-ECD was comparable to that seen after immunization 
with hwnan TSHR-ECD. 
Despite all efforts, none of the above studies induced mouse hyperthyroidism in a 
consistent and reproducible manner. The apparent variation and discrepancies in the 
results can be attributed to many factors including the adjuvant used, route and frequency 
of antigen administration, the TSHR form (truncated or combined to a fusion protein), 
lack of the transmembrane region, differential glycosylation and inappropriate folding of 
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the receptor. Altogether, the data argued strongly in favor of using the native form of 
TSHR for the production of agonist Abs. 
1.3.4 Immunization with synthetic TSHR peptides 
Several studies have reported induction of TBIIs, TSAbs, and TSBAbs in mice, 
rabbits, and birds immunized with synthetic TSHR peptides corresponding to various 
regions of the TSHR molecule including: a) the unique insertion sequences of the TSHR 
molecule (a.a. 38-45 and 317-366); b) potential TSH-binding sites (a.a. 372-397 and 341-
358); and c) extracellular loops from the transmembrane region (a.a. 478-497, 561-580, 
649-652)69-74• Surprisingly, only two of these studies measured thyroid hormone 
levels72;7\ one of which mentioned an increase in T3 and T4levels that correlated with 
TSAb activity following immunization with the unique N-terminal region (a.a. 29-57) of 
the hTSHR74. These results imply that linear epitopes can induce production ofTSAbs, 
contradicting the general concept that TSAb only recognize conformational epitopes33A7. 
This interpretation, however, has to be confirmed since this group did not attempt to 
block the functional activity ofTSAbs with the immunizing antigen. This is particularly 
important since immunization with some peptides can cause the breakdown of tolerance 
to self-TSHR, resulting in a much broader immune response than the one against the 
immunizing peptide3. Nevertheless, the above observations as well as the fact that a great 
majority of GD patient sera recognize linear TSHR epitopes do not exclude the 
possibility that linear epitopes recognized by TSAb exist. 
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1.3.5 Immunization with fibroblasts or B cells stably expressing native TSHR 
To achieve native expression ofTSHR, Shimojo et al.75 transfected the RT4.15HP 
murine fibroblast cell line (L cells) expressing MHC class II molecules (Ak) with the full-
length human TSHR. They challenged AKR/N (H-2k) mice intraperitoneally six times 
every 2 weeks with 107 mitomycin-C-treated fibroblasts and reported thyroid 
enlargement, TSAbs, and increased T4 levels in 20% (5/24) of experimental mice. 
Histological examination of the thyroids revealed hypercellularity but no lymphocytic 
infiltration. In a second series of experiments, the non-MHC genetic control of the 
induced disease was investigated in five different H-2k strains ofmice76• Differences in 
TBII titers were observed between strains indicating non-MHC genetic effect on TSHR-
Ab formation. Surprisingly, CBA and C3H strains had circulating TBII following 
challenge with fibroblasts expressing TSHR only, but this was not associated with 
development ofhyperthyroidism. Elevated T4levels were only observed in mice 
immunized with fibroblasts expressing both MHC class II and hTSHR suggesting that 
aberrant class II expression is necessary for the development of GO, whereas non-MHC 
genes play a more limited role. In 1999, Kita et al.77 and Jaume et al.78 independently 
confirmed and extended Shimojo' s original findings using similarly transfected 
RT4.15HP fibroblasts. In the former study, most animals developed TBII, and elevated 
T4levels were induced in 5/20 (25 %) recipients of fibroblasts expressing receptor and 
MHC class II. One mouse had elevated TSH and reduced T4levels but the thyroid was 
normal. The five animals with increased T4 had enlarged thyroids with signs of 
hypertrophy and colloid droplet formation but no lymphocytic infiltration. Mice 
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immunized using the same protocol, but with the addition of a 1b2 adjuvant (alum and 
pertussis toxin) had an earlier onset of disease (9 weeks compared to 11 weeks), and 
elevated T4 and goiters were found in a larger proportion of the mice (47% compared to 
25 %). In contrast, i.p. injection of AKR/N mice with hTSHR+ and MHC class II+ 
fibroblasts together with a Thl adjuvant (CFA), resulted in a slower onset of 
hyperthyroidism with 10/31 mice having increased T 4 by 14 weeks. Like many 
autoimmune diseases, GO occurs predominantly in women 1, yet Jaume et al. 78 observed 
no difference between male and female AKR/N mice in terms of susceptibility to TSHR 
antibody induction or development ofhyperthyroidism following injection ofTSHR+, 
MHC class 11+ fibroblasts. 
The mechanisms behind the induction of hyperthyroidism using transfected 
fibroblasts in these initial studies were not understood. For instance, how was the antigen 
processed and presented? Fibroblasts cannot act as APC initiating the immune response 
since they lack 87-1/87-2 co-stimulatory molecules required forT cell activation79;80. 
Were thyroid antigens shed from dying fibroblasts and presented by conventional host 
APCs? Why is aberrant expression of MHC class II required for disease induction? Why 
was disease induced in only 20-30% of the animals? Finally, why does this model, like 
many others, fail to induce intrathyroidallymphocytic infiltrate? Clearly, the mechanisms 
underlying Shimojo's model have to be further investigated. Kaithamana et al.80 used a 
variation of this approach by immunizing BALB/c mice with a B lymphoblastoid cell line 
(M12; derived from BAL8/c mice) stably transfected with either murine TSHR (mM12) 
or human TSHR (hM12). They reported disease induction characterized by the presence 
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TBII, TSAb, elevated thyroid hormone levels (T3 and T4), and weight loss in almost 
100% of the mice. Hyperthyroid mice had enlarged thyroid glands relative to control 
thyroids, and histological examination revealed hypertrophy, enlarged colloids with 
thinning epithelium, and in some cases, focal necrosis and inflammation characterized by 
lymphocytic infiltration. The authors attributed the greater success rate to several factors 
including the expression ofB7-costimulatory molecules on M12 cells making them more 
efficient APC in. vivo, the different and potentially more susceptible mouse strain used, 
and native expression ofthe MHC class II molecules. However, B7 expression on Ml2 
cells was not confirmed in this study, and in other studies, M12 cells were shown to lack 
B7 co-stimulatory molecules81 . Regardless ofB7 expression or lack thereof, Ml2 cells 
transfected with either the human or murine TSHR induced hyperthyroidism in almost 
100 % of experimental mice. Surprisingly, a later study performed by Y an, et al. 79 
showed that RT4.15HP fibroblasts do indeed express B7-l co-stimulatory molecules, 
which may be associated with the widespread immune activation observed in AKR/N 
mice when challenged with RT4.HP15 fibroblasts alone. Initially, the goal of the 
experiment was to determine whether the lack of thyroid lymphocytic infiltration in 
AKRIN mice was related to an inability of this strain to develop a Th2 response 
following injection with TSHR+, MHC class It, RT4.15HP fibroblasts. While attempting 
to characterize the Thl/Th2 cytokine profile through IgG subclass analysis of TSHR-
specific antibodies, Yan et al.79 found that recipients of RT4.15HP fibroblasts, whether 
transfected or not with the TSHR, displayed high-levels of non-specific binding to 
TSHR-coated ELISA wells or to TSHR-expressing cells. Moreover, splenocytes from all 
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fibroblast-injected (but not from unimmunized) AKR/N mice spontaneously secreted 
high levels ofinterferon-y in vitro. These results indicate that B7-l+, RT4.15HP 
fibroblasts have the potential to act as APC and may be responsible for the initiation of 
the immune response to the TSHR, as well as the non-specific immune activation. 
Alternatively, the widespread immune activation may be caused by an alloreactive 
response against the chimeric class II p 1 domain derived from H-2d 82 as suggested by 
Kaithamana et al. 80 since alloantigens are more potent immunogens than self Ags. 
Shimojo's approach for establishing a mouse model for GD succeeded in 
reproducing major features of GD including elevated thyroid hormone levels, TSAb 
activity, goiter, and minimal lymphocytic infiltration. However, the lack of similar 
derived fibroblasts expressing class II molecules from other mouse strains limits 
investigation to mice with an H-2k haplotype. Kaithamana et al.80 were able to immunize 
BALB/c mice, a different mouse strain with an H-2d haplotype, only because they used a 
B cell line derived from BALB/c. It would be interesting to see whether a non-specific 
immune response also occurred in these mice. 
1.3.6 Genetic immunization with hTSHR eDNA 
In 1998, genetic immunization with a human TSHR eDNA construct in a 
mammalian expression vector mounted a very strong immune response in BALB/c 
mice83• Anti-TSHR antibodies recognizing the native TSHR were readily observed in all 
mice, and both TBII and TSBAb activities were present in their serum. However, in the 
only instance in which it was observed, TSAb activity was not associated with 
hyperthyroidism. Convinced that the failure to develop hyperthyroidism was related to an 
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inadequate genetic background, the same group proceeded to genetically immunize 
NMRI outbred mice84• This time, five out of29 female mice showed signs of 
hyperthyroidism including elevated total T4 and suppressed TSH levels correlating with 
TSAb activity. In addition, hyperthyroid animals had goiters with extensive lymphocytic 
infiltration and displayed ocular signs reminiscent of Graves' ophthalmopathy. In spite of 
these encouraging results, less than 20% of the animals developed hyperthyroidism, 
which the authors suggested was due to the outbred nature ofNMRI mice, thus providing 
no further information in regards to the genetic requirement for susceptibility. Another 
group85 recently used a similar DNA immunization regime in BALB/c mice and obtained 
results conflicting with those of Costagliola's et al.83;84. Mice vaccinated with hTSHR 
eDNA had low or undetectable levels ofTSHR antibodies as determined by ELISA or 
flow cytometry and virtually no detectable TBII or TSAb. Moreover, thyroid histology 
revealed no architectural changes or lymphocytic infiltration85. The underlying 
mechanisms involved with DNA immunization, need to be further investigated to enable 
the establishment of a consistent and reproducible animal model ofGD. 
1.4 Genetic Immunization 
Genetic immunization, also known as DNA or polynucleotide immunization is a 
novel approach for achieving both humoral and cellular immune responses. The concept 
behind genetic immunization is simple: genes encoding an antigen (or antigens) specific 
for a particular pathogen are cloned into a plasmid with an appropriate promoter, and the 
plasmid DNA is administered to the vaccine recipient. Host cells take up the DNA and 
express the encoded protein, which is then processed and presented to the immune 
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system, inducing a specific immune response. The efficacy of DNA immunization was 
first demonstrated in 1992 when Tang et a1.86 reported that inoculation of mice with gene 
gun-delivered plasmid DNA induced antibody responses to the encoded human growth 
hormone (hGH) protein. Shortly thereafter, DNA vaccines were shown to generate 
immune responses against influenza87;88, human-immunodeficiency virus (HIV)-1 89, and 
hepatitis B90. These earlier studies not only demonstrated that DNA vaccination could 
induce immunity in several different disease models, but also that antibody, T-helper 
(Th), and cytotoxic T-lymphocyte (CTL) responses could all be generated through 
various immunization routes (i.e. intramuscular, epidermal, or mucosal). Furthermore, in 
the case of influenza, immunization with plasmid DNA encoding nucleoprotein (NP) of 
influenza A could protect animals from subsequent challenge with pathogenic virus. 
DNA vaccine development against other infectious disease models including herpes-
simplex virus (HSV)-1 91 , rabies92, malaria93, and mycoplasma94 are currently under 
investigation. The generation of immune responses through genetic immunization has not 
been limited solely to viral, bacterial, and parasitic diseases. Injection of plasmid DNA 
encoding tumor-associated antigens has been shown to cause a tumor-antigen-specific 
immune response, and can protect mice from subsequent lethal tumor challenge95;96. In 
addition, numerous studies have prevented or suppressed experimental or spontaneous 
autoimmune disease induction in mice following immunization with DNA encoding the 
appropriate self-antigen97- 101 • The list of potential applications for DNA immunization 
has generated considerable excitement in the vaccine field, especially for pathogens such 
as HIV, Plasmodiumfalciparum, Mycobacterium tuberculosis, for which no conventional 
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vaccines are available. However, before it is tested in humans, the underlying 
mechanisms must be understood (Section 1.4.1 ), immune responses need to be optimized 
(Section 1.4.2), and the safety concerns (Section 1.4.3) need to be addressed. 
1.4.1 Mechanisms of immunity induced by DNA immunization 
Although a remarkable number of publications have reported the efficacy of DNA 
vaccination in animal models, the exact mechanism by which the antigen encoded by the 
foreign gene introduced into the bacterial plasmid is processed and presented to immune 
system remains unclear. Since DNA vaccination has been shown to induce both humoral 
and cell-mediated immune responses, each of the three arms of the immune system must 
encounter the encoded antigen in the appropriate context. B cells should recognize and 
bind to soluble antigen, CD4+ T cells should recognize peptide-MHC class II complexes 
on the surfaces of APCs that have endocytosed and processed exogenous antigens, and 
CD8+ T cells should recognize peptide-MHC class I complexes derived from 
endogenously produced protein that has undergone proteosome-dependent-intracellular 
processing. Three mechanisms have been proposed to explain how the antigen encoded 
by plasmid DNA is processed and presented to immune cells: a) direct priming by 
somatic cells that have taken up DNA; b) direct transfection of professional APCs; and c) 
cross-priming102;103. Since intramuscular (i.m.) DNA immunization primarily transfects 
myocytes104; it was originally thought that these cells act as antigen-presenting cells. 
Myocytes, which constitutively express class I molecules105, could induce CD8+ CTL 
responses through the continuous processing of plasmid-derived antigen, whereas soluble 
protein, either secreted from myocytes or released upon myocyte death, could generate 
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antibody responses and T cell help. One conceptual difficulty with this premise is that, 
myocytes lack important co-stimulatory molecules necessary for priming naive T cells106. 
The second hypothesis proposes that a small number of professional APCs are directly 
transfected with the injected DNA. These cells, expressing high levels ofMHC class I, as 
well as co-stimulatory molecules, then traffic to regional lymphoid tissue, where they can 
activate CD8+ T cells. Meanwhile, CD4+ T cell and humoral immune responses are 
generated by soluble antigen produced by somatic cells or APCs. This mechanism seems 
plausible following epidermal (e.d.) or intradermal (i.d.) immunization, because the skin 
is rich in potential APCs including Langerhans cells (LCs), and tissue macrophages107. 
However, it seems less likely to occur following i.m. immunization, since muscle 
contains few if any APCs 105, although some professional APCs may be recruited to the 
muscle by the local irritation that follows injection. Finally, the cross-priming hypothesis 
suggests that antigen produced by transfected myocytes or keratinocytes is transferred to 
bone-marrow-derived APCs that have infiltrated the muscle as part of an inflammatory 
response to the immunization procedure. The internalized protein would then either be 
processed through the endocytic pathway resulting in peptide-MHC class II complexes, 
or will 'cross over' into the MHC class I pathway allowing the APC to activate both 
CD4+ and CD8+ T lymphocytes. Although the cross-priming theory contradicts the 
dogma that only endogenously produced proteins can enter the MHC class I pathway, 
recent reports have described how exogenously produced protein can be taken up by 
APCs and then presented in the context ofMHC class I molecules106; JOB-lll. 
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Various experiments were undertaken to directly test whether muscle cells alone 
were sufficient to prime CTL immune responses or whether bone marrow-derived APCs 
were required for CTL priming. Using bone marrow chimeric mice and plasmid DNA 
encoding the influenza nucleoprotein (NP), Corr and colleagues 112, demonstrated that 
NP-specific CTL responses were restricted to the MHC haplotype of the donor bone 
marrow-derived cells and not by the haplotype expressed by the recipient's myocytes. 
Similar findings for i.m. immunization were reported by Doe et al. 113 and for e.d. gene 
gun immunization by Iwasaki, et al. 114 The latter group also showed that even if 
myocytes were co-transfected with a plasmid encoding co-stimulatory molecules along 
with the influenza NP plasmid, they were still unable to prime CTL responses. These 
. results, however, contradict those obtained by Agadjanyan et al. 115 where Ag-specific 
CTL responses could be induced by muscle cells when mice were co-injected with DNA 
encoding Ag and CD86. Nevertheless, these studies strongly support the requirement of 
APCs for priming CTL responses, and that nonhematopoietic cells such as myocytes or 
keratinocytes are not being converted into APCs by naked plasmid transfection. 
The exact mechanism by which bone marrow-derived APCs obtain antigen, 
however, remains under considerable debate. Evidence supporting direct transfection of 
APCs by plasmid DNA comes from a study by Casares, et al. 116 who were able to isolate 
plasmid DNA from lymph node-derived and skin-derived dendritic cells after i.m. and 
i.d. immunization respectively. Further support comes from the finding that removing the 
muscle immediately (within 10 minutes) after immunization does not alter the subsequent 
immune response indicating that the role played by myocytes as an 'antigen factory' is 
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minimal10:4. Other research groups, however, argue against the 'direct transfection ' 
hypothesis, and have obtained evidence supporting the 'transferred antigen' hypothesis. 
Ulmer and colleagues117, for example, were able to induce both anti-NP Abs and NP-
specific CTL responses in mice previously transplanted with myoblasts stably transfected 
with influenza NP DNA. As there was obviously no free plasmid available to directly 
transfect specializedAPCs, these studies strongly suggest that antigen expressed by the 
transfected myoblasts was transferred to APCs and processed through the cytosolic MHC 
class I pathway. Similar findings were also found following transplantation of transfected 
tumor cells109;118• The strong evidence supporting both theories implies that both 
mechanisms probably play a role in the generation of immunity through genetic 
immunization, or alternatively, other mechanisms not yet discovered, may be involved. 
1.4.2 Approaches to DNA vaccine optimization 
Different diseases have specific requirements for protective immunity; thus a 
rational approach to optimize DNA vaccination would reflect these distinct conditions. A 
key advantage that DNA vaccination has over conventional vaccines is the ease with 
which plasmid DNA can be manipulated to alter the quantitative and qualitative aspects 
of an immune response. Simple vector modifications, supplementing Ag-encoded vectors 
with vectors encoding cytokines and co-stimulatory molecules, altering plasmid DNA 
dose or mode of DNA administration, can easily enhance and/or redirect the immune 
response which benefits the recipient most. 
One of the most important consideration in optimizing a DNA vaccine is the 
appropriate choice of a vector. The essential features for a plasmid DNA vector include: 
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a) a strong viral promoter active in mammals (i.e. cytomegalovirus) for optimal Ag 
expression; b) an insert encoding the Ag; and c) a termination sequence (i.e. BGH poly A 
tails) that stabilizes mRNA transcripts103• In addition, DNA vaccines require 'cytosine-
phosphate-guanine (CpG) motifs' or immunostimulatory sequences (ISS) known to 
impart adjuvanticity and mitogenicity to plasmid DNA. This CpG motif/ISS consists of 
an unmethylated cytosine-phosphate-guanosine dinucleotide with appropriate 5' and 3' 
flanking regions. Such motifs are 20-fold more common in microbial than mammalian 
DNA and have been shown to directly activate B cells to proliferate and produce Ab 119, 
induce various APCs to secrete cytokines120-122 that indirectly activate natural killer (NK) 
cells, and directly or indirectly stimulate T cells123• The immunogenicity ofCpG motifs 
became relevant when Sato et al. 124 reported that a DNA vaccine whose plasmid 
backbone contained CpG ISS induced a more vigorous antibody and CTL response than 
an otherwise identical vaccine lacking ISS, despite a higher level of gene expression 
produced by the latter plasmid. Thus, reengineering plasmid backbones to contain 
additional CpG motifs is one way to enhance the immune response against the encoded 
Ag. Interestingly, ISS that induce optimal stimulation in mice are less effective when 
tested on cells of primate origin. Attempts to identify sequence motifs that are equally 
immunogenic in humans have, so far, revealed two different CpG motifs capable of 
stimulating different cell populations125;126• These results suggest that a wide variety of 
motifs exist, each of which may target and stimulate different immune cells. Thus, 
selectively engineering DNA vaccines to contain one or various stimulatory sequences 
may help tailor the type of immune response elicited against the encoded A g. 
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Cytokine and co-stimulatory DNA adjuvants have also been shown to enhance or 
bias the immune response generated by DNA vaccination (reviewed by Gurunathan, et 
al. 103). This is not surprising since cytokines and co-stimulatory cell surface molecules 
play a crucial role in generation of effector T -cell subsets and in determining the 
magnitude ofthe response. Co-administration of DNA immunogens (e.g. hepatitis C 
virus core protein, HIV envelope protein, or ovalbumin) with either IL-2 or IL-4 cytokine 
genes, for example, has been shown to enhance T cell proliferative responses to the 
respective protein antigen in vitro, with cytokine profiles corresponding to Th 1 and Th2 
phenotypes respectively127-132. Enhancement of overall antibody production in mice was 
also demonstrated, with a bias toward lgG2a and lgG 1 isotypes by co-injection with IL-2 
and IL-4 DNA expression constructs respectively127-132• Similarly, intramuscular injection 
of a B7 -2 gene expression cassette along with cassettes for influenza nucleoprotein 133 or 
HIV proteins134 results in a significant enhancement of cytotoxic T cells responses to the 
encoded Ag in mice. 
Successful DNA vaccinations have been demonstrated via a number of different 
routes including: i.m., i.d., e.d., intravenous (i.v.), intraperitoneal (i.p.), oral, intranasal, 
and vaginal. Not only does the site of inoculation affect the induced immunity, but also 
the method the plasmid is delivered can qualitatively affect the immune response. 
Plasmid delivery is predominantly accomplished by one of two methods: needle injection 
of DNA suspended in saline or in a saline mixture containing a facilitator, such as 
bupivac~ine, designed to enhance DNA uptake102; or propulsion ofDNA-coated-
microprojectiles (gold beads) directly into the target tissue using a gene-gun. In terms of 
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DNA dosage, gene-gun-mediated immunization is far more efficient than needle injection 
since similar levels of Ab and cellular responses are elicited with 100- to 5000-fold less 
DNA89;IJS; IJ6. Nevertheless, there has been no compelling evidence to indicate that gene-
gun-based immunizations lead to longer lived responses or greater protection from 
pathogenic challenge. However, the way a DNA vaccine is administered can affect the T 
helper cell profile that is ultimately generated. While i.m. needle injection of DNA 
produces a predominantly Thl-type response, with an elevated IgG2a:IgG 1 ratio, IFN-y 
production, and little IL-4 production135;!37;!38, successive e.d. gene gun inoculations 
generate mostly IgG 1 antibodies, less IFN-y, and more IL-4, indicative of a Th2-type 
response135;137;139• Induction of both Th1 135;140 and Th2137 profiles has been reported 
following i.d. injection of DNA. It remains unclear why different T helper subsets arise 
after different immunization regimes; however, one possibility is a dosage phenomenon. 
As mentioned above, needle injections require larger quantities of DNA than gene-gun 
inoculations to induce the same magnitude of an immune response. Larger amounts of 
DNA introduce significantly more ISS to the challenge site, and ISS have been shown to 
preferentially induce a type 1 helper T lymphocyte response121;124;141 ;142. Experimental 
evidence supports the claim that when a few micrograms of DNA are used, delivery by 
both gene gun and i.m. needle injections induces predominantly lgG 1 Abs, indicative of a 
Th2 response143, but when 50 Jlg of DNA are used both methods induce more lgG2a Abs, 
indicative of a Th 1 response. Other studies, however, found that as little as 1-2 Jlg of 
DNA after i.m. injection, still elicits lgG2a Abs, while equivalent doses using a gene gun 
elicit predominantly IgG 1 Abs 135• Alternatively, different ways of DNA uptake by 
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surrounding tissue cells may affect the differentiation of the two Th subsets following 
needle or gene gun DNA administration. Needle injection delivers DNA to the 
extracellular space, where it is taken up by cells by some poorly understood mechanism, 
perhaps inducing a set of intracellular signals that ultimately leads to the increased 
production ofThl-type cytokines. A different set of intracellular signals, however, may 
be generated following gene gun delivery since target cells are directly transfected with 
plasmid, and therefore bypass any uptake mechanisms102. 
1.4.3 Safety consideration of DNA vaccination 
DNA vaccines offer several advantages over many of the existing vaccines. For 
example, plasmid DNA: a) is easier to manufacture b) obviates the need for protein 
production and purification, and c) circumvents the use of external adjuvants because 
plasmids impart their own adjuvanticity (e.g. ISS). In addition, immunization with 
plasmid DNA induces both humoral and cellular immune responses, which can easily be 
enhanced or manipulated through co-delivery to cytokine-encoding vectors or co-
stimulatory molecules, and because DNA immunization provides prolonged Ag 
expression, immunological memory is generated. All of these advantages, however, 
coincide with an equal number of safety concerns described in detail by Klinman, et 
al. 144. Briefly, potential risks include: a) plasmid integration into the host genome, 
thereby increasing the risk of malignancy (by activating oncogenes or inactivating tumor 
suppressor genes); b) induction of responses against transfected cells or worse, against 
host DNA, thereby triggering the development of autoimmune diseases; c) induction of 
tolerance rather than immunity; and/or d) non-specific stimulation of cytokine production 
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that could alter the host's ability to respond to other vaccines and resist infection. Clearly, 
these safety issues need to be addressed and evidence disproving these risks is required 
before DNA vaccination can be introduced to the general population. 
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2.1 ANIMALS 
CHAPTER TWO 
MATERIALS AND METHODS 
Female BALB/cJ (H-2d) or AKR/J (H-2k) mice were purchased from Jackson 
Laboratories (Bar Harbor, ME, USA) and used for immunizations between 6-12 weeks of 
age. 
2.2 TISSUE CULTURE AND CELL LINES 
All tissue culture media including Ham's Fl2, RPMI-1640, and DMEM 
(GibcoBRL, Burlington, ON, Canada) were supplemented with 10% fetal bovine serum 
(FBS) ((Bioproducts for Science, Indianapolis, IN, USA), 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 )lg/ml streptomycin (all from Gibco). RPMI-1640 and DMEM were 
also supplemented with 10 mM Hepes buffer and 50 J!M 2-mercaptoethanol (Sigma, St. 
Louis, MO, USA). 
CHO-Kl, JP09, CHOl, and GPI9-5 cells were derived from the Chinese hamster 
ovarian (CHO) cell line, and were cultured in Ham's F12 complete medium. They were 
kindly provided by Dr. J.P. Banga (King's College School of Medicine). JP09 and GPI9-
5 cells are CHO cells stably expressing native hTSHR (90 000 hTSHR/cell)145 and GPI-
anchored hTSHR-ECD (unpublished) respectively, while CHOl cells are vector-
transfected control cells. JP09, CHO 1, and GPI9-5 cells were positively selected every 10 
to 12 passages, using 200 J.lg/ml ofGeneticin (G418) (GibcoBRL, Burlington, ON, 
Canada). Trypsin-EDT A mixture (GibcoBRL, Burlington, ON, Canada) was used for 
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routine passaging of CHO cells, while the non-enzymatic cell dissociation medium 
(Sigma Chemicals, St. Louis, MO, USA) was used to harvest cells prior to experiments. 
The IL-4 dependent cell line, CT.4S146 was a kind gift from W.E. Paul (National 
Institute of Allergy and Infectious Diseases) and was courteously provided by Dr. T 
Watts (University ofToronto). It was cultured in RPMI-1640 containing 10 ng/ml 
recombinant interleukin-4 (PeproTech, Inc., Rocky Hill, NJ, USA). The AIO hybridoma 
formed between spleen cells from C57/BL6 mice previously immunized with purified 
insect cell-derived TSHR-ECD and the non-immunoglobulin-secreting myeloma cell line 
X63-Ag8'653 147 was kindly provided by Dr. J.P. Banga (King's College School of 
Medicine). The AIO mAb (IgG2b), known to recognize the epitope formed by a.a. 22-35 
of the hTSHR was purified from culture supernatants by affinity chromatography on 
protein G-Sepharose 4 Fast Flow columns (Pharmacia, Baie D'Urfe, Quebec, Canada). 
The purified material was then dialyzed in PBS, concentrated to 1-2 mg/ml, filter 
sterilized, and stored at -20°C in 50% glycerol for future use. 
The IL-2-dependent cell line, CTLL-2148, was grown in DMEM supplemented 
with 10% supernatant from concanavalin-A activated rat splenocytes as a source of IL-2. 
The antigen-presenting cell line LS 102.9149, a B-cell hybridoma expressing H-2A dis and 
H-Ed and the CTLL-2 cell line were purchased from ATCC (Rockville, MD, USA). The 
T A3 cell line, produced by the fusion of B cells from CAF 1 mice with the M 12.4 .1 
BALB/c B lymphoma150, was a kind gift from L. Glimcher (Harvard Medical School, 
Cambridge, MA), and courteously provided by Dr. T. Watts (University ofToronto). 
TA3 cells are known to express H-2Ak!d' Ek!d' KdDd molecules150. The T cellhybridomas 
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4A12.1 (Ak-restricted), 4A2.3 (Ek-restricted), 5E8.6 (A5-restricted), and 6E10 (A5-
restricted) recognizing murine thyroglobulin (mTg) peptides: p2494 (4A12, 4A2, and 
5E8) and p2694 (6E10) were generated and characterized as previously described151 ;152• 
2.3 MOLECULAR CLONING OF MURINE TSHR 
2.3.1 RNA Extraction from Mouse Thyroid Tissue 
Two 13-week old BALB /cJ mice were euthanised using ether and their thyroid 
glands removed en bloc (still attached to the trachea). The thyroid lobes were teased 
away from the trachea and immediately placed in 0.8 ml ofTRizol Reagent (GibcoBRL, 
Burlington, ON, Canada) containing 250 J.lg/ml of glycogen (Ambion, Austin, TX, USA). 
The tissue was then homogenized using a micro-tissue grinder and centrifuged at 12 000 
x g for 10 minutes at 4 °C to remove insoluble material. The homogenate was then 
separated into three phases following the addition of 0.16 ml chloroform (Molecular 
Biology Grade, Sigma, St. Louis, MO, USA) and brief centrifugation (12 000 x g for 15 
minutes at 4°C). RNA remains exclusively in the upper aqueous phase. This phase was 
placed into a new diethyl-pyrocarbonate (DEPC)-treated microcentrifuge tube and RNA 
was precipitated following the addition of 0.4 ml of isopropanol (Molecular Biology 
Grade, Sigma, St. Louis, MO, USA) and another brief centrifugation (12 000 x g for 10 
min at 4°C). The resultant pellet was then washed with 1 ml of75% ethanol, air dried, 
and resuspended in 20 J.ll DNase-RNase-free water (Sigma Chemicals, St. Louis, MO, 
USA). The purified RNA absorbance was read using a Beckman Du® 64 
spectrophotometer (Fullerton, CA, USA) at the optical density of260 and 280 nm to 
determine RNA yield and purity. 
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2.3.2 First-strand eDNA Synthesis 
First-strand eDNA synthesis was performed using a kit from Amersham 
Pharmacia Biotech Inc. (Uppsala, Sweden). Briefly, 5 Jlg of purified RNA (made up to a 
final volume of20 Jll with DEPC-treated water) was placed in an Eppendorftube and 
denatured in a Perkin-Elmer™ thermo-cycler (Cetus, Norwalk, CT, USA) at 65°C for 10 
minutes, then chilled on ice. The RNA was then added to a pre-mixed solution containing 
11 Jll first-strand bulk mix, 1 f.!l dithiothreitol (DTT) solution, 1 j..tl Not I-d(T)18, all 
provided with the First-strand eDNA synthesis kit. The resultant mixture was then 
incubated for 1 hour at 37°C. Heating the tube at 75°C for 10 minutes terminated the 
reaction and the eDNA was stored at -20°C for future use. 
2.3.3 Amplification ofmTSHR eDNA and Subcloning into pcDNA3.1zeo + 
Mammalian Expression Vector 
The entire mTSHR eDNA insert (2295 bp) was amplified from first-strand eDNA 
by the polymerase chain reaction (PCR) using mTSHR specific primers. The sequences 
of the two oligonucleotide primers were as follows (5 ' ----7 3'): mTSHR-F = GCC GOA 
ATT CAT GAG GCC AGO GTC CCT and mTSHR-R = COG COG CCG CTT ACA 
AGO CTG TTT OCT (GibcoBRL, Burlington, ON, Canada). These primers included 
the native translation start and stop codons (bold and italiciz ed) as well as unique EcoRI 
and Not! restriction sites (underlined) outside of the 5' and 3' coding regions (bold ) 
respectively to facilitate subcloning. DNA amplification was carried out using 
deoxynucleotide triphosphates (dNTPs) from Promega (Madison, WI, USA) and 
Platinum Taq DNA Polymerase (GibcoBRL, Burlington, ON, Canada). Briefly, 1 Jll of 
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eDNA was added to a PCR cocktail containing lx PCR buffer, 2 mM MgCh, 200 J.lM 
dNTPs, 200 J..LM ofboth forward and reverse primers, and 2.5 U of platinum Taq. The 
resultant mixture was then layered with 50 J.ll of mineral oil (Sigma Chemicals, St. Louis, 
MO, USA) and placed in the Perkin Elmer DNA thermocycler (Cetus, Norwalk, CT, 
USA). A 35-cycle step program (denaturation = 94°C for 1 min, annealing= 55°C for 1 
min, and extension= 72°C for 2.5 min) was preceded by a 5 minute denaturation step at 
94°C and was followed by a 10 minute extension step at 72°C. The amplified PCR 
product was subject to electrophoresis on 0.7% agarose gel, and the 2.3 kb fragment was 
purified using CONCERT™ Rapid Gel Extraction System (GibcoBRL, Burlington, ON, 
Canada). This fragment was then digested with EcoRI and Not! (Promega, Madison, WI, 
USA) and subcloned into a similarly digested and purified pcDNA3.1zeo +mammalian 
expression vector (Invitrogen, Carlsbad, CA, USA) using T4 DNA ligase (GibcoBRL, 
Burlington, ON, Canada). Ligation reactions were diluted 5-fold in nuclease-free water 
(Sigma Chemicals, St. Louis, MO, USA) prior to transforming bacteria. 
2.4 MOLECULAR CLONING OF HUMAN TSHR 
The plasmid, peN eo, containing the human TSHR eDNA insert (pcNeo/hTSHR) 
between Xhol (5') andNot/(3') restriction enzyme sites was kindly provided by Dr. J.P. 
Banga (King' s College School of Medicine). The hTSHR eDNA insert was cut from 
pcNeo/hTSHR and pasted into pcDNA3.1zeo+ mammalian expression vector forming 
pcDNA3 .1 zeo + /hTSHR as follows. First, the hTSHR insert was released from 
pcNeo/hTSHR by cutting the plasmid with Xhol creating 5' and 3' sticky ends, which, 
after purification, were filled in creating blunt ends. Next, the hTSHR insert was 
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completely released from pcNeo/hTSHR by digesting with Notl Meanwhile, the 
pcDNA3 .1 zeo + mammalian expression vector was cut with BamHI resulting in 5' and 3' 
sticky ends, which, after purification were filled in creating blunt ends. Next the 
pcDNA3.1zeo +vector was digested with Not!, purified and used to ligate with the 
purified hTSHR eDNA. During the cutting and pasting of the vector and hTSHR insert, a 
Xhol site was created in the 5' flanking region of the insert, which, together with the 
downstream Xhol site of the vector enabled the release of the hTSHR insert from 
pcDNA3.1zeo +with Xhol. 
2.5 AMPLIFICATION OF MURINE THYROGLOBULIN eDNA SEGMENTS 
ENCODING PATHOGENIC T-CELL EPITOPES AND SUBCLONING 
INTO pcDNA3.1zeo + 
Total thyroid RNA was extracted from two 21-week old AK.R/J mice as described 
in Section 2.3.1, and first-strand eDNA was synthesized as described in Section 2.3.2. 
Complementary DNA segments encoding murine Tg pathogenic T cell epitopes, p2494 
(2494-251 0; GLINRAKA VKQFEESQG) and p2694 (2694-2711; CSFWSKQUQTLKD 
ADGAK), or the carboxyl terminus of the murine Tg (2494-2746; mTg-C), were 
amplified from first-strand eDNA by the polymerase chain reaction using Tg-specific 
primers. Amino acid coordinates of the peptides were assigned according to Kim et al. 153 
and do not include the 20 a. a. leader sequence. The sequences of the oligonucleotide 
primers were as follows (5' ~ 3'): p2494-Kpnl-F = CGG GTA CCG CCA TGG GGC 
TTA TCA ATA G, p2494-Xbal-R = CGT CTA GA T CAG CCT TGG CTC TCT T , 
p2694-Kpni-F = CGG GTA CCG CCA TGf GCT CCT TCT GGT, p2694-Xbal-R = 
CGT CTA GAT CAT GCA TCC TTG GCT C , mTg-Xbai-R = CGT CTA GAT CAT 
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TTG CTG TAG CTC TTG (GibcoBRL, Burlington, ON, Canada). Artificial start and 
stop codons (bold and italicized) as well as unique Kpnl and Xbal restriction sites 
(underlined) were introduced in the forward and reverse primers respectively, outside the 
5' and 3' coding regions (bold), to promote translation of the peptides and facilitate 
subcloning. DNA amplification was carried out as described in Section 2.3.3. The p2494-
Kpni-F and mTg-Xbai-Rprimers were used to amplify the carboxyl terminus ofthe Tg 
gene containing both p2494 and p2694 T-cell epitopes. The p2694-Xbai-R primer was 
designed to amplify 2 additional a. a. ( -DA-) at the 3 ' -end ofthe p2694 T -cell epitope due 
to the differences between the two published mTg sequences153;154• The amplified PCR 
products were subject to electrophoresis on 4% (p2494 and p2694) and 1.5% (mTg-C) 
agarose gels, and the 72 bp (p2494), 81 bp (p2694), and 780 bp (mTg-C) fragments were 
purified as described in Section 2.3 .3. Fragments were then digested with Kpni and Xbal 
and subcloned into a similarly digested and purified pcDNA3.lzeo +mammalian 
expression vector as described in Section 2.3.3. 
2.6 AMPLIFICATION OF THE MUR INE IL-2 and IL-4 eDNA BY PCR AND 
SUBCLONING INTO pcDNA3.l zeo+ 
The pGCVII mammalian expression vector (Eppendorf - 5 prime, Boulder, CO, 
USA) containing the murine IL-4 eDNA (423 bp) was a kind gift from Dr. Brian Barber 
(University of Toronto). Unfortunately, using restriction enzyme analysis, we were 
unable to determine where the gene was inserted; therefore we amplified the murine IL-4 
eDNA insert from the vector using the polymerase chain reaction (PCR) and murine IL-4 
specific primers. Similarly, we received the pcDVl vector containing the miL-2 eDNA 
(510 bp) from ATCC (Rockville, MD, USA). The murine IL-2 eDNA insert was also 
31 
amplified from the vector using the polymerase chain reaction and murine IL-2 specific 
primers due to the difficulties in obtaining sufficient amounts of the pcDVl-miL-2 
plasmid for future miL-2 insert excision and ligation. Sequences of the oligonucleotide 
primers (5' ~ 3') were as follows: miL-4-Kpni-F = GCG GTA CCA TGG GTC TCA 
ACC CC, miL-4-Xbai-R = CGT CTA GAC TAC GAG TAA TCC ATT TGC, miL-2-
Kpni-F = CGG GTA CCA TGf ACA GCA TGC AG and miL-2-Xbai-R = CCT CTA 
GAT TAT TGA GGG CTT GTT G (GibcoBRL, Burlington, ON, Canada). These 
primers included the native translation start and stop codons (bold and italicized) as well 
as unique Kpnland XbaJrestriction sites (underlined) outside of the 5' and 3' coding 
regions (bold) respectively, to facilitate subcloning. DNA amplification was carried out 
as described in Section 2.3.3. The amplified PCR products were subject to 
electrophoresis on a 1.5 % agarose gel, and the 435 bp (miL-4) and 522 bp (miL-2) 
fragments were purified as described in Section 2.3.3. These fragments were then 
digested with Kpni and Xbai (Promega, Madison, WI, USA) and subcloned into a 
similarly digested and purified pcDNA3.lzeo+ mammalian expression vector as 
described in Section 2.3 .3. 
2.7 PLASMID PREPARATIONS 
2. 7.1 Preparation of Fresh Competent E. coli using Calcium Chloride 
Competent Escherichia coli (strain: XLI-Blue) cells were prepared using a 
modified calcium chloride protocol described in Current Protocols in Molecular 
Biology155• Briefly, 5 ml of Luria Bertani (LB) media (10 g tryptone peptone, 5 g yeast 
extract, and 10 g NaCl per liter) was inoculated with a single colony taken from a freshly 
32 
streaked LB agar plate, and incubated overnight at 37°C with vigorous shaking (~250 
rpm). This starter culture was then diluted (1/100) into 100 ml ofLB medium and 
incubated at 37°C with vigorous shaking (~250 rpm) until the culture OD6oonm was 
between 0.3-0.4 (~ 108 cells/ml). The bacterial culture was aliquoted into two 50 ml 
polypropylene tubes (50 mlltube) and incubated on ice for 5-10 minutes. Bacterial cells 
were harvested by centrifugation at 1600 x g for 7 min at 4°C. Bacterial pellets were 
resuspended in 10 ml of filter-sterilized ice-cold 0.1 M CaCh and re-centrifuged at 1100 
x g for 5 minutes at 4°C. Supernatant was discarded, and bacterial pellets were 
resuspended again in 10 ml of ice-cold 0.1 M CaCb and incubated on ice for 30 minutes. 
Following another centrifugation (1100 x g for 5 minutes at 4°C), supernatant was 
removed by aspiration and each pellet was resuspended in 2 ml of ice-cold 0.1 M CaCh 
containing 15% glycerol. Competent cells were then aliquoted into pre-chilled sterile 
microcentrifuge tubes (100 f..Llltube) and stored at -70°C (maximum 6 months) for future 
transformations. 
2.7.2 Transformation of Competent E. coli with Plasmid DNA or Ligation 
Reactions 
Competent Escherichia coli (XL 1-Blue) cells were transformed with various 
plasmid DNA or ligation reactions using a modified transformation protocol46• Briefly, 
competent cells were thawed on ice, gently mixed, and transferred to a pre-chilled 
microcentrifuge tube (1 00 f..ll). Plasmid DNA (1-50 ng) or 5 f..ll of a ligation reaction was 
then added to the cells and incubated on ice for 10-30 minutes. No DNA was added for a 
negative control. Next, the cells were heat-shocked for 45-50 seconds in a 42°C water 
bath, and then immediately returned on ice for 2 minutes. Cold LB media (900 f..ll) was 
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then added to each transformation reaction followed by a 60 minute incubation at 37°C 
with vigorous shaking (250 rpm). An aliquot of each transformation reaction (100 J..Ll) 
was plated onto LB agar plates containing 100 J..Lg/ml of ampicillin (Sigma Chemicals, St. 
Louis, MO, USA) and incubated overnight (12-16 hours) at 37°C. 
2.7.3 Plasmid Purification 
All plasmids were initially purified using Qiagen plasmid mini-prep kits 
(Mississauga, ON, Canada) to ensure correct plasmid sizes through restriction enzyme 
analysis (Section 2.7.4), test gene functionality (Section 2.9), and sequence eDNA inserts 
(Section 2.8). Plasmids used for DNA immunizations were purified using QIAGEN 
EndoFreeTM Plasmid Giga Kits (Mississauga, ON, Canada). Briefly, 5 ml ofLB media 
containing 100 J..Lg/ml of ampicillin (Sigma Chemicals, St. Louis, MO, USA) was 
inoculated with a single isolated transformed XLl-Blue (Escherichia coli) colony taken 
from a freshly streaked selective plate, and incubated for ~8 hours at 3 7°C with vigorous 
shaking (~300 rpm). This starter culture was then diluted (1 /1000) into 2.5 L of selective 
LB medium and incubated overnight at 37°C with vigorous shaking (~300 rpm). 
Bacterial cells were harvested by centrifugation at 6000 x g for 15 min at 4°C, and the 
bacterial pellet was resuspended in 125 ml of buffer Pl containing 100 J..Lg/ml RNase A 
provided with the QIAGEN kit. An equivalent amount of buffer P2 was then added, 
mixed gently but thoroughly by inverting 4-6 times, and incubated at room temperature 
for exactly 5 minutes to lyse the bacterial cells. Buffer P3 was immediately added 
following cell lysis, gently mixed to enhance precipitation of proteins, genomic DNA, 
and detergent, and poured into the QIAfilter Mega-Giga Cartridge. Following a 10 
minutes incubation period, the bacterial cell lysate was obtained by vacuum filtration and 
washing with buffer FWB. Next, buffer ER was added to the filtered lysate and incubated 
on ice for 30 minutes. Buffer ER, or endotoxin removal buffer prevents 
lipopolysaccharide (LPS) molecules (cell membrane components of Gram negative 
bacteria) from binding to the resin in the QIAGEN-tips allowing purification of DNA 
containing less than 0.1 endotoxin units per Jlg plasmid DNA. Treated filtered lysate was 
then added to an equilibrated QIAGEN-tip 10 000 and allowed to empty by gravity flow. 
After the QIAGEN-tip was washed 2x with 300 ml of buffer QC, DNA was eluted using 
QN buffer. Plasmid DNA was then precipitated following the addition of 52.5 ml of 
isopropanol and then immediately centrifuged at~ 15 000 x g for 30 minutes at 4°C. The 
DNA pellet was washed with 10 ml of70% endotoxin-free ethanol, recentrifuged (15 000 
x g, 15 min, 4°C), air dried (~15 minutes), and resuspended in ~2 ml of0.9% NaCl 
solution (pyrogen free). The double-stranded plasmid DNA absorbance was then read 
using a spectrophotometer at an optical density of 260 and 280 nm to determine DNA 
yield and purity. The A26o/ A2so ratio for each plasmid prep were between 1. 8 - 1.9, with a 
characteristic yield of approximately 10 mg per column. 
2.7.4 Restriction Enzyme Analysis of Plasmid DNA 
Purified plasmid DNA was subject to restriction enzyme analysis to ensure the 
correct plasmid size and confirm the presence of the gene insert. All restriction enzymes 
were purchased from Promega (Madison, WI, USA) and each digestion was performed 
according to Promega' s Product Information sheet provided with each restriction enzyme 
purchase. Briefly, 0.5 ~g of supercoiled plasmid DNA was added to a solution containing 
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IX of the appropriate restriction enzyme buffer, 5 f.!g of acetylated BSA, and 5 units of 
the appropriate restriction enzyme (final volume= 20 f.ll) , and then incubated at 37°C for 
1 hour. If two restriction enzymes were required to release the gene insert from the 
plasmid, then 5 units of each restriction enzyme was added to the digestion reaction. The 
digested plasmids were then subjected to electrophoresis on agarose gel containing 0.5 
f.lg/ml of ethidium bromide (Sigma Chemicals, St. Louis, MO, USA). Gel images were 
captured using the Chemimager™ 4000 (Canabera Packard Canada Ltd, Montreal, QU, 
Canada). 
2.8 SEQUENCING OF CLONED eDNA 
Selected plasmids were sent to the University of Toronto DNA Sequencing 
Facility for analysis. The full coding sequence and portions of the 5' and 3' flanking ends 
of the human and murine TSHR, miL-4, miL-2 eDNA inserts and p2494, p2694, and 
mTg-C eDNA segments were derived using the dideoxynucleotide chain termination 
method and AmpliTaq DNA polymerase (PE Biosystems). Custom primers for the 
hTSHR and mTSHR were designed based on the published sequences ofNagayama, et 
al.25 and Stein, et al.63 respectively (Table 2.1) and synthesized by GibcoBRL 
(Burlington, ON, Canada). Primers designed from the T7 promoter priming site and BGH 
reverse priming site ofpcDNA3.lzeo+ expression vector were also used to sequence the 
flanking ends of the human and murine TSHR eDNA inserts, as well as sequence the 
entire miL-4, miL-2, p2494, p2694, and mTg-C eDNA inserts. 
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TABLE 2.1 List of forward and reverse primers used to sequence cloned eDNA inserts 
Primer N arne Primer Sequence ( 5' ~ 3 ') Primer Coordinate sa 
hTSHR394R GTA GAA GGA GTG TGA 374-394 
hTSHR63 3 F TTC CAG 633-652 
hTSHR1065F AAA CCT TGA CAC TGA 1065-1084 
hTSHR2052F AGC TG 2052-2071 
hTSHR2077R TCC ACC AGG AAT ATG 2057-2077 
mTSHR174F 
mTSHR344R 
mTSHR946F 
mTSHR1171R 
mTSHR1377F 
mTSHR2130F 
mTSHR2298R 
T7-F 
BGH-R 
AAG AG 
AGC CTC TCA TCA CTG 
TTA GC 
GGA GTT GCT AAC AGT 
GAT GAG 
GAG GAC GAC TTC AGA 
GTC AC 
CTG CAG AGT TGC ATC 
TAT AG 
AAA TCA GGG GAA TCC 
TGG AG 
AAA CCA ACG ACC TCA 
TCC TC 
GTC CTG CTC ATT CTG 
CTA AC 
CAG AGG GAC GTG TTC 
ATC CTG 
GCA GTT CAT AGG TAT 
CTT GC 
TAA TAC GAC TCA CTA 
TAG GG 
TAG AAG GCA CAG TCG 
AGG 
174-193 
325-344 
946-965 
1152-1171 
1377-1396 
2130-2150 
2279-2298 
863-882 
1022-1039 
"Primer coordinates based on the hTSHR and mTSHR published sequences ofNagayama, et al.25 and Stein, 
et al.63 respectively and the pcDNA3.lzeo+ vector sequence (InVitrogen, Carlsbad, CA, US). 
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2.9 EXPRESSION AND FUNCTIONALITY TESTS OF CLONED eDNA 
Expression and functionality of cloned eDNA inserts were tested by transiently 
transfecting the Chinese hamster ovarian cell line (CHO-K1), or antigen presenting cell 
lines (T A3 or LS 1 02.9) with pcDNA3 .1 zeo + containing the cloned insert of interest using 
TransFast™ Transfection Reagent (Promega, Madison, WI, USA). Transfection 
efficiency of each cell line was predetermined using the luciferase assay (Section 2.9.2). 
Transiently transfected cells or cell supernatants were then used in various assays to test 
eDNA insert expression and functionality. 
2.9.1 Transient Transfection ofCHO-K1, TA3, or LS102.9 Cells 
CHO-K1 cells were plated in 24-well (1 x 105 cells/well) or 6-well plates (5 x 105 
cells/well) one day prior to transfection so that the cells were ~ 70-80% confluent on the 
day oftransfection. TA3 and LS 102.9 cells were plated in 6-well plates in serum-free 
media (0.5 ml of2 x 106 cells/ml) the same day as the transfection. A 1:1 TransFast™ 
Reagent to DNA charge ratio was prepared in serum-free medium and incubated at room 
temperature for 15 minutes. Following careful removal ofthe growth medium, 1 ml of 
the TransFast™ Reagent/DNA mixture (a total of0.5~g or 2.5 ~g of DNA/well) was 
added to the CHO-Kl cells and incubated for 1 hour at 37°C. TA3 and LS102.9 cells 
were transfected with 0.5 ml of the TransFast™ Reagent/DNA mixture (a total of 3 ~g of 
DNA/well) and also incubated for 1 hour at 37°C. At the end of the incubation period, 5 
ml of prewarmed complete medium was added to each well and the plate was returned to 
the incubator for an additional 48 hours. 
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2.9.2 Luciferase Assay 
Prior to transfecting CHO-K1, TA3, and LS 102.9 cell lines with pcDNA3.lzeo+ 
containing the cloned eDNA of interest, transfection efficiency of each cell line was 
predetermined using a luciferase assay system. Each cell line was transiently transfected 
(Section 2. 9.1) with varying amounts of either pGL3-Basic or pGL3-Control vectors 
(Promega, Madison, WI, USA) kindly provided by Dr. G. Paterno (Memorial University 
of Newfoundland). The pGL3 reporter vectors contain a modified firefly luciferase gene, 
which encodes a monomeric 61 kDa protein that catalyzes the oxidation of beetle 
luciferin with concomitant production of photons (light), which can be measured using a 
luminometer46• Unlike pGL3-Control plasmid, pGL3-Basic lacks eukaryotic promoter 
and enhancer sequences and therefore is unable to express the luciferase gene in 
mammalian cells making this vector a suitable control. Following transfection, cells were 
harvested, washed lx with PBS, and then lysed with cell culture lysis reagent provided 
with the luciferase assay system (Promega, Madison, WI, USA). Twenty microlitres of 
cell lysate was then dispensed into Falcon tubes and the reaction initiated by pipetting 
100 f.!l ofluciferase assay reagent (substrate) into the tube. Light intensity was measured 
using a Monolight® 2010 luminometer and results are expressed in relative light units. 
2.9.3 cAMP Assay: Testing Expression and Functionality of cloned hTSHR and 
mTSHRcDNA 
The Biotrak™ cAMP competitive enzyme immunoassay (EIA) system from 
Amersham Pharmacia Biotech Inc. (Uppsala, Sweden) was used to test the expression 
and functional activity of human and murine TSHR. CHO-K1 cells transiently transfected 
with either pcDNA3.lzeo+ (control), pcDNA3.lzeo+lhTSHR or pcDNA3.lzeo+/mTSHR 
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were harvested following the 48 hour transfection period, washed, and resuspended in 
Ham' s F12 medium supplemented with 0.1% (w/v) BSA and 0.2 mg/ml3-isobutyl-1-
methylxanthine (Sigma Chemicals, St. Louis, MO, USA). CHO stably expressing native 
hTSHR (JP09 cells) that exhibit an increase of cAMP following stimulation with TSH30 
were used as a positive control. In 96-well plates, transiently transfected CHO-Kl cells or 
JP09 cells ( 4 x 104 cells/well) were incubated in the presence or absence of 5 m U/ml of 
bovine TSH (Sigma Chemicals, St. Louis, MO, USA) for 2 hours at 37°C. Immediately 
following stimulation, cells were lysed by the addition of lysis reagent 1A (2.5% 
dodecyltrimethylammonium bromide in .05 M acetate buffer, pH 5.8 containing .02% 
BSA and .01% preservative) provided with the Biotrak cAMP competitive EIA kit. Total 
cellular cAMP released from the lysed cells was measured using the reagents provided 
with the assay kit. Briefly, 100 ~I of diluted cell lysate (1: 10 to 1:40 in lysis reagent 1 B) 
or standard concentrations of cAMP and 100 ~l of rabbit anti-cAMP antibody were added 
to the wells of a 96-well plate pre-coated with anti-rabbit IgG and incubated at 4°C for 2 
hours. cAMP conjugated to horseradish peroxidase was then added to each well (50 
~1/well) and incubated for an additional hour at 4°C. After the plate was washed 4x with 
buffer, 150 ~l of the enzyme substrate was dispensed into all wells and incubated at room 
temperature for 1 hour with moderate shaking on a plate shaker (~250 rpm). The reaction 
was terminated following the addition of 1 M sulfuric acid (100 ~1/well) and then the 
plate was read using a microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 
450 nm. Duplicate samples were assayed in all experiments; results are expressed as 
pmol cAMP/mi. 
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2.9.4 CTLL-2 and CT.4S Bioassays: Testing Functionality of cloned miL-2 and 
miL-4 eDNA 
The IL-2 and IL-4 dependent cell lines (CTLL-2 and CT.4S respectively) were 
used to test the supernatants ofpcDNA3.lzeo+/miL-2 and pcDNA3.1zeo+/miL-4 
transfected CHO-K1 cells for functional IL-2 and IL-4 expression. Supernatants from 
pcDNA3.1zeo + transfected CHO-K1 cells were used as a control. Sample supernatants 
were serially diluted using complete medium in a 96-well microwell plate (1 00 ~-tllwell). 
CTLL-2 and CT.4S cells were harvested in active log-phase growth, washed 2x in 
complete medium, and resuspended at 1 x 105 cells/ml. Cells were then added to the 
wells containing the samples (100 J..tl/well), and incubated for 24 (CTLL-2) or 48 hours 
(CT.4S) at 37°C. Eight (CTLL-2) or 24 hours (CT.4S) prior to harvesting, 3[H] thymidine 
(NEN Life Science Products, Boston, MA, USA) was added to each well (1 ~-tCi/well) in 
25 ~-tl of culture medium. Cells were harvested using the Harvester 96® Mach III M 
(Tomtec, Hamden, CT, USA) and incorporated radioactivity was measured using the 
TopCount NXT™ Microplate Scintillation & Luminescence Counter (Canberra Packard 
Canada, Mississauga, Ontario, Canada). 
2.9.5 T Cell Activation Assay: Testing the ability of transfected APC to activate 
peptide-specific T cell bybridomas 
The APC lines, TA3 or LS 102.9, were transiently transfected with 
pcDNA3.lzeo+ constructs containing mini-eDNA inserts encoding the pathogenic T cell 
epitopes p2494 or p2694 (Section 2.6). These transfected APC were used to activate the 
MHC class II-restricted T-cell hybridomas, 4A2, 4A12, and 5E8 recognizing p2494 and 
6E 10 recognizing p2694 (Section 2.2) peptides. In a flat-bottom 96-well plate, 105 
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hybridoma cells/well were incubated with an equal number ofT A3 or LS 1 02.9 antigen 
presenting cells previously transfected with the indicated DNA constructs. Untransfected 
TA3 or LS 102.9 cells were used as controls. To ensure that the antigen presenting ability 
of the APCs remained intact following transfection, hybridomas were also incubated with 
the APCs previously transfected with pcDNA3 .1 zeo +in the presence of appropriate 
peptides (10 f.tg/ml). The cells were cultured in a total of200 fll culture medium per well. 
After 24 hours, 100 fll of supernatant was collected from each well, transferred to a new 
plate, and kept frozen at -70°C. The relative IL-2 content of culture supernatant from the 
T cell activation assay was determined by thawing the microtitre plates and performing a 
CTLL-2 proliferation bioassay (section 2.9.4). 
2.10 DNAIMMUNIZATION 
2.10.1 Antigenic challenge of animals 
Plasmid DNA was delivered intradermally (i.d.) to the shaved posterior-dorsal 
skin ofkentamine/xylazine-anesthetized (CDMV, Inc., Quebec, Canada) mice (BALB/cJ 
or AKR/J) using a 30-guage needle. Each mouse received a total of 10 or 50 flg of the 
appropriate plasmid DNA (in 0.9% NaCl) given in five 10 fll i.d. inoculations. Mice that 
were co-injected with two different plasmids received 50 flg of each plasmid given in 
five 10 fll injections. Mice were boosted with the same amount of DNA in the same 
manner at 3 and 6 weeks postpriming. Blood samples were obtained from the retro-ocular 
plexus 8, 10 and in some cases 12 weeks after the initial immunization. Mice were 
sacrificed at 1 0 or 12 weeks and thyroids were removed for gross and histological 
examination. 
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2.10.2 Detection ofTSHR-specific Autoantibody by Flow Cytometry 
Chinese hamster cells (CHO) stably transfected with human TSHR-ECD eDNA 
(GPI9-5 cells) or control vector-transfected CHO cells (CHOl) were used to detect the 
presence of TSHR-specific autoantibody in immune mouse sera. GPI9-5 or CHO 1 cells 
were detached from the culture flasks after 2 washes with PBS using non-enzymatic cell 
dissociation solution (Sigma Chemicals, St. Louis, MO, USA), washed 2x and transferred 
into a 96-V shaped microwell plate (2 x 105 cells/well). Cells were centrifuged at 500 x g 
for 5 minutes at 4°C, washed once with PBS (1x) containing 1% (w/v) BSA (w/v) and 
0.1% (w/v) NaN3 (F ACs buffer) and the supernatant removed by aspiration. Cells were 
then incubated on ice for 30 minutes at 4°C with 50 j..tl ofF ACs buffer containing 10 J.!l of 
neat mouse sera. Purified A10 mAb (IgG2b) known to recognize TSHR-ECD amino 
acids 22-35 147 was used as a positive control (1 0 f.!g/ml) and purified HB65 mAb (IgG2a) 
specific for nucleoprotein of the influenza type A virus was used as a nonspecific 
negative control (10 f.lg/ml). Cells were washed 4x with 150 f.ll ofFACs buffer and 
centrifuged as described above. Cells were subsequently incubated at 4°C in the dark for 
30 minutes with 50 J.!l offlourescein-conjugated y-chain and Fc-specific goat anti-mouse 
IgG (Sigma Chemicals, St. Louis, MO, USA) diluted (1 :80) in F ACs buffer. Cells were 
washed 4 more times with F ACs buffer, suspended in 500 f.ll of 1 x PBS buffer containing 
1% (w/v) paraformaldehye (Sigma Chemicals, St. Louis, MO, USA) and transferred to 
"Falcon" tubes. The fluorescence of 10 000 cells/tube was analyzed by a F ACStar Plus 
flow cytometer and Cellquest software (Becton-Dickinson Inc., Franklin Lakes, NJ, 
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USA). Results are expressed as the mean channel fluorescence (MCF) ratio between 
GPI9-5 and CHOl. 
2.10.3 Detection of Thyroid-Stimulating Autoantibodies to TSHR using cAMP 
Assay 
Thyroid-stimulating autoantibodies were detected in mouse sera using CHO cells 
stably expressing native hTSHR (JP09)30. Briefly, 4 x 104 JP09 cells were plated in 96-
well flat-bottomed plates and cultured for 24 hours in growth medium. Medium in the 
wells was removed by aspiration and immune mouse sera diluted (1:10) in Ham's Fl2 
containing 0.1 % (w/v) BSA, 0.2 mg/ml 3-isobutyl-1-methylxanthine (Sigma Chemicals, 
St. Louis, MO, USA) was added to these wells (90 )..tl/well) and incubated for 2 hours at 
37°C. Immediately following stimulation, cells were lysed by the addition of 10 ).11 of 
lysis reagent 1A (2.5% dodecyltrimethylammonium bromide in assay buffer) provided 
with the Biotrak cAMP competitive enzyme immunoassay kit. Celllysates were diluted 
with lysis reagent 1 B (1: 1 0) and total cellular cAMP released from the cells was 
measured according to the manufacturer' s protocol and as previously described in 
Section 2.9.3. Duplicate samples were assayed in all experiments; results are expressed as 
pmol cAMP/mi. 
2.10.4 Total T4 Determination 
A radioimmunoassay (RIA) kit (DYNOtest; BRAHMS Diagnostica GmbH, 
Berlin, Germany) was used for total T4 determination in which mouse T4 competes with 
1251-T 4 for the antigen binding sites of a T 4-specific antibody immobilized on the inner 
surface of plastic tubes. A standard curve was constructed with reference standards 
provided by the manufacturer; TT4 values are expressed in ).lg/dl. 
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2.10.5 Thyroid Histology 
Thyroid glands were removed en block(still attached to the trachea) 10 or 12 
weeks postpriming and fixed in 10% buffered formalin. The lobes were then dissected 
from the trachea and embedded in methacrylate. Approximately 21 sections at 3.0 J.lm 
intervals were obtained throughout each gland. They were fixed to glass slides and 
stained with hematoxylin and eosin. Thyroids were scored for the presence of 
mononuclear cell infiltration as previously described156: 0 =no infiltration; 1 =interstitial 
accummulation of inflammatory cells; 2 = one or more foci of inflammatory cells at least 
the size of one follicle; 3 = extensive inftltration, 10-40% of the total area, 4 = extensive 
infiltration, 40-80% of the total area; 5 = extensive infiltration, > 80% of the total area. 
The highest infiltration score observed per gland was assigned to each mouse. 
2.11 PEPTIDES 
2.11.1 Peptide Synthesis 
Peptides designated hTSHR438-449 [ILLTSHYKLNVP], and hTSHR 716-731 
[STDIQVQKVTHDMRQG] were synthesized to >80% purity at Sigma-Genosys Ltd 
(The Woodlands, TX, USA). The Tg peptides p2494 (a.a. 2494-2510) [GLINRAKAVK 
QFEESQG] and p2694 (a.a. 2694-2711) [C(acm)SFWSKYIQTLKDADGAK] and 
mouse lysozyme peptide [DRGDQSTDYFILFINSR] were synthesized to >80 % purity at 
the Alberta Peptide Institute (Edmonton, Alberta, Canada). All peptides were blocked 
with an acetyl group at theN-terminal and an amide group at the C-terminal end. Mass 
spectrometry and HPLC analysis were performed on each peptide to verify composition 
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and purity. Human TSHR peptides used to immunize mice were chosen using 
overlapping A and B motifs from Altuvia et al. 157, as outlined in Section 2.11.2. 
2.11.2 Algorithm-Based Search for Ak-Binding Peptides in the Human TSHR 
From the study of Altuvia et al. 157, two motifs were used to screen hTSHR for 
peptides that may bind to the A k molecule (Table 2.2). The Pole Bio-Informatique 
Lyonnais: Network Protein Sequence analysis website (http://npsa-pbil.ibcp.fr/cgi-
bin/npsa automat.pl?page=npsa pattern.html) was used to scan the 764 amino acid residues 
of the human TSHR molecule. Using this program, sequences were found within the 
human TSHR that fit both motif A and motif B. We chose peptides in which motif A and 
motif B completely overlapped within the human peptide sequences. 
2.11.3 Peptide Immunizations 
AKR/J (H-2k) mice were immunized with 200 nmol ofhTSHR438-449 or 
hTSHR716-731 peptides in a 1:1 emulsion in Complete Freund's Adjuvant (CFA) (with 
Mycobacterium butyricum, Difco Laboratories Inc., Detroit, MI, USA). Each mouse was 
immunized subcutaneously (under ether anaesthesia) at 2 sites (base of tail and 
interscapular region). 
2.11.4 Proliferation Assay: Induction of Antigen-specific LNCs 
Nine days following peptide immunization, mice were euthanised with ether and 
their draining inguinal, axillary, and brachial lymph nodes were collected aseptically. A 
single cell suspension was prepared by passing the lymph node tissue through a sterile 
stainless steel wire mesh (Sigma, St. Louis, MO, USA), and washed in complete DMEM. 
LNC were cultured in 96-well plates at a concentration of 4 x 105 cells/well for 4 days in 
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Table 2.2 Motifs A and B within 1-Ak-binding peptides157 
Position # Amino Acid Attributes [Includes]/ {Excludes} A.A. 
MOTIF A 
1 
2 
3 
4 
5 
6 
7 
MOTIFB 
1 
2 
3 
4 
5 
Hydrogen acceptor, polar, not 
hydrophobic, not small, not aliphatic 
Not an amide 
Any amino acid 
Medium-sized, aliphatic, hydrophobic, no 
charge, not aromatic or an amide 
[DEHNQ] 
{NQ} 
any amino acid 
[ILTV] 
Any amino acid any amino acid 
Not aromatic {FHWY} 
Hydrophobic, no charge, not an amide [ ACFILMPTVWY] 
[DEHNQ]-{NQ}-X-[ILTV]-X-{FHWY}-[ACFILMPTVWYI 
Hydrogen acceptor, not small, polar, not 
aliphatic 
Not negatively charged 
Any amino acid 
Medium-sized, aliphatic, hydrophobic, no 
charge, not aromatic or an amide 
[CDEHNQY] 
{DE} 
any amino acid 
[ILTV] 
Hydrogen acceptor, non-hydrophobic, not [DEHQN] 
small, not aliphatic 
[CDEHNQY]-{DE}-X-[ILTV]-[DEHQN] 
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the presence of titrated amounts of the appropriate antigen in 200 Ill microcultures. 
Eighteen hours prior to harvesting, 1 !-!Ci of 3[H] thymidine was added to each culture in 
25 Ill of culture medium. Cells were harvested and incorporated radioactivity was 
measured as described in Section 2.9.4. Stimulation index is defined as CPM in the 
presence of antigen/CPM in the absence of antigen. 
2.11.5 Cytokine ELISA for assessment of cytokines in culture 
The concentration of interferon-y, IL-4, IL-2, and IL-l 0 in 48 hour culture 
supernatants collected from primed LNCs cultured in the presence of 15 !lM of indicated 
Ag were determined using a cytokine sandwich ELISA. Polyvinyl chloride (PVC) 96-
well ELISA plates were coated with purified anti-cytokine capture mAbs (50 Ill) 
overnight at 4°C diluted in a phosphate binding solution (0.1 M Na2HP04, pH 9.0 with 
0.1 M NaH2P04) to a concentration of 1 !lglml (anti-IL-2, IL-4, and IL-l 0) or 4 J...Lg/ml 
(anti-IFN-y). Anti-IL-2 capture mAb (JES6-1A12 antibody) was purchased from 
PharMingen (San Diego, CA, USA), while anti-IL-l 0 capture antibody was purchased 
from Peprotech Inc. (Rocky Hill, NJ, USA). Anti-IL-4 and anti-IFN-y capture mAbs were 
purified and concentrated as described in Section 2.2 from the supernatant of the 
hybridoma cell lines 11Bll (HB188, IgG1 , anti-IL-4)158 and R4-6A2 (HB170, IgGl , 
anti-IFN-y)159 previously purchased from ATCC. Plates were washed 2x with PBS and 
blocked for 2 hours at room temperature with 1% (w/v) BSA. After washing 3x with 
PBS-Tween, 1 00 J.ll of sample supernatants, and serially diluted recombinant cytokines 
were added to the wells. Recombinant murine IL-2 and IFN-y were obtained from 
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PharMingen (San Diego, CA, USA), while IL-4 and IL-l 0 cytokines were obtained from 
Peprotech Inc. (Rocky Hill, NJ, USA). The plates were incubated overnight at 4°C, 
washed 3x with PBS-T, and incubated with 100 f.!l of 1 f.!g/ml (anti-IL-4 and IFN-y) or 2 
f.!g/ml (anti IL-2 and IL-10) ofbiotinylated anti-cytokine mAb for 1 hour at room 
temperature. Biotinylated anti-IL-2 (JES6-5H4, rat IgG2b), IL-4 (BVD6-24G2, rat lgG 1) 
and IFN-y (XMG 1.2, rat IgG 1) detection antibodies were obtained from PharMingen 
(San Diego, CA, USA), while biotinylated anti-IL-l 0 antibody was purchased from 
Peprotech Inc. (Rocky Hill, NJ, USA). The plates were washed 4x with PBS-T and then 
incubated with 100 f.!l of streptavidin-alkaline phosphatase (Sigma Chemicals, St. Louis, 
MO, USA) diluted (1 :3000) in 1% BSA-PBS-T. After a one-hour incubation at room 
temperature and washing (5x with PBS-T), 100 f.!l ofp-nitrophenylphosphate substrate 
(Sigma Chemicals, St. Louis, MO, USA) diluted to 1mg/ml in 10% diethanolamine 
(Fisher Scientific, Napean, Ontario, Canada) was added. Following a one-hour 
incubation period at room temperature, the plate was read ( 405 nm) using a microplate 
reader (Molecular Devices, Sunnyvale, CA, USA). 
2.11.6 Antibody Blocking Assays: Determination of Ak or Ekpeptide binding 
To determine whether hTSHR peptides bind to I-A k or I-Ek MHC class II 
molecules, primed LNCs (Section 2.11.3) were cultured in the presence of titrated 
amounts of the appropriate antigen and either anti-IAk, anti-IEk, or anti-influenza A 
nucleoprotein (non-specific control) mAbs (1 0 f.!g/ml) for 24 hours at 37°C. MAbs were 
purified and concentrated as described in Section 2.2 from culture supernatants of the 
hybridoma cell lines 10.3.62 (TIB 92, IgG2a, anti-IA k)160, 14-4-4S (HB32, lgG2a, anti-
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1Ek)161 , and H16-L10-4R5 (HB65, IgG2a, anti-influenza A nucleoprotein (NP))162 
obtained from ATCC. Six hours prior to harvesting, lJ.tCi of 3[H]-thymidine was added 
to each culture well in 25 J.tl of medium. Cells were harvested and incorporated 
radioactivity was measured as described in Section 2.9.4. Percent inhibition of 
proliferation by blocking mAb is expressed as (1-(cpm in the presence ofmAb)/(cpm in 
the absence ofmAb)) x 100. 
2.11.7 EAT Induction 
To determine whether the hTSHR peptides were thyroiditogenic, mice (n=6) were 
boosted 3 weeks after initial priming (Section 2.11.3) with 100 nmol of peptide in 
Incomplete Freund's Adjuvant (IF A). After two weeks, these mice were bled, and their 
sera were tested in an ELISA (Section 2.11 .8). Their thyroids were also removed for 
histological analysis (Section 2.1 0.5). 
2.11.8 Detection of peptide-specific Abby ELISA 
An indirect antibody ELISA was used to detect the presence of hTSHR peptide-
specific IgG in pooled mice sera (5-6 mice/group). PVC microwell plates (Dynatech 
Laboratories, Chantilly, VA, USA) were coated with the immunizing peptide or non-
specific lysozyme peptide (0.2 J..tg/well) dissolved in carbonate buffer (pH 9.6) and 
incubated overnight at 4°C. The plates were then blocked overnight at 4°C with PBS 
containing 1% BSA. Serially diluted pooled sera samples were added to the wells ( 1 00 
J.lllwell) for one hour at room temperature and then washed three times with PBS-T. The 
second antibody, an alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma, St. 
Louis, MO, USA) diluted (1 :3000) in 1% BSA-PBS-Tween was then added to each well 
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(100 ~l/well). After an hour incubation at room temperature, the plates were washed 
again 3x with PBS-T followed by the addition of 100 ~l of p-nitrophenylphosphate 
substrate (Sigma, St. Louis, MO, USA) solution (1 mg/ml p-nitrophenylphosphate in 
10% diethanolamine, pH 9.8). Absorbance of the p-nitrophenylphosphate product was 
measured 30 minutes later at 405 nm using an automated microplate reader (Molecular 
Devices, Sunnydale, CA, USA). 
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CHAPTER THREE 
INDUCTION OF HYPERTHYROIDISM IN BALB/cJ MICE BY GENETIC 
IMMUNIZATION WITH hTSHR 
3.1 ABSTRACT 
An animal model that exhibits most ofthe clinical signs and symptoms of GO 
would be a valuable tool for studying the pathology and aetiology of this autoimmune 
thyroid disease (AITD). Previous attempts to establish a mouse model of GD by i.m. 
immunization of mice with plasmid DNA encoding the hTSHR gene have yielded 
conflicting results. In this study, we have used DNA immunization to examine the effect 
of several parameters on the immune response including: a) homologous (murine; 
pcDNA3.lzeo+/mTSHR) versus heterologous (human; pcDNA3.lzeo+/hTSHR) TSHR 
Ag, b) Ag dose (50 ~g vs. 10 ~g of DNA), c) cytokine-vector co-delivery 
(pcDNA3.lzeo +/IL-2 or pcDNA3.lzeo +/IL-4), and d) genetic background of the host 
(BALB/cJ versus AKR/J mice). Disease induction was assessed by measuring TSHR-
specific antibodies, TSAb activity, and TT4 levels in the sera of immunized mice as well 
as by histological examination of the thyroid gland. Surprisingly, very few BALB/cJ 
mice produced autoantibodies specific for the TSHR molecule following i.d. DNA 
immunization with pcDNA3.lzeo+encoding the homologous (murine) TSHR, regardless 
of antigen dose or co-delivery of cytokine-vectors indicating that tolerance to the mTSHR 
could not be broken. In contrast, between 50-60% ofBALB/cJ and AKR/J mice 
produced TSHR-specific Ab following i.d. immunization with the heterologous (human) 
TSHR eDNA. Three out of the 8 BALB/cJ mice immunized with the larger dose of 
hTSHR-encoding plasmid also became thyrotoxic with TT4 levels as high as 16.21 ~g/dl 
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(normal range= 5.09-6.51 J..Lg/dl), and thyroids from 2 ofthese 3 thyrotoxic mice 
exhibited signs ofhyperactivity, but lacked lymphocytic infiltration. Thyroid 
hyperactivity, however, did not coincide with TSAb activity, which may have been 
masked by TSBAbs or neutral TSHR antibodies. Surprisingly, co-delivery of either miL-
2 or miL-4 cytokine vectors did not enhance antibody and hyperthyroidism induction in 
BALB/cJ mice for unknown reasons. These results confirm the efficacy of i.d. DNA 
immunization in inducing immune responses against the encoded heterologous hTSHR as 
well as the ability ofhTSHR autoantibodies to recognize and bind to mTSHR 
determinants stimulating thyroid hyperactivity and excessive hormone production. 
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3.2 INTRODUCTION 
Currently, an animal model developing spontaneous GD does not exist; thus much 
of the research has focused on experimentally inducing GD in mice. Numerous attempts 
using purified TSHR from thyrocytes or recombinant protein expressed in bacteria or 
insect cells and conventional immunization protocols have failed to establish a disease 
model (Section 1.3.1 and 1.3.3). However, some new approaches for generating animal 
models of Graves' hyperthyroidism have recently been demonstrated. First, a novel 
immunization protocol described by Shimojo et al. 75 using transfected fibroblasts 
coexpressing hTSHR and MHC class II molecules induced hyperthyroidism in a small 
proportion ( ~ 20%) of immunized syngeneic AKR mice. This finding was later 
confirmed by two other groups77;78• Subsequently, using a variation ofShimojo' s 
protocol, Kaithamana, et al. 80 were able to induce hyperthyroidism in almost 1 00% of the 
BALB/c mice receiving i.p. injections of B lymphoblastoid cells expressing TSHR. 
Although these studies reproduced several major features ofGD, some of the drawbacks 
include cell line availability for only certain strains of mice, minimal lymphocytic thyroid 
infiltration, as well as the unexplained widespread immune activation recently reported 
by Y an et al. 79 Genetic immunization with an eukaryotic expression vector containing 
hTSHR eDNA has also proven to be useful in inducing hyperthyroidism in a small 
proportion(~ 20%) of outbred NMRI 84, but not inbred BALB/c mice83. However, the 
low rate of disease induction, as well as the inability of other research groups85 ;~ 63 to 
reproduce comparable results using similar immunization regimes, necessitates further 
investigation. 
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Since plasmid DNA can be manipulated to alter the quantitative and qualitative 
aspects of an immune response, it prompted us to modify previous DNA immunization 
protocols in an effort to establish a more reliable method for inducing GD in mice. First, 
in lieu of i.m. DNA immunization, mice were immunized intradermally with various 
doses of plasmid DNA because the skin, in contrast to muscle, has an established immune 
surveillance function carried out by a variety of professional antigen presenting cells 
including specialized bone-marrow derived Langerhans cells (LCs)112;164;165• Following 
direct transfection with plasmid DNA or internalization of antigen produced by 
transfected keratinocytes (skin cells), LCs migrate to the draining lymph nodes and 
present Ag toT and B cells106. Second, since GD is a Th2 mediated autoimmune 
disease9;166, attempts to bias the immune response toward a Th2 type of response were 
made through co-delivery of plasmid DNA encoding miL-4, a cytokine known to 
promote Th cell differentiation toward a Th2 pathway167• Third, although there is 86% 
homology between the human and murine TSHR sequences, limited a.a. differences may 
alter the tertiary structure of the receptor and cause production ofTSHR-specific Abs that 
cannot bind or stimulate the endogenous mTSHR. The fact that only a minority of 
hTSHR antibodies that bind to the mTSHR act as agonist, stimulating the receptor, agrees 
with this interpretation64-66. To circumvent this, both the homologous (murine) and 
heterologous (human) TSHR eDNA were used as DNA immunogens. Finally, to 
determine whether the genetic background of the host plays a role in disease 
susceptibility, i.d. immunizations were performed in two different strains of mice 
(BALB/cJ and AKRIJ). 
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3.3 RESULTS 
3.3.1 Sequencing of cloned eDNA inserts 
The dideoxynucleotide chain termination method was used to sequence the entire 
coding region and portions of the 5' and 3' flanking regions ofhuman and murine TSHR 
eDNA and murine IL-4 and IL-2 cytokine inserts. The nucleotide and derived amino acid 
sequences of the cloned eDNA inserts are shown in Figures 3.1-3.3. The hTSHR 
sequence (Figure 3.1) was almost identical to the published sequence25 with the exception 
of two nucleotide substitutions at positions 1477 (g ~a) and 1801 (c ~ t). The latter 
nucleotide substitution caused an amino acid change at position 601 (H ~ Y). The 
sequence ofmTSHR (Figure 3.2), miL-4, and miL-2 (Figure 3.3A & B respectively), on 
the other hand, were identical with the published sequences63;168;169• 
3.3.2 Restriction Enzyme Analysis of Plasmid DNA 
Purified plasmid DNA was subject to various restriction enzyme digestions and 
gel electrophoresis to ensure correct plasmid size and confirm the presence of eDNA 
inserts (Figure 3.4). Kpnl digested each plasmid at one site yielding the actual size of 
each plasmid: pcDNA3.1zeo+ = 5015 bp (lane 1), pcDNA3.1zeo+/hTSHR = 7428 bp 
(lane 2), pcDNA3.lzeo+/mTSHR = 7249 (lane 3), pcDNA3.1zeo+/miL-2 = 5469 bp (lane 
4), and pcDNA3.lzeo+/miL-4 = 5382 (lane 5). The hTSHR insert(~ 2.5 kb) was released 
when pcDNA3.1zeo+/hTSHR was digested withXho/(lane 6), while miL-2 (~0.5 kb), 
miL-4 ( ~0.4 kb ), and mTSHR (~ 2.4 kb) were released when digested with both Kpn! and 
Xbal (lane 7-9 respectively). 
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0001 atg agg ccg gcg gac ttg ctg cag ctg gtg ctg ctg etc gac ctg ccc agg gac ctg ggc gga atg ggg tgt tcg tct cca ccc tgc gag tgc cat cag 
H R P A D L L Q L V L L L D L P R D L G G H G C 5 S P P C E C H Q 033 
0100 gag gag gac ttc aga gtc ace tgc aag gat att caa cgc ate ccc age tta ccg ccc agt 
EEDFRVTCKDIQRIPSLPP5 
0199 att cca agt cat gca ttt tct aat ctg ccc aat att tee aga ate tac gta tct ata gat 
IP5HAFSNLPNISRIYV5ID 
acg cag act ctg aag ctt att gag act cac ct g aga act 
T Q T L K L I E T H L R T 
gtg act ctg cag cag ctg gaa tea cac tee ttc tac aat 
VTLQQLE5H5FYN 
0298 ttg agt aaa gtg act cac ata gaa att egg aat ace agg aac tta 
L5KVTHIEIRNTRNL 
0397 att ttc aac act gga ctt aaa atg ttc cct gac ctg ace aaa gtt 
IFNTGLKHFPDLTKV 
act tac ata gac cct gat gee etc aaa gag etc ccc etc eta aag t t c ct t ggc 
TY I D P DALKE L P L L K F L G 
tat tee act gat ata ttc ttt ata ctt gaa att aca gac aac cct tac atg acg 
YSTDIFFILEITDNPYHT 
0496 tea ate cct gtg aat get ttt cag gga eta tgc aat gaa ace ttg aca ctg aag ctg tac aac aat ggc ttt act tea gtc caa gga tat get ttc aat 
066 
099 
132 
165 
5 I P V N A F Q G L C N E T L T L K l Y N N G F T 5 V Q G Y A F N 198 
0595 ggg aca aag ctg gat get gtt tac eta aac aag aat aaa tac ctg aca gtt att gac aaa gat gca ttt gga gga gta t ac agt gga cca age ttg ctg 
G T K L D A V Y L N K N K Y l T V I D K D A F G G V Y 5 G P S L L 231 
0694 gac gtg tct caa ace agt gtc act gee ctt cca tee aaa ggc ctg gag cac ctg aag gaa c tg ata gca aga aac ace t gg act ctt aag aaa ctt cca 
D V S Q T 5 V T A L P 5 K G L E H L K E L I A R N T W T L K K L P 2~ 
0793 ctt tee ttg agt ttc ctt cac etc aca egg get gac ctt tct tac cca age cac tgc tgt get ttt aag aa t cag aag aaa ate aga gga ate ctt gag 
L 5 L 5 F L H L T R A D L 5 Y P S H C C A F K N Q K K I R G I L E D7 
0892 tee ttg atg tgt aat gag age agt atg cag age ttg cgc cag aga aaa tct gtg aat gee ttg aat age ccc etc cac cag gaa tat gaa gag aat ctg 
5 L H C N E 5 5 H Q 5 L R Q R K 5 V N A L N 5 P L H Q E Y E E N L 330 
0991 ggt gac age att gtt ggg tac aag gaa aag tee aag ttc cag gat act cat aac aac get cat tat tac gtc t tc ttt gaa gaa caa gag gat gag ate 
G D 5 I V G Y K E K 5 K F Q D T H N N A H Y Y V F F E E Q E D E I 363 
1090 att ggt ttt ggc cag gag etc aaa aac ccc cag gaa gag act eta caa get ttt gac age cat tat gac tac ace ata tgt ggg gac agt gaa gac atg 
I G F G Q E L K N P Q E E T L Q A F D 5 H Y D Y T I C G D S E D H 396 
1189 gtg tgt ace ccc aag tee gat gag ttc aac ccg tgt gaa gac ata atg ggc tac aag ttc ctg aga att gtg gtg tgg t t c gtt agt ctg ctg get etc 
V C T P K 5 D E F N P C E D I H G Y K F L R I V V W F V 5 L L A L 429 
1288 ctg ggc aat gtc ttt gtc ctg ctt att etc etc ace age cac tac aaa ctg aac gtc ccc cgc ttt etc atg tgc aac ctg gee tt t gc& gat ttc tgc 
L G N V F V L L I L L T 5 H Y K L N V P R F L H C N L A F A D F C 462 
1387 atg ggg atg tac ctg etc etc ate gee tct gta gac etc tac act cac tct gag tac tac aac cat gee ate gac tgg cag aca ggc cct ggg tgc aac 
H G H Y l L l I A 5 V D L Y T H 5 E Y Y N H A I D W Q T G P G C N 495 
1486 acg get ggt ttc ttc act gtc ttt gca age gag tta tcg gtg tat acg ctg acg gtc ate ace ctg gag cgc tgg tat gee ate ace ttc gee atg cgc 
T A G F F T V F A 5 E L 5 V Y T L T V I T L E R W Y A I T F A H R 528 
1585 ctg gac egg aag ate cgc etc agg cac gca tgt gee ate atg gtt ggg ggc tgg gtt tgc tgc ttc ctt etc gee ctg ctt cct ttg gtg gga ata agt 
L D R K I R L R H A C A I H V G G W V C C F L L A l L P L V G I 5 S~ 
1684 age tat gee aaa gtc agt ate tgc ctg ccc atg gac ace gag ace cct ctt get ctg gca tat att gtt ttt gtt ctg acg etc aac ata gtt gee ttc 
S Y A K V S I C L P H D T E T P L A L A Y I V F V L T L N I V A F S~ 
1783 gtc ate gtc tgc tgc tgt tat gtg aag ate tac ate aca gtc ega aat ccg cag tac aac cca ggg gac aaa gat ace aaa att gee aag agg atg get 
V I V C C C ,l V K I Y I T V R N P Q Y N P G D K D T K I A K R H A 627 
1882 gtg ttg ate ttc ace gac ttc ata tgc atg gee cca ate tea ttc tat get ctg tea gca att ctg aac aag cct etc ate act gtt age aac tee aaa 
V L I F T D F I C H A P I 5 F Y A L S A I L N K P L I T V 5 N 5 K 660 
1981 ate ttg ctg gta etc ttc tat cca ctt aac tee tgt gee aat cca ttc etc tat get att ttc ace aag gee ttc cag agg gat gtg ttc ate eta etc 
I L L V L F Y P L N 5 C A N P F L Y A I F T K A F Q R D V F I L L 6~ 
2080 age aag ttt ggc ate tgt aaa cgc cag get cag gca tac egg ggg cag agg gtt cct cca aag aac age act gat att cag gtt caa aag gtt ace cac 
5 K F G I C K R Q A Q A Y R G Q R V P P K N 5 T D I Q V Q K V T H 726 
2179 gac atg agg cag ggt etc cac aac atg gaa gat gtc tat gaa ctg att gaa aac tee cat eta ace cca aag aag caa ggc caa ate tea gaa gag t at 
D H R Q G L H N H E D V Y E L I E N 5 H L T P K K Q G Q I 5 E E Y 759 
2278 atg caa acg gtt ttg taa 
H Q T V L Z 
Figure 3.1 Nucleotide and derived amino acid sequence of the eDNA encoding the hTSHR protein. The sequence is identical to the 
published hTSHR sequence with the exception of 2 nucleotide substitutions at positions 1377 (g ~a) and 1801 (c ~ t) (double 
underlined). The latter nucleotide sustitution caused an amino acid change at position 601 (H ~ Y) (double underlined). 
Vl 
00 
0001 atg agg cca ggg tee ctg ctg ctg ctt gtt ctg ctg etc gee ctg tee agg age ctg egg ggc aaa gag tgt gcg tct cca ccc tgt gag tgt cac cag 
H R P G S L L L L V L L L A L S R S L R G K E C A S P P C E C H Q ro3 
0100 gag gac gac ttc aga gtc ace tgc aag gag etc cac ega ate ccc age ctg ccg ccc age ace cag act ctg aag etc ate gag act cat ctg aag ace 
E D D F R V T C K E L H R I P 5 L P P S T Q T L K L I E T H L K T 066 
0199 ata ccc agt ctt gca ttt tcg agt ctg ccc aat att tee agg ate tat tta tct ata gat gca act ctg cag egg ctg gaa cca cat tct ttc tac aat 
I P S L A F S S L P N I S R I Y L S I D A T L Q R L E P H 5 F Y N 099 
0298 ttg agt aaa atg act cac ata gaa ate egg aac ace aga age tta ace tat ata gac cct gat gee ttg aca gag etc ccc ttg etc aag ttt ctt ggc 
L 5 K H T H I E I R N T R 5 L T Y I D P D A L T E L P L L K F L G 132 
0397 att ttc aat act gga ctt aga ata ttc cct gac ttg ace aaa att tat tee acg gac ata ttc ttt ata ctt gaa ate aca gac aac cct tac atg act 
I F N T G L R I F P D l T K I Y S T D I F F I L E I T D N P Y H T 165 
0496 tcg gtc cct gaa aac gca ttc cag ggc eta tgc aat gaa ace ttg ace ctg aaa ctg tac aac aat gga ttt act tea gtc caa gga cat get t t c aat 
S V P E N A F Q G L C N E T L T L K L Y N N G F T S V Q G H A F N 1~ 
0595 gga aca aag ctg gat get gtt tac eta aac aag aat aaa tac ctg aca get ata gac aac gat gee ttt gga gga gta tac agt gga cca act ttg et a 
G T K L D A V Y L N K N K Y L T A I D N D A F G G V Y 5 G P T L L 2D 
0694 gat gtg tct tee ace age gtc act gee ctt cct tee aaa ggc ctg gag cac etc aaa gaa ctg ate gca aaa gac ace tgg act etc aaa aag etc ccg 
D V 5 5 T S V T A L P S K G L E H L K E L I A K D T W T L K K L P 264 
0793 ctg tcg ttg agt ttc etc cac etc act egg get gac etc tct tac ccg age cac tgc tgc get ttt aag aac cag aag aaa ate agg gga ate ctg gag 
L S L S F L H L T R A D L S Y P S H C C A F K N Q K K I R G I L E 297 
0892 tct ttg atg tgt aat gag age agt ate egg aac ctt cgt caa agg aaa tea gtg aac ate ttg agg ggt ccc ate tac cag gaa tat gaa gaa gat ccg 
S L H C N E S 5 I R N L R Q R K S V N I L R G P I Y Q E Y E E D P DO 
0991 ggt gac aac agt gtt ggg tac aaa caa aac tee aag ttc cag gag age cca age aac tct cac tat tac gtc ttc ttt gaa gaa caa gag gat gag gtc 
G D N 5 V G Y K Q N 5 K F Q E 5 P 5 N 5 H Y Y V F F E E Q E D E V 363 
1090 gtt ggt ttc ggc caa gag etc aaa aat cct cag gaa gag act etc caa gee ttc gag age cac tat gac tac acg gtg tgt ggg gac aac gag gac atg 
V G F G Q E L K N P Q E E T L Q A F E S H Y D Y T V C G D N E D H 396 
1189 gtg tgt ace ccc aag tcg gac gag ttt aac ccc tgt gaa gat ate atg ggc tac agg ttc ctg aga ate gtg gtg tgg ttt gtc agt ctg ctg get etc 
V C T P K S D E F N P C E 0 I H G Y R F L R I V V W F V 5 L L A L 429 
1288 ctg ggc aat ate ttc gtc ctg etc att ctg eta ace age cac tac aaa ttg ace gtg ccg egg ttc etc atg tgc aac ttg gee tt t gca gat ttc tgc 
L G N I F V L L I L L T S H Y K L T V P R F L M C N L A F A D F C 4~ 
1387 atg ggg gta tac ctg ctt etc att gee tct gta gac ctg tac aca cac tct gag tac tac aac cac gee ate gac tgg cag acg ggc cct ggg tgc aac 
H G V Y L L L I A S V D L Y T H S E Y Y N H A I D W Q T G P G C N 495 
1486 acg get ggc ttc ttc act gtt ttc gee agt gag tta tea gtg tac aca ctg acg gtc ate ace ctg gag ega tgg tac gee ate ace ttc gee atg cgc 
T A G F F T V F A S E L S V Y T L T V I T L E R W Y A I T F A M R ~8 
1585 ctg gat agg aag ate cgc etc agg cac gcg tac ace ate atg get ggg ggc tgg gtt tee tgc ttc ctt etc gee ctg etc ccg atg gtg gga ate age 
L D R K I R L R H A Y T I M A G G W V S C F L L A L L P M V G I 5 561 
1684 age tat gee aag gtc age ate tgc ctg cca atg gac ace gac ace cct ctt gca etc gca tac att gtc etc gtt ctg ctg etc aat gtt gtt gee t t t 
S Y A K V S I C L P M D T D T P L A L A Y I V L V L L L N V V A F 594 
1783 gtt gtc gtc tgt tee tgc tat gtg aag ate tac ate acg gtc ega aat ccc cag tac aac cct ega gat aaa gac ace aag att gee aag agg atg get 
V V V C 5 C Y V K I Y I T V R N P Q Y N P R D K 0 T K I A K R H A 627 
1882 gtg ttg ate ttc act gac ttc atg tgc atg gcg ccc ate tee ttc tat gcg ctg tcg gca ctt atg aac aag cct eta ate act gtt act aac tee aaa 
V L I F T D F M C H A P I S F Y A L S A L M N K P L I T V T N 5 K 660 
1981 ate ttg ttg gtt etc ttc tac ccc etc aac tee tgt gee aat ccg ttt etc tat get att ttc ace aag gee ttc cag agg gac gtg ttc ate ctg etc 
I L L V L F Y P L N S C A N P F L Y A I F T K A F Q R D V F I L L 693 
2080 age aag ttt ggc ate tgc aaa cgc cag gee cag gee tat cag ggt cag aga gtc tgt ccc aac aat age act ggt att cag ate caa aag att ccc cag 
S K F G I C K R Q A Q A Y Q G Q R V C P N N 5 T G I Q I Q K I P Q 726 
2179 gac acg agg cag agt etc ccc aac atg caa gat ace tat gaa ctg ctt gga aac tee cag eta get cca aaa ctg cag gga caa ate tea gaa gag tat 
D T R Q 5 L P N M Q D T Y E L L G N S Q L A P K L Q G Q I S E E Y ~9 
2278 aag caa aca gee ttg taa 
K Q T A L Z 
Figure 3.2 Nucleotide and derived amino acid sequence of the eDNA encoding the rnTSHR protein. The sequence is completely 
identical to the published mTSHR sequence. 
A 001 atg ggt etc aac ccc cag eta gtt gtc ate ctg etc ttc ttt etc gaa tgt ace agg age M G L N P Q L V V I L L F F L E C T R S 
061 cat ate cac gga tgc gac aaa aat cac ttg aga gag ate ate ggc att ttg aac gag gtc 
H I H G C D K N H L R E I I G I L N E V 
121 aca gga gaa ggg acg cca tgc acg gag atg gat gtg cca aac gtc etc aca gca acg aag 
T G E G T P C T E M D V P N V L T A T K 
181 aac ace aca gag agt gag etc gtc tgt agg get tee aag gtg ctt cgc ata ttt tat tta 
N T T E S E L V C R A S K V L R I F Y L 
241 aaa cat ggg aaa act cca tge ttg aag aag aac tet agt gtt etc atg gag ctg cag aga 
K H G K T P C L K K N S S V L M E L Q R 
301 etc ttt egg get 
l F R A 
361 tee aca tea ctg 
S T S L 
421 tag 
z 
ttt ega tge ctg gat tea tcg ata age tgc ace atg aat gag tee aag 
F R C L D 5 S I S C T M N E S K 
aaa gac ttc ctg gaa age eta aag age ate atg caa atg gat tac tcg 
K D F L E S L K S I M Q M D Y 5 
020 
040 
060 
080 
100 
120 
140 
B 001 atg tac age atg cag etc gca tee tgt gtc aca ttg aca ctt gtg etc ctt gtc aac age M Y 5 M Q L A S C V T L T L V L L V N 5 020 
061 gca ccc act tea age tee act tea age tct aca gcg gaa gca cag cag cag cag cag cag 
A P T S S S T S 5 S T A E A Q Q Q Q Q Q 040 
121 cag cag cag cag cag cag cac etg gag eag ctg ttg atg gae eta cag gag etc ctg age 
Q Q Q Q Q Q H L E Q L L M D L Q E L L 5 OW 
181 agg atg gag aat tac agg aac ctg aaa etc ccc agg atg etc ace ttc aaa ttt tac ttg 
R M E N Y R N L K L P R M L T F K F Y L 080 
241 ccc aag cag gee aca gaa ttg aaa gat ctt cag tgc eta gaa gat gaa ctt gga cct ctg 
P K Q A T E L K D L Q C L E D E L G P L 100 
301 egg cat gtt ctg gat ttg act eaa 
R H V L D L T Q 
361 ate age aat ate aga gta act gtt 
I S N I R V T V 
421 caa ttc gat gat gag tea gca act 
Q F D D E S A T 
age aaa age ttt caa ttg gaa gat get gag aat ttc 
5 K S F Q L E D A E N F 
gta aaa eta aag ggc tct gac aac aca ttt gag tgc 
V K L K G S D N T F E C 
gtg gtg gae ttt ctg agg aga tgg ata gee ttc tgt 
V V D F L R R W I A F C 
481 caa age ate ate tea aca age cct caa taa 
Q 5 I I S T S P Q Z 
120 
140 
1W 
Figure 3.3 Nucleotide and derived amino acid sequences of the eDNA encoding the 
miL-4 (A) and miL-2 (B) genes. The sequences are completely identical to the 
corresponding published sequences. 
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Figure 3.4. Restriction enzyme analysis ofpcDNA3.lzeo+ alone or 
containing hTSHR, mTSHR, miL-2 or miL-4 eDNA inserts. Kpnl digested 
each of the five plasmids yielding the actual size of each plasmid: 
pcDNA3.1zeo+ = 5015 bp (lane 1), pcDNA3.1zeo+fhTSHR = 7428 bp (lane 
2), pcDNA3.lzeo+fmTSHR = 7249 bp (lane 3), and pcDNA3.lzeo+~-2 = 
5469 bp (lane 4), and pcDNA3.lzeo+fmiL-4 = 5382 bp (lane 5). The hTSHR 
insert ( -2.5 kb) was released when digested with Xhol (lane 6), while mll.__-2 
(- .5 kb), miL-4 (-.4 kb), and mTSHR (-2.3 kb) eDNA inserts were released 
when digested with both Kpnl and Xbal (lane 7-9 respectively). 
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3.3.3 Transfection Efficiency of CHO Cells: Luciferase Assay 
Transfection efficiency of CHO cells was determined using the luciferase reporter 
gene system. Celllysates of CHO cells transiently transfected with varying amounts of 
either pGL3-Basic or pGL3-Control vectors were mixed with luciferase assay reagent 
(substrate) and light intensity was measured using a luminometer. As shown in Figure 
3.5, celllysates from CHO cells transiently transfected pGL3-Control, but not pGL3-
Basic vectors, contain the luciferase gene product based on the its ability to produce light 
following the addition of luciferin substrate. The inability of pGL3-Basic transfected 
CHO cells to produce light following substrate addition was expected due to the lack of 
eukaryotic promoter and enhancer sequences preventing luciferase gene expression in 
mammalian cells. No difference in light intensity was observed when cells were 
transfected with 0.25 or 0.5 jlg of DNA. These results confirm CHO cells ability to be 
transfected with plasmid DNA. 
3.3.4 Expression and Functionality of hTSHR and mTSHR 
Expression and functionality ofhTSHR and mTSHR eDNA inserts were tested by 
measuring the cAMP response of CHO cells transiently transfected with pcDNA3.1 zeo + 
containing either the hTSHR or mTSHR insert following stimulation with the TSHR 
agonist, TSH. CHO cells stably expressing native hTSHR (JP09 cells)30 were used as a 
positive control. Following bTSH stimulation, an increase in cAMP concentration was 
observed in JP09 as well as CHO cells transiently transfected with either 
pcDNA3.1zeo+lhTSHR or pcDNA3.1zeo+/mTSHR (Figure 3.6). Under similar 
conditions, no cAMP response was observed from CHO cells transiently transfected with 
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Figure 3.5. Luciferase gene expression in CHO cells. Cell 
lysates (20 ~l) of CHO cells transiently transfected with either 
pGL3-Basic or pGL3-Control vectors (0.25 ~g or 0.5 ~g) were 
mixed with luciferin substrate, and the light produced 
following the reaction between luciferase and luciferin was 
measured using a Mono light® 2010 luminometer. Results are 
expressed as mean of duplicates ± SD. 
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80 
Figure 3.6. Bovine TSH-induced cAMP responses of CHO-Kl 
cells transiently transfected with pcDNA3.1zeo+ alone or 
pcDNA3.lzeo+ containing the hTSHR or mTSHR eDNA insert. 
Cells were stimulated in the presence or absence of 5 mU/ml 
bTSH for 2 hr, lysed, and celllysates assayed for total cellular 
cAMP using a commercial enzymeimmunoassay kit. A 7-fold 
cAMP increase was observed when CHO stably expressing native 
hTSHR (JP09 cells) were stimulated with bTSH (data not shown). 
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the empty vector. Although all cells produced similar baseline levels of cAMP, JP09 cells 
produced significantly higher amounts of cAMP following bTSH stimulation compared 
to CHO cells. The reason for this is uncertain, but may be attributed to the high level of 
hTSHR protein expressed on JP09 cells (90 000 molecules/cell) compared to the 
unknown level of receptor expression on transiently transfected CHO cells. 
3.3.5 Expression and Functionality of miL-2 and miL-4 
A CT.4S and CTLL-2 proliferation bioassay confirmed the expression and 
functionality of IL-4 and IL-2 released in tissue culture supernatants from 
pcDNA3.lzeo+/miL-4 and pcDNA3.zeo+/miL-2-transfected CHO cells (Figure 3.7A & B 
respectively). Supernatants from CHO cells transfected with the empty vector 
(pcDNA3.lzeo+) were devoid ofiL-4 or IL-2 activity. 
3.3.6 Specificity of TSHR antibodies for GPI9-5 cells 
CHO cells stably expressing GPI-anchored hTSHR-ECD (GPI9-5) or vector-
transfected CHO cells (CHOl) were used to detect TSHR-specific autoantibodies in 
immune mouse sera by flow cytometry. Prior to analysis of sera, the specificity of TSHR 
antibodies for GPI9-5 cells was determined using the AI 0 mAb known to recognize a 
TSHR-ECD peptide (a.a. 22-35). As shown in Figure 3.8, no shift in the mean channel 
fluorescence (MCF) was observed when GPI9-5 or CHOI cells were incubated in the 
presence of the HB65 mAb specific for the nucleoprotein of the influenza type A virus or 
when CHOI cells were incubated in the presence of AlO mAb. However, a large shift 
was observed when GPI9-5 cells were incubated with AlO mAb. These results confirmed 
TSHR-ECD expression on GPI9-5 cells. For normalization purposes, in subsequent 
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Figure 3.7 Expression and functionality ofmiL-4 (A) and miL-2 (B). Supernatants 
collected from CHO cells transiently transfected with pcDNA3.1 zeo+ alone or 
pcDN A3.1 zco+ containing the IL -4 (A) or IL-2 (B) eDNA insert were serially diluted and 
incubated with 104 CTLL-2 or CT.4S cells for 24 or 48 hours respectively. Twenty four 
(CT.4S) or eight hours (CTLL-2) prior to harvesting, 3[H] thymidine was added to each 
well (1 J.1Ci/well). Cells were harvested using the Harvester 96® Mach III M and 
incorporated radioactivity was measured using the TopCount NXTfM Microplate 
Scintillation & Luminescence Counter. Results are expressed as mean of triplicates± SD. 
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Figure 3.8 Detection ofGPI-anchored hTSHR-ECD expressed on CHO 
cells (GPI9-5). GPI9-5 and empty vector transfected CHO cells (CH01) 
(2 x 105 cells/tube) were incubated in the presence (black histogram) or 
absence (white histogram) ofTSHR-specific (A10) or non-specific 
(HB65) mAb (1 0 J.Lg/ml), washed, and subsequently incubated with 
fluorescein-conjugated y-chain-Fc-specific goat anti-mouse IgG (1 :80). 
Fluorescence of 10 000 cells were analyzed using a FACStar Plus 
analyzer and CellQuest software. 
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experiments results were expressed as the MCF ratio between GPI9-5 and CHO I cells 
and values greater than 3SD above the control mean were considered positive. 
3.3.7 Intradermal DNA immunization with heterologous TSHR induces TSHR-
specific autoantibody production in BALB/cJ mice 
To determine whether i.d. DNA immunization of BALB/cJ with pcDN A3 .I zeo + 
encoding the heterologous or homologous TSHR ~ould induce an immune response 
against the TSHR molecule, individual serum samples were tested for: a) TSHR-specific 
antibodies, b) TSAb activity, c) elevated TT4, and d) lymphocytic infiltration of the 
thyroid gland. As shown in Table 3.1, sera from 4 out of the 8 BALB/cJ mice (50%) 
immunized 3x with 10 J..lg ofpcDNA3.lzeo+/hTSHR contained TSHR-specific 
autoantibodies in week 8 and 10. One of these 4 mice (mouse no. 7), however, exhibited 
only marginal antibody production with GPI9-5/CH01 MCF ratios (2.08 and 1.92) only 
slightly greater than control values (mean+ 3SD = 1.83 and 1.54). The other three mice 
had GPI9-5/CH01 MCF ratios between 7.56 and 85.72; up to a 45-fold increase 
compared to control MCF ratios. In contrast, when BALB/cJ mice were immunized with 
pcDNA3.lzeo + containing the homologous TSHR insert (mTSHR), only 1 mouse was 
positive for TSHR antibodies in week 8 (mouse no. 7), and 3 were positive in week 10 
(mouse no. 4, 7, and 8). Once again, however, the MCF ratios of these mice were only 
marginally greater than control values. Of the mice that were positive for TSHR 
antibodies, none had detectable TSAb activity or elevated TT4levels. Furthermore, 
thyroid size and morphology were comparable with thyroids of control mice, and no 
lymphocytic infiltration was observed (data not shown). These results confirm the 
efficacy of intradermal DNA immunization to induce a humoral immune response in 
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Table 3.1 Comparison of the humoral immune response (TSHR-specific Ab production) 
and thyroid function of BALB/cJ mice following i.d. DNA immunization with varying 
doses of homologous {murine} and heterologous {human) TSHR antigen 
Antigen Mouse GPI9-S/CH01 MCF cAMP (pmollml)c TT4 (t..Lgldl)d 
(Dose)" No. Ratiob 
Week8 Week 10 Week8 Week 10 Week8 Week 10 
E (10 t..Lg) 1 1.66 1.44 18.5 27.4 4.80 5.69 
2 1.58 1.39 17.5 21.8 5.44 5.26 
3 1.55 1.45 21.5 20.1 6.12 5.83 
4 1.50 1.34 19.0 22.5 5.20 6.13 
s 1.36 1.43 17.9 21.7 4.98 5.29 
6 1.46 1.36 21.4 25.4 6.27 6.56 
M (10 t..Lg) 1 1.79 1.41 19.5 20.7 5.57 5.97 
2 1.57 1.40 22.5 20.7 4.87 6.05 
3 1.54 1.29 19.8 21.3 6.58 4.95 
4 1.61 1.88 20.0 19.7 4.86 5.93 
s 1.64 l.l1 19.2 18.2 5.74 5.51 
6 1.78 21.9 6.83 
7 2.04 1.57 18.2 20.7 4.66 5.84 
8 1.72 1.59 19.4 18.6 5.37 6.16 
H (10 t..Lg) 1 1.52 1.38 21.2 18.9 6.83 6.58 
2 1.68 1.40 22.6 27.2 5.23 6.49 
3 1.53 1.37 24.2 26.7 6.29 6.23 
4 1.67 1.47 20.0 21.8 6.44 6.36 
5 30.83 18.49 18.2 21.1 5.00 5.87 
6 7.66 7.56 16.9 24.3 5.16 6.18 
7 2.08 1.92 17.3 23.6 4.48 6.06 
8 85.72 69.51 19.5 29.0 5.83 6.05 
E (SO t..Lg) l 1.63 1.59 17.7 18.9 4.93 5.24 
2 1.46 1.43 19.2 23.7 5.97 5.86 
3 1.48 1.40 21.6 21.7 5.21 6.46 
4 1.54 1.34 22.2 21.9 6.14 6.50 
5 2.84 1.95 22.5 23.8 4.96 6.47 
6 1.46 1.38 31.0 28.6 4.65 5.39 
M (50 t..Lg) 1 1.77 1.63 18.0 22.2 4.95 5.48 
2 1.74 1.50 24.5 27.3 6.73 4.70 
3 1.97 1.40 25.4 26.8 5.71 5.65 
4 1.55 1.42 18.7 21.7 5.70 6.57 
5 2.10 1.49 20.4 23.9 5.61 6.47 
6 2.08 1.58 22.0 23.5 5.72 6.12 
7 1.43 1.44 22.4 26.3 5.76 5.80 
8 3.09 2.13 24.4 25.0 5.66 5.24 
•sALB/cJ mice were immunized i.d. with the indicated plasmid and dose as described in Materials and Methods.·E = 
pcDNA3.lzeo +alone, Hand M = pcDNA3.lzeo +containing the hTSHR and mTSHR eDNA insert respectively. Mice 
were boosted with the same amount of DNA 3 and 6 weeks postpriming. 
bTSHR-specific autoantibodies were detected in immunized mouse sera by flow cytometry as described in Materials 
and Methods. Results are expressed as the MCF ratio between GPI9-5 and CHOI cells. 
0JP09 cells were stimulated with immune mouse serum (I: 10) for 2 hours, and total cAMP was measured as described 
in Materials and Methods. 
dAn RIA kit was used for TT4 determination as described in Materials and Methods. 
"Values greater than control mean + 3SD were considered positive and are represented in bold typeface. 
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BALB/cJ mice against the antigen (TSHR) encoded in the plasmid vector. Nonetheless, 
the antibodies produced against the TSHR lacked biological activity since the TT4 levels 
in these mice remained normal. Moreover, a stronger immune response was observed 
following immunization with the heterologous rather than the homologous TSHR, based 
on the larger proportion of mice producing TSHR antibodies (50%), as well as the higher 
GPI9-5/CHO 1 MCF ratios. 
To test whether an increase of the immunizing DNA dose would enhance the 
immune response (i.e. induce TSHR-Ab in a larger proportion of mice) against the 
homologous TSHR, BALB/cJ mice were challenged with 5x more 
pcDNA3.1zeo+/mTSHR (50 J...lg) per immunization. As shown in Table 3.1 , none of the 
mice produced antibodies that could bind to the hTSHR-ECD expressed on CHO cells 
(GPI9-5 cells), correlating with the lack ofTSAb activity and the presence of normal TT4 
serum levels and normal thyroid size and histology. 
3.3.8 Attempts to modulate the immune response through co-delivery of cytokine 
plasmid vectors 
Several research groups have used plasmid DNA encoding various cytokines to 
enhance or bias the immune response generated by DNA vaccination (reviewed in 
Gurunathan et al. 103) . In an effort to bias the immune response toward a Th2 response and 
promote Ab production, BALB/cJ mice were co-injected with plasmid DNA containing 
the mTSHR eDNA insert together with the plasmid encoding the miL-4 cytokine. 
Surprisingly, none of the mouse sera contained TSHR-specific antibodies, detectable 
TSAb activity, or elevated TT4levels (Table 3.2). Histologic examination of the thyroids 
also appeared normal (data not shown). Similar results were obtained while attempting to 
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Table 3.2 Effect ofmiL-4 cytokine co-delivery on TSHR-specific Ab production and 
thyroid function in BALB/cJ mice 
Antigen Mouse GPI9-S/CH01 MCF cAMP (pmol/ml)< TT4 (J.1g/dl)d 
(Dose)" No. Ratiob 
W8 WJO W/2 W8 W/0 W12 W8 W/0 W/2 
M (SO 11g) 1 1.77 1.63 18.0 22.2 4.95 5.48 
2 1.74 1.50 24.5 27.3 6.73 4.70 
3 1.97 1.40 25.4 26.8 5.71 5.65 
4 1.55 1.42 ND 18.7 21.7 ND 5.70 6.57 ND 5 2.10 1.49 20.4 23.9 5.61 6.47 
6 2.08 1.58 22.0 23.5 5.72 6.12 
7 1.43 1.44 22.4 26.3 5.76 5.80 
8 3.09 2.13 24.4 25.0 5.66 5.24 
M (SO 11g) 1 2.09 1.45 27.3 22.5 7.01 6.05 
+ 2 2.03 1.58 33.4 23.3 6.14 6.39 
IL-4 (SO 11g) 3 2.02 1.42 17.1 24.3 5.74 6.50 
4 1.67 1.41 ND 20.6 20.0 ND 6.23 6.48 ND 
5 1.50 1.55 17.7 24.9 4.67 5.86 
6 1.56 1.65 19.2 22.7 4.56 6. 18 
7 1.69 1.48 17.4 23.0 4.48 5.86 
8 1.67 1.60 21.4 23.9 5.96 6.54 
E (50 11g) 1 1.40 1.82 2.08 20.7 36.5 36.2 5.90 5.09 5. 11 
+ 2 1.51 1.70 2.07 19.1 35.3 34.7 6.25 5.50 5.86 
IL-4 (SO 11g) 3 1.42 1.76 1.64 21.4 31.0 29.3 6.17 5.93 6.3 1 
4 1.40 1.69 1.79 21.3 33.9 34.0 5.43 6.51 5.2 1 
5 1.45 1.55 2.37 27.8 31.2 31.9 6.14 5.85 5.37 
6 1.37 1.58 1.86 29.5 36.1 37.2 6.15 5.19 5.94 
7 1.18 1.48 1.64 24.5 37.8 36.2 6.10 5.15 6.17 
H (SO 11g) I 6.46 21.02 10.05 20.6 49.5 38.6 5.36 5.48 5.33 
2 6.40 26.33 11.98 24.7 34.5 31.0 13.49 13.40 11.12 
3 10.96 56.64 22.69 17.5 30.8 28.0 6.36 6 .11 6. 19 
4 1.52 1.67 2.26 18.3 25.7 20.3 6.13 5.31 4 .74 
5 1.07 1.28 1.69 20.3 24.2 24.6 6.01 5.58 4.93 
6 38.62 27.5 9.80 
7 10.24 30.69 34.8 22.1 7.73 16.21 
8 1.56 1.95 2.40 30.5 30.5 22.7 5.06 5.06 4.38 
H (50 11g) I 1.78 1.34 2.55 30.7 32.7 21.9 5.51 5.38 4.72 
+ 2 1.32 1.78 2.34 28.1 36.1 26.0 4.41 4 .50 5.23 
IL-4 (SO 11g) 3 1.82 2.23 2.42 23.5 27.7 31.4 5.60 4.72 4.27 
4 1.36 2.16 2.17 24.5 23.8 26.2 6. 15 5.74 5.56 
5 1.51 1.91 2.09 25.3 22.6 26.4 5.53 5.76 5.90 
6 1.81 1.62 1.94 26.4 22.1 18.0 5.54 5.26 5.60 
7 1.73 3.16 2.85 31.3 20.3 18.0 6.28 6.52 6.47 
•sALB/cJ mice were immunized i.d. with the indicated plasmid and dose as described in Materials and Methods. E = 
pcDNA3.1 zeo +alone, H, M, and IL-4 = pcDNA3.1zeo + containing the hTSHR, mTSHR, and miL-4 eDNA insert 
respectively. Mice were boosted with the same amount of DNA 3 and 6 weeks postpriming. 
bTSHR-specific autoantibodies were detected in immunized mouse sera by flow cytometry as described in Materials 
and Methods. Results are expressed as the MCF ratio between GPI9-5 and CH01 cells. 
cJP09 cells were stimulated with immune mouse serum (I : 10) for 2 hours, and total cAMP was measured as described 
in Materials and Methods. 
dAn RIA kit was used for TT4 determination as described in Materials and Methods. 
•values greater than control mean + 3SD were considered positive and are represented in bold typeface. 
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enhance the immune response through co-injection of pcDN A3 .1 zeo + /m TSHR together 
with pcDNA3.lzeo+ containing the miL-2 gene (Table 3.3). Based on these results, as 
well as those obtained in the previous experiment, it appears that mice immunized with a 
high dose ofpcDNA3.1zeo +/mTSHR are not induced to respond against the self-antigen 
regardless of co-delivery of cytokine vectors. 
Experiments based on co-delivery of cytokine vectors were also performed using 
the heterologous hTSHR, and because the larger dose (50 j..tg of DNA/immunization) of 
pcDNA3.1zeo+/hTSHR had not been tested in the previous experiment, BALB/cJ mice 
were also immunized with 50 j..tg ofpcDNA3.1zeo+/hTSHR alone. Interestingly, 
immunization with the larger dose ofpcDNA3.1zeo+lhTSHR, not only induced TSHR-
antibody production in a larger proportion of mice (62.5 %, week 8), but 3 of these mice 
(mouse no. 2, 6, and 7) exhibited elevated TT4 levels (Table 3.2). The TT4 levels for 
mouse no. 7 in week 10, for example, almost exceeded 3x the normal range ( 16.21 j..tg/dl 
compared to 5.09-6.51 j..tg/dl). Unfortunately, 2 ofthe 3 thyrotoxic mice died following 
blood collection in week 8 (mouse no. 6) and week 10 (mouse no. 7) and therefore no 
data was obtained for these mice in subsequent weeks. However, antibody detection and 
elevated TT4 levels in the remaining hyperthyroid mouse (no. 2) persisted for the 
duration of the experiment (12 weeks). In addition, thyroid glands from 2 of the 3 
thyrotoxic mice (mouse no. 2 and 7) showed marked hypertrophy (Figure 3.9A and C 
respectively) and exhibited follicular hyperplasia and thyrocyte hypercellularity (Figure 
3.9D, F, G, and I) compared to control thyroids (Figure 3.9B, E, and H). Yet the marked 
increase in serum TT4 in 3 of the 8 BALB/cJ mice immunized with pcDNA3.1zeo +; 
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Table 3.3 Effect of miL-2 cytokine co-delivery on TSHR-specific Ab production and 
thyroid function in BALB/cJ mice 
Antigen Mouse GPI9-5/CH01 MCF cAMP (pmol/mlt TT4 (!J.g/dl)d 
(Dose)" No. - - -----=Ra=t·=-=·o_b ___________________ __ _ 
E (50 J.Lg) 
+ 
IL-2 (50 !J.g) 
H (50 !J.g) 
+ 
IL-2 (50 !J.g) 
M (50 !J.g) 
+ 
IL-2 (50 !J.g) 
1 
2 
3 
4 
5 
6 
7 
8 
1 
2 
3 
4 
5 
6 
7 
8 
1 
2 
3 
4 
5 
6 
7 
8 
Week 8 Week 10 Week 8 Week 10 Week 8 
1.13 1.24 22.7 20.1 6.30 
1.04 1.28 21.0 26.3 6.29 
1.10 1.13 17.0 25.1 6.17 
1.10 1.22 15.4 26.5 5.73 
1.16 1.26 17.3 19.4 5.88 
1.05 1.10 16.8 18.7 4.96 
1.17 1.24 19.2 24.5 5.88 
1.05 1.37 21.6 21.1 5.59 
1.13 1.12 24.3 32.3 5.70 
1.27 1.36 22.4 22.7 6.70 
1.28 1.31 17.3 24.0 6.98 
1.16 1.17 18.1 20.4 5.59 
1.88 1.28 20.3 16.1 6.81 
1.18 1.04 18.2 16.8 6.35 
1.15 1.07 16.7 18.5 6.22 
1.09 1.10 22.9 22.9 6.03 
1.33 l.l8 28.3 28.5 6.50 
1.12 1.12 22.2 27. 1 6.52 
1.11 1.08 22.1 29.2 5.82 
1.14 19.0 5.68 
1.54 1.14 23.1 29.9 6.47 
1.15 1.09 22.0 29.9 6.03 
1.43 1.03 18.1 26.7 5.13 
0.75 0.85 22.5 28.4 5.98 
Week TO 
6.03 
6.05 
6.17 
6.43 
5.89 
6.44 
5.79 
5.60 
6.54 
6.58 
6.11 
5.95 
5.89 
5.57 
6.07 
5.99 
5.99 
5.74 
6.10 
6.03 
5.88 
6.03 
5.91 
•sALB/cJ mice were immunized i.d. with the indicated plasmid and dose as described in Materials and Methods. E = 
pcDNA3.lzeo+ alone, H, M, and IL-2 = pcDNA3. lzeo+ containing the hTSHR, mTSHR, and miL-2 eDNA insert 
respectively. Mice were boosted with the same amount of DNA 3 and 6 weeks postpriming. 
bTSHR-specific autoantibodies were detected in immunized mouse sera by flow cytometry as described in Materials 
and Methods. Results are expressed as the MCF ratio between GP19-5 and CHO l cells. 
cJP09 cells were stimulated with immune mouse serum (l : 10) for 2 hours, and total cAMP was measured as described 
in Materials and Methods. 
dAn RIA kit was used for TT4 determination as described in Materials and Methods. 
•values greater than control mean + 3SD were considered positive and are represented in bold typeface. 
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Figure 3.9 Gross and histological examination ofBALB/cJ mouse thyroids following 
genetic immunization. Thyroid glands of control (B) and hyperthyroid mice (A & C) 
immunized with pcDNA3.1zeo+ alone (mouse no. 1, Table 3.1) or pcDNA3.l zeo+ 
containing the hTSHR eDNA insert (mouse no. 2 and 7, Table 3.2) respectively. 
Hematoxylin and eosin-stained methacrylate sections of thyroids from normal (E & H) or 
hyperthyroid (D, F, G, and I) mice (D-F, lOOOx; G-I, 2000x). Note the enlarged follicles 
(follicular hyperplasia) and the columnar shape of follicular cells with enlarged nuclei 
from hyperthyroid mice. 
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hTSHR and the gross and histological changes in 2 of these 3 thyrotoxic thyroids, did not 
correlate with TSAb activity (Table 3.2). The serum obtained from 
mouse no. 1 within the same group, however, stimulated JP09 cells to produce 
significantly higher cAMP concentrations (49.5 pmoVml) than sera from control mice 
previously immunized with the empty vector and pcDNA3.lzeo +/miL-4 (control mean+ 
3SD = 42.4 pmol/ml). Unfortunately, this TSAb activity was only detected in week 10 
and also did not correlate with elevated T4 levels. 
Encouraged by these results, we proceeded to co-inject BALB/cJ mice with the 
same dose of pcDNA3.lzeo + lhTSHR together with pcDNA3.1zeo +encoding miL-4 
cytokine. Co-delivery of pcDNA3.1 zeo + lhTSHR together with pcDNA3.1 zeo + /miL-4, 
however, did not induce hyperthyroidism or goiter in any mice. Only a few mice 
produced antibodies specific for the TSHR, and those that did had GPI9-5/CHO l MCF 
ratios only slightly above MCF ratios obtained from mice immunized with the empty 
vector and pcDNA3.lzeo+/miL-4. Moreover, mice that were positive for TSHR 
antibodies in week 8 were not necessarily positive in week 10 and 12 and vice versa 
(Table 3.2). Comparable results were obtained when BALB/cJ mice were co-injected 
with pcDNA3.lzeo+lhTSHR and plasmid encoding miL-2 (Table 3.3). These results do 
not support previous findings that co-delivery of cytokine-encoding DNA can enhance or 
bias the immune response generated by DNA vaccination127-132• 
3.3.9 TSHR-specific antibody production in AKR/J mice following i.d. 
immunization with pcDNA3.1zeo+lhTSHR 
To test whether intradermal DNA immunization with pcDNA3.1 zeo + lhTSHR could also 
induce hyperthyroidism in a different mouse strain, AKR/J (H-2k) mice were immunized 
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3x with 50 J.Lg ofpcDNA3.lzeo+/hTSHR. As shown in Table 3.4, four out of the seven 
(57%) immunized mice (mouse nos. 3, 4, 5, and 7) were consistently positive for TSHR-
specific antibodies in week 8, 10 and 12. Two additional mice (nos. 2 and 6) were 
positive in week 10 only, but their GPI9-5/CH01 ratios were only marginally higher 
(1.87 and 1.99) when compared to control mice (control mean+ 3SD = 1.80). None of 
the mice contained TSAb activity in their sera, although the TT4level of one mouse (no. 
6) was significantly higher (3.79 J.Lg/dl) in week 10 than the normal range (1.81-2.97 
J.Lg/dl). However, unlike BALB/cJ mice where elevated TT4levels corresponded with 
thyroid hypertrophy, follicular hyperplasia, and thyrocyte hypercellularity, gross and 
histological analysis of the thyroid obtained from this thyrotoxic mouse (no. 6), was 
comparable with control mouse thyroids (data not shown). This was not surprising since 
at the time of thyroid removal (week 12); mouse no. 6 was no longer thyrotoxic. These 
results confirm that a humoral immune response against the TSHR molecule can also be 
induced in a different MHC haplotype (H-2k) following intradermal DNA immunization 
with pcDNA3.lzeo+!hTSHR. However, AKR/J mice appear less susceptible to 
hyperthyroidism than BALB/cJ based on the lower proportion of mice (1/7 versus 3/8) 
with elevated TT4levels, as well as the lack of gross and histological features of thyroid 
hyperactivity. 
Efforts to modulate the immune response through co-delivery of cytokine-plasmid 
vectors were also examined in AKR/J mice. Sera from 3 out of the 7 AKR/J mice (mouse 
nos. 1, 2 and 4) co-injected with pcDNA3.l zeo +/hTSHR and pcDNA3.l zeo +/IL-4 
contained antibodies that recognized the TSHR-ECD expressed on CHO cells (GPI9-5) 
76 
Table 3.4 TSHR-specific Ab production and thyroid function of AKR/J mice following 
i.d. DNA immunization with pcDNAzeo+lhTSHR alone or together with 
QCDNA3.lzeo +/miL-4 
Antigen Mouse GPI9-5/CH01 MCF cAMP (pmol/ml)c TT4 (J.lg/dl)d 
(Doset No. Ratiob 
W8 WJO W12 W8 WJO Wl2 W8 W/0 W/2 
E (50 !lg) 1 1.55 1.44 3.48 35.3 27.1 32.5 2.64 2.64 2.76 
+ 2 1.69 1.41 2.13 31.4 27.2 35.2 2.37 1.81 2.19 
IL-4 (50 f.lg) 3 1.13 1.48 2.23 30.7 24.6 27.6 2.74 2.97 2.25 
4 1.50 1.68 2.42 26.5 36.8 29.6 2.49 2.36 3.64 
5 1.60 1.52 2.51 26.9 27.9 34.7 2.22 2.19 1.86 
6 1.87 1.61 2.34 31.6 29.7 34.1 2.72 2.54 2.27 
7 1.69 1.47 1.48 30.1 25.3 30.4 2.30 2.36 2.7 1 
8 1.72 1.38 1.82 38.6 27.7 36.1 1.75 2.14 2.48 
H (50 1-1g) 1 1.68 1.40 1.76 32.9 31.3 40.7 2.30 2.74 3.45 
2 1.57 1.87 2.32 33.5 32.7 39.3 2.29 2.92 2.57 
3 4.84 28.25 10.26 32.5 36.1 35.8 2.35 2.41 2.63 
4 9.78 37.01 16.52 38.0 38.7 31.5 2.46 2.80 2.95 
5 2.30 3.41 4.53 39.8 35.5 37.8 2.69 2.98 3.34 
6 1.62 1.99 3.16 40.9 27.5 39.3 2.55 3.79 3.35 
7 3.46 27.74 7.26 39.2 30.4 37.4 2.41 2.29 2.63 
H (50 f.lg) 1 2.64 1.64 1.95 36.3 27.6 36.8 3.42 2.59 2.80 
+ 2 5.14 34.51 43.1 32.0 3.20 1.84 
IL-4 (50 J.lg) 3 1.81 1.24 2.03 36.4 27.9 24.0 2.24 1.99 3.53 
4 3.91 8.17 5.37 39.3 35.5 26.4 3.11 3.09 2.89 
5 
6 1.82 1.92 2.01 41.4 33.5 38.4 3.35 2.71 2.72 
7 2.21 1.92 2.28 36.9 37.9 27.2 3.32 2.89 2.99 
8 1.54 1.45 2.04 37.1 33.3 31.6 3.18 2.91 2.7 1 
•AKR/J mice were immunized i.d. with the indicated plasmid and dose as described in Materials and Methods. E = 
pcDNA3.1zeo+ alone, Hand IL-4 = pcDNA3.Izeo+ containing the hTSHR and miL-4 eDNA insert respectively. Mice 
were boosted with the same amount of DNA 3 and 6 weeks postpriming. 
~SHR-specific autoantibodies were detected in immunized mouse sera by flow cytometry as described in Materials 
and Methods. Results are expressed as the MCF ratio between GPI9-5 and CH01 cells. 
cJP09 cells were stimulated with immune mouse serum (I :10) for 2 hours, and total cAMP was measured as described 
in Materials and Methods. 
dAn RIA kit was used for TT4 determination as described in Materials and Methods. 
evalues greater than control mean+ 3SD were considered positive and are represented in bold typeface. 
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in week 8 (Table 3.4). One of these 3 mice (no. 1) also had elevated serum TT4 (3.42 
j.tg/dl) the same week, but this elevation did not persist through week 10 and 12, nor did 
the antibody response. The other two mice, however, maintained antibody production 
against the TSHR in week 10, but because mouse no. 2 died following blood collection in 
week 10, only serum from mouse no. 4 was confirmed to contain TSHR antibodies in 
week 12. Two additional mice (nos. 6 and 7) were positive for TSHR-specific antibodies 
in week 10 only, but only marginal difference between GPI9-5/CH01 ratios ofthese 
mice (1.92 and 1.92) and control mice (control mean+ 3SD = 1.80) was observed. None 
of the mice, regardless of antibody production or elevated TT4 exhibited gross or 
histological thyroid features indicative ofhyperactivity. These results do not support the 
concept that co-delivery ofmiL-4 DNA with TSHR-encoding plasmid alters the immune 
response to TSHR in AKR/J mice. 
3.4 DISCUSSION 
Genetic immunization with naked plasmid DNA was developed primarily to 
induce protective immunity, especially against infectious pathogens (i.e. malaria and 
HIV) and cancer for which, to date, there are no available safe and effective vaccines103 . 
Vaccination with naked DNA has also been used to protect animals from developing 
autoimmune disease97"101;170• Here we have used DNA immunization in an attempt to 
abrogate self-tolerance and induce an autoimmune response against TSHR, the known 
autoantigen in Graves' disease, in an effort to develop an animal model for this disease. 
Very few BALB/cJ mice(< 20%) produced autoantibodies specific for the TSHR 
molecule following i.d. DNA immunization with pcDNA3.1zeo+ encoding the 
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homologous (murine) TSHR, regardless of antigen dose (Table 3.1) or co-delivery of 
cytokine-vectors (Table 3.2 & 3.3). Moreover, mice that were positive for TSHR-specific 
antibodies, exhibited only slightly higher GPI9-5/CH01 MCF ratios than the control 
MCF ratio+ 3SD. Whether antibodies were produced in a larger proportion of these mice 
and just not detected because the cells used to detect TSHR antibodies expressed 
heterologous (human) TSHR-ECD remains unclear. Studies using recombinant mTSHR 
as the immunogen, however, have shown that murine TSHR-specific autoantibodies 
inhibited up to 78% of the binding of labeled TSH to native hTSHR, indicating mTSHR-
specific autoantibodies are capable ofbinding to heterologous TSHR molecules67 . The 
lack ofTSAb or elevated T4levels, together with normal thyroid size and histology in 
these mice suggests that DNA immunization with murine TSHR was unable to abrogate 
self-tolerance. Interestingly, tolerance to the mTSHR was broken following i.p. injection 
ofmitomycin-C-treated M12 cells expressing native mTSHR80• Mice developed most of 
the symptoms of Graves' disease including TBII, TSAb activity, elevated T4 levels, and 
mild lymphocytic infiltration. Differences in the immunization route and antigen form 
used most likely contribute to these conflicting findings. 
Several studies have used DNA immunization to protect or ameliorate 
autoimmune disease induction in animals. Ruiz, et al.99, for example showed that 
immunization of SJL/J mice with DNA encoding the encephalitogenic residues of myelin 
proteolipid protein, PLPt39-tsJ , delayed onset of disease, and reduced mean peak disease 
severity and mean disease score following subsequent induction ofEAE with PLPt39- tst 
and CF A. The exact mechanisms behind the protection afforded by DNA vaccination are 
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unclear, but may involve generation of antigen-specific regulatory cells or induction of 
anergy in autoreactive T cells. Perhaps, the immune response to a DNA vaccine encoding 
self Ag is different from what is observed with DNA vaccination to foreign Ags. 
On the other hand, when BALB/cJ and AKR/J mice were immunized 3x with 
varying doses ofpcDNA3.lzeo+ encoding a heterologous TSHR (hTSHR), between 50 
and 60% of the mice developed antibodies that recognized GPI-anchored hTSHR-ECD 
expressed on CHO cells (Table 3.1, 3.2, and 3.4). These results are comparable to those 
obtained in a previous study where sera from 3/5 (60%) BALB/cJ mice immunized 
intramuscularly with pcDNAIII containing the hTSHR gene insert, recognized native 
TSHR by F ACS analysis83. Pre-treatment of the muscle with cardiotoxin or immunizing 
mice with the vector prepared in a 25% sucrose solution induced antibodies in 4/4 and 
4/5 mice respectively. Notably, twice as much DNA (1 00 f..lg) was injected 
intramuscularly; and JP09 cells, known to express 90 000 hTSHR/cell145 were used to 
detect antibodies. In another study, the same intramuscular immunization regime did not 
generate TSHR-specific antibodies in BALB/c or AKR/J mice as assessed by flow 
cytometry, even when using CHO cells which express ~20 x greater number hTSHR 
molecules ( ~ 2 x 106 TSHR/cell) than JP09 cells85• The authors speculated that the 
conflicting data were a result of the different breeding colonies or the pathogen-free 
animal facility used to house the mice85• In both studies, no changes to thyroid hormone 
levels were observed following intramuscular immunization. In contrast, we were able to 
induce consistent hyperthyroidism, with TT4 values as high as 16.21 J.tg/dl (normal 
range: 5.09-6.51 J.tg/dl), in 3 of the 8 BALB/cJ mice immunized with the higher dose (50 
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J.Lg/immunization) ofhTSHR eDNA (Table 3.2). In addition, thyroid glands from two of 
these mice showed marked hypertrophy (Figure 3.9A & C), and histological examination 
revealed follicular hyperplasia and thyrocyte hypercellularity indicative of thyroid 
hyperactivity (Figure 3.9D, F, G, I). However, unlike Costagliola who observed signs of 
thyroiditis in 14 immunized BALB/cJ mice83, no lymphocytic infiltration was seen in the 
thyroids of thyrotoxic mice or any other mouse that remained euthyroid. 
For many years, it has been clear that two types of functional TSHR 
autoantibodies exist in Graves' disease patients: TSAb that activate the TSHR and cause 
hyperthyroidism, and TSBAbs that block TSH binding and action, thereby causing 
atrophic hypothyroidism6. Clearly in GD patients the relative amounts or affinities of 
these two types of autoantibodies determine the net biological effect on thyroid cell 
function. In addition, evidence exists for the presence of neutral TSHR autoantibodies in 
GD patients, which neither activate the TSHR nor block ligand action4• Despite the 
induction of hyperthyroidism in 3 BALB/cJ mice following i.d. immunization with 
pcDNA3.lzeo+lhTSHR, none ofthe mice exhibited detectable TSAb activity. Perhaps the 
inability to detect TSAbs in these hyperthyroid mice has to do with the delicate balance 
between these different types of TSHR autoantibodies. In other words, TSAb may very 
well be present in the sera of these thyrotoxic mice, but their actions are masked or 
prevented by the presence and actions of TSBAb and neutral TSHR autoantibodies. We 
cannot, however, exclude the possibility that TSAb were not detected in these mice for 
other, technical reasons such as the cell line used, sera dilution, incubation period, and 
culture conditions. It was difficult to establish optimal assay conditions based on previous 
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literature because of the enormous variation of assay conditions among various studies. 
The most common bioassay for measuring TSAb activity today uses TSHR-expressing 
CHO cells. Yet, different groups use different cell lines (i.e. 5'3 'TR-ECE, JP09, and 
JP26) all of which express varying numbers of receptors/cell. In 1999, Wallaschofski et 
al. 171 found that CHO cells expressing higher TSHR numbers (JP09; 90 000 hTSHR 
molecules/cell) than normal thyroid epithelial cells are less sensitive in detecting TSHR 
autoantibodies from GD patients than CHO cells that express comparable numbers of 
TSHR (JP26; 2000 hTSHR molecules/cell). This decreased sensitivity was attributed to 
the high nonspecific stimulation by normal sera. We used JP09 cells to detect thyroid-
stimulating antibodies, seeding 40 000 cells per well of a 96-well plate overnight before 
the addition of diluted serum ( 1: 1 0). Other groups, using different cell lines, have 
detected TSAbs using pooled and protein A-purified IgG75;172, while others have detected 
stimulatory antibodies with neat sera diluted as low as 1:7077. We chose a serum dilution 
of 1 : 1 0 based on the study by Wallaschofski et al.171, however it remains to be 
determined whether TSAb would have been detectable had we purified IgG from the sera 
or used a higher or lower serum dilution. Nevertheless, our data clearly demonstrate 
thyroid hyperactivity based on gross and histological examination, as well as elevated 
TT4. Together, this data argue strongly in favour ofTSAb activity, even though we were 
unable to detect it. 
The inherent bias toward a Thl or Th2 response of a particular immunization 
method can sometimes be overcome. For instance, Prayaga, et al. 173 was able to reverse 
the Th2 immune response induced in nlice following epidermal gene gun delivery of 
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plasmid encoding HIV-1 gp120 or influenza nucleoprotein to a Thl-like response 
through co-administration ofplasmids encoding IL-2, IL-7 and IL-12. Cytokines play 
important roles in the immune and inflammatory responses as the initiators and regulators 
of the immune network. Interleukin-2, for example, is a Thl cytokine produced primarily 
by activated T cells, which plays a critical role in directing cell-mediated immune 
responses. Interleukin-4, on the other hand, is a Th2 cytokine, and plays an important role 
in the humoral immune response174• Several other groups have used plasmid DNA 
encoding various cytokines to enhance or bias the immune response generated by DNA 
vaccination (reviewed by Gurunathan, et al. 103). Co-administration ofDNA immunogens 
(i.e. HCV core protein, HIV envelope protein, or ovalbumin) with either IL-2 or IL-4 
cytokine genes, for example, has been shown to enhance T cell proliferative responses to 
the respective protein antigen in vitro, with cytokine profiles corresponding to Thl and 
Th2 phenotypes respectively127• Enhancement of overall antibody production in mice was 
also demonstrated, with a bias toward IgG2a and lgG 1 isotypes when the DNA 
immunogen was co-injected with IL-2 and IL-4 DNA expression constructs, 
respectivelyi03;127-I32. 
The fact that TSAb are of the lgG 1 isotype9 and intrathyroidallymphocytes of 
GD patients predominantly produce Th2 cytokines166, prompted us to examine whether 
co-delivery ofmiL-4-expressing vectors with TSHR-encoding plasmid DNA would bias 
the response to a Th2-type. Surprisingly, fewer BALB/cJ mice produced TSHR-specific 
antibodies following co-injection ofpcDNA3.lzeo+/hTSHR and pcDNA3.lzeo+/miL-4, 
and those that did had GPI9-5/CH01 MCF ratios only slightly greater than control MCF 
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ratios (Table 3.2) indicative of a weak immune response. In addition, none of the mice 
showed signs of hyperthyroidism (i.e. elevated TT4 or changes to thyroid architecture). 
Comparing the proportion of mice producing TSHR-specific autoantibodies as well as the 
fold-increase in GPI9-5/CH01 MCF ratios between experimental and control groups may 
not be the best approach to measure enhancement of an immune response. A more 
quantitative approach such as determining specific antibody titers using an ELISA might 
have been more reliable and would have enabled us to determine whether the immune 
response was biased toward a Th2-type by measuring the lgG2a:lgG 1 ratio frequently 
used to reflect Thl and Th2 immune responses. However, due to the inherent difficulties 
in obtaining appropriately folded TSHR protein, as discussed in Section 1.3.3, we chose 
to detect TSHR autoantibodies using CHO cells expressing native hTSHR-ECD. 
Collectively, our data do not support the view that co-injection ofhTSHR-encoding and 
IL-4-encoding plasmids augments the TSHR-specific response. Our attempts to enhance 
the immune response through co-delivery of miL-2 cytokine vectors also failed. Once 
again, fewer BALB/cJ mice produced antibodies specific for the TSHR following co-
injection with pcDNA3.1zeo+/hTSHR and pcDNA3.zeo+/miL-2 (Table 3.3), as compared 
to pcDNA3.lzeo+/hTSHR alone (Table 3.2), and those that did had low GPI9-5/CH01 
MCF ratios. 
It remains unclear why immunization ofBALB/cJ mice with hTSHR eDNA 
alone, but not in conjunction with cytokine-vectors can induce a strong humoral immune 
response against the TSHR, which sometimes resulted in hyperthyroidism. Perhaps the 
weaker immune response (as determined by GPI9-5/CH01 ratios) may be due to the 
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competition of plasmid uptake after challenge when a mixture of plasmid is used. Co-
expressing the TSHR gene together with a cytokine gene using a bicistronic plasmid 
vector may alleviate such competition if it exists. Further experimentation using a more 
quantitative approach to measure TSHR-specific autoantibodies may also give us a better 
understanding the effect cytokine co-delivery had on the immune responses in these 
mice. 
Overall, intradermal DNA immunization with larger doses ofpcDNA3.lzeo+ 
containing the heterologous, but not the homologous TSHR was an effective method to 
induce hyperthyroidism in a small proportion (37.5 %) ofBALB/cJ mice. Surprisingly, 
this was not enhanced through co-delivery of cytokine-vectors. These results confirm that 
hTSHR-specific autoantibodies produced in these mice can recognize determinants of the 
murine TSHR that stimulate the thyrocytes and cause thyroid hyperactivity. The lack of 
disease induction in all antibody-positive mice most likely reflects the delicate balance 
between different TSHR autoantibodies in vivo (i.e. TSAb, TSBAb, and neutral TSHR 
Ab ), an obstacle that will be difficult to overcome in future experiments when trying to 
induce hyperthyroidism in 1 00% of the mice. 
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CHAPTER FOUR 
AN ALGORITHM-BASED APPROACH FOR MAPPING A K-BINDING 
IMMUNOGENIC TSHR EPITOPES 
4.1 ABSTRACT 
Autoantibodies specific for the TSHR have a major aetiological role in Graves' 
disease. However, very little is known about the T cells that regulate TSHR autoantibody 
production or what epitopes they recognize. Using an algorithm-based approach, we 
identified 3 hTSHR peptides with Ak-binding potential. Two of these peptides, 
hTSHR438-449 and hTSHR716-731, corresponding to regions ofthe transmembrane and 
intracellular domains of the hTSHR molecule respectively, were synthesized and their 
immunogenicity and pathogenicity was tested in AKR/J (H-2k) mice. In vivo priming 
with either peptide led to moderate proliferative secondary LNC responses to each 
peptide in vitro and low levels ofiL-2 production. Peptide-specific serum lgG Abs were 
also induced following priming and boosting of mice with either peptide, confirming 
their immunogenicity. hTSHR438-449-specific proliferation was inhibited(~ 50%) in the 
presence of both anti-Ak and anti-Ek mAb confirming the predictive value of the 
algorithm used for identifying Ak-binding peptides. Peptide immunogenicity, however, 
did not correlate with pathogenicity, since neither peptide caused mononuclear cell 
infiltration of the thyroid. This lack of correlation may be due to the heterologous nature 
of the peptides or may be characteristic of the mouse strain used. Immunization of 
additional H-2k mouse strains, and adoptive transfer experiments should be carried out 
before the pathogenic potential of these peptides is ruled out. 
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4.2 INTRODUCTION 
Although it is well established that autoantibodies to the TSH receptor play a 
central role in the pathogenesis of GD, little is known about the T cells that regulate 
TSHR-specific autoantibody production. Recognition of the TSHR by T-helper (Th) cells 
in vivo must be carried out by T cell receptors (TCR) specific for TSHR peptides 
presented in the context of MHC class II molecules on autologous APCs. Identifying the 
T cell epitopes within the TSHR, the MHC molecule(s) involved in their antigen 
presentation, and the genes encoding TSHR-specific TCRs, would improve our 
understanding of the pathogenesis of autoimmune GD, and might facilitate development 
of specific immunosuppressive therapies. 
Among the different methods employed to map T -cell epitopes in autoantigens, 
the use of computerized algorithms is quite common. Carayanniotis and colleagues, for 
example, have mapped two pathogenic Tg epitopes using both the 'AMPHI' and 
'tetramer motif algorithms (reviewed in Carayanniotis et al. 175). Both peptides (p2494-
2510 and p2694-2711) induced strong secondaryproliferative responses in cultures of 
LNCs from EAT susceptible mice and lymphocytic infiltration in their thyroids. More 
recently, computer algorithms have been shown to predict peptide sequences that can 
bind to Ak and Ek molecules (reviewed in Nelson, et al. 176). The computer algorithm 
developed by Altuvia et al. 157, for example, was created by identifying common motifs of 
known A k_ or Ek -binding peptides. These motifs rely on unique features of the a.a. in 
each position, such as polarity, charge, size, and hydrophobicity. Preliminary data have 
87 
identified 5 new pathogenic T-cell epitopes from the mouse Tg sequence using this 
particular algorithm (G. Carayanniotis, unpublished data). 
The objective of my research was to use the same algorithm to scan the entire 
hTSHR molecule for peptides that may bind to Ak. Candidate peptides were then tested in 
AKR/J (H-2k) mice for their capacity to bind to A k and Ek molecules and induce T -cell 
and antibody responses, as well as for their ability to generate pathogenic T cells that 
infiltrate the thyroid gland. 
4.3 RESULTS 
4.3.1 Identification of potential A k-binding hTSHR peptides 
Potential A k-binding human TSHR peptides were identified using motifs A and 8 
(Table 2.2) from the computer algorithm described by Altuvia et al. 157• The 764 amino 
acid residues of the hTSHR molecule were scanned using the Network Protein Sequence 
analysis website and 26 peptides that fit motif A as well as 9 peptides that fit motif 8 
were identified (Table 4.1). Of these, 3 peptides contained partially overlapping and 4 
sequences contained completely overlapping A and 8 motifs (Table 4.2A & 8 ). Closer 
examination of these peptides revealed three distinct sequences corresponding to the 
extracellular, transmembrane, and intracellular domains of the native hTSHR protein. 
Peptides designated hTSHR79-94, hTSHR 438-449, and hTSHR716-731 (Table 4.3) 
were selected as sites of putative T-cell epitopes. The hTSHR79-94 was also identified 
when the mTSHR sequence was scanned using motif A and B (Table 4.4A & B). In 
addition, another Ak-peptide binding motif(D-X-X-[IL VN]-X-[EQ]-{HRK}-X-
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Table 4.1 Identification ofhuman TSHR sequence coordinates that fit Ak-binding motifs 
A and B from the computer algorithm described by Altuvia et al. 157 
Motif Peptide Coordinates8 hTSHR Sequence 
A 61-67 ETHLRTI 
86-92 DVTLQQL 
105-111 HIEIRNT 
124-130 ELPLLKF 
135-141 NTGLKMF 
178-184 ETL TLKL 
210-216 NKYLTVI 
235-241 QTSVTAL 
289-295 QKKIRGI 
360-366 EDEIIGF 
374-380 QEETLQA 
375-381 EETLQAF 
394-400 EDMVCTP 
432-438 NVFVLLI 
443-449 HYKLNVP . 
506-512 ELSVYTL 
573-579 DTETPLA 
575-581 ETPLALA 
601-607 HVKIYIT 
617-623 DKDTKIA 
650-656 NKPLITV 
658-664 NSKILL V 
674-680 NPFL Y AI 
686-692 QRDVFIL 
718-724 DIQVQKV 
722-728 QKVTHDM 
B 41-45 CKDIQ 
82-86 YVSID 
86-90 DVTLQ 
319-323 NSPLH 
443-447 HYKLN 
474-478 DLYTH 
483-487 NHAID 
718-722 DIQVQ 
722-726 QKVTH 
aCoordinates correspond to published a.a. positions within the mature hTSHR polypeptide including the signal 
sequence25. 
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Table 4.2A Prediction of1-Ak-binding T-cell epitopes within the human TSHR using 
partially overlapping A and B motifs from Altuvia et al. 157 
Peptide Coordinates• hTSHR Sequence6 
82-92 YVSIDVTLQQL 
718-726 DIOVOKVTH 
718-728 DIQVOKVTHDM 
"Coordinates correspond to published a.a. positions within the mature hTSHR polypeptide including the 
signal sequence25• 
bSequences denoted by motif A and Bare underlined and represented in bold letters respectively. 
Table 4.2B Prediction ofi-Ak-binding T-cell epitopes within the human TSHR using 
completely overlapping A and B motifs from Altuvia et a1. 157 
Peptide Coordinates• hTSHR Sequence6 
86-92 DVTLOOL 
443-449 HYKLNVP 
718-724 DIQVQKV 
722-728 QKVTHDM 
•coordinates correspond to published a.a. positions within the mature hTSHR polypeptide including the 
signal sequence25• 
bSequences denoted by motif A and B are underlined and represented in bold letters respectively. 
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Table 4.3 hTSHR peptides chosen as sites of putative T cell epitopes 
Peptide Coordinates8 hTSHR Sequence6 
79-94 SRIYVSIDVTLQQLES 
438-449 ILL TSHYKLNVP 
716-731 STDIQV(QKVTHDM)RQG 
3Coordinates correspond to published a.a. positions within the mature hTSHR polypeptide including the 
signal sequence25• 
bSequences denoted by motif A are underlined or (bracketed), while sequences denoted by motif Bare 
represented in bold or striketiH=eHgh letters. 
91 
Table 4.4A Prediction of1-Ak-binding T-cell epitopes within the murine TSHR using 
partially overlapping A and B motifs from Altuvia et al. 157 
Peptide Coordinates8 mTSHR Sequence6 
82-92 YISIDATLQRL 
120-130 DALTELPLLKF 
"Coordinates correspond to published a.a. positions within the mature mTSHR polypeptide including the 
signal sequence63 • 
bSequences denoted by motif A and Bare underlined and represented in bold letters respectively. 
Table 4.4B Prediction ofi-Ak-binding T-cell epitopes within the murine TSHR using 
completely overlapping A and B motifs from Altuvia et a1. 157 
Peptide Coordinates8 mTSHR Sequence6 
86-92 DATLQRL 
120-126 DALTELP 
•coordinates correspond to published a.a. positions within the mature mTSHR polypeptide including the 
signal sequence63• 
bSequences denoted by motif A and Bare underlined and represented in bold letters respectively. 
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[STRQAG]) published by Fremont et al. 177 derived from features ofthe crystal structure 
of A k also identified the hTSHR sequence (hTSHR86-94) that corresponded to part of the 
hTSHR79-94 peptide. The fact that 2 different algorithms identified the same region of 
the hTSHR as a potential Ak-binding peptide, and that scanning the mTSHR sequence 
identified the same sequence coordinates that fits motif A and Bas the hTSHR sequence 
strongly suggests the potential importance of this peptide. Unfortunately, this peptide 
could not be synthesized due to technical problems in its quality control and was not 
included in this study. The hTSHR438-449 peptide, on the other hand is 92% 
homologous to the corresponding murine sequence63, differing by only 1 amino acid at 
position 447 (N ~ T) (Figure 4.1A). Unlike the hTSHR438-449 peptide sequence, which 
contains completely overlapping A and B motifs (Table 4.3), the corresponding mTSHR 
sequence only contains a sequence that fit motif A (mTSHR443-449) (data not shown). 
In contrast, the hTSHR716-731 peptide is only 56% homologous to its mouse counterpart 
(Figure 4.1 B), and despite the existence of 4 different sequences that fit motif A and B 
within the 16-mer peptide (Table 4.3), the corresponding murine sequence lacks the A or 
B motifs (data not shown). 
4.3.2 Immunogencity of hTSHR peptides 
To determine the imrnunogenicity of the hTSHR peptides, AKR/J mice (H-i) 
were challenged s. c. with 200 nmol ofhTSHR438-449 or hTSHR716-731 , and 9 days 
later, peptide-specific proliferative LNC responses were determined. As shown in Figure 
4.2, LNC from AKRJJ mice proliferated moderately to both hTSHR438-449 and 
h TSHR 716-731 peptides in vitro, exhibiting stimulation index (S.I.) values ;?: 2 when 
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(A) 
Human 
Murine 
(B) 
Human 
Murine 
(438-449) I L L T S H Y K L N V P 
(438-449) - - - - - - - - - T - -
(716-731) 
(716-731) 
S T D I Q V Q K V T H D M R Q G 
- - G - - I - - I P Q - T - - S 
Figure 4.1 Primary a.a. sequence ofhTSHR438-449 (A) and hTSHR716-731 (B) 
peptides and homologies with its murine counterpart. hTSHR438-449 and hTSHR716-
731 peptide sequences are 92% and 56% homologous to the corresponding murine 
sequence respectively. Identical a.a. between human and murine TSHR sequences are 
represented by a(-). Numbers indicate relative a.a. positions within the human and 
murine TSHR sequences. 
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Figure 4.2 Proliferative in vitro responses to titrating amounts of the indicated peptides of 
pooled LNC from AKR/J mice (two mice per group) s.c. primed 9 days earlier with 200 
nmol of either hTSHR438-449 (A) or hTSHR716-731 (B) peptide. Stimulation index is 
defined as CPM in the presence of antigen/CPM in the absence of antigen. Background 
cpms were between 963 and 1240. Murine Tg peptide p2495 (a.a. 2495-2503) was used as 
a non-specific peptide control. The data are representative of 2 experiments. 
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peptide concentrations were between 2 and 20 fJM. The responses were specific since no 
proliferation (S.I.::;; 2) was observed in cultures containing a control mTg peptide (a.a. 
2495-2503; LINRAKA VK). To ascertain the cytokine profiles ofT cells responding to 
hTSHR peptides, supernatants were collected from cultures of primed LNCs incubated 
with 15 fJM of the appropriate peptide. The supernatants were assayed for IL-2, IFN-y, 
IL-4, and IL-10 using a cytokine sandwich ELISA. As shown in Table 4.5, both peptides 
induced the production ofiL-2 from specific T cells, correlating with T-cell proliferation. 
IL-2 production, however, did not correlate with IFN-y production since IFN-y levels 
were less than the detection limit (62.5 pg/ml, Table 4.5). IL-4 and IL-10 were also not 
detected in the same supernatants. These results suggest that both hTSHR peptides are 
weak immunogens at the T -cell level. 
4.3.3 The hTSHR438-449 peptide is recognized by 1-A k and 1-Ek restricted T cells 
in proliferative assays 
To determine whether hTSHR peptides bind to 1-Ak or 1-Ek MHC class II 
molecules, a proliferation assay was performed in the presence of either anti-A k or anti-Ek 
mAbs. The functionality of both monoclonal Abs was verified by their ability to inhibit 
the proliferative responses ofi-Ak and 1-Ek restricted T cell hybridomas152 in a dose-
dependent manner (data not shown). As shown in Table 4.6, hTSHR438-449-specific 
proliferation of primed LNCs from AKRJJ mice was inhibited(~ 50%) in the presence of 
both anti-A k and anti-Ek rnA b. No significant blocking was observed in the presence of 
control mAb (HB65) specific for influenza A nucleoprotein. These data confirm the 
predictive value of algorithms used for identifying A k -binding peptides. Similar 
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Table 4.5 Cytokine production from primed AKR/J mouse LNCs in response to hTSHR 
peptide in vivo 
Peptide Cytokine Production (pg/ml)c 
in vivo8 in vitrob IL-2 IFN-y IL-4 IL-10 
hTSHR438-449 hTSHR438-449 
mTg (p2495-2503) 
26.7 
8.7 
<62.5 
<62.5 
hTSHR716-731 hTSHR716-731 17.0 <62.5 
mTg (p2495-2503) <7.8 <62.5 
"AKRIJ mice were s.c. immunized with 200 nmol ofthe indicated peptide in CFA. 
<7.8 
<7.8 
<7.8 
<7.8 
70.53 
79.72 
48.68 
54.72 
bLNCs obtained 9 days following priming mice were restimulated in vitro with 15 11M of the indicated 
peptide. 
cCulture supernatants were collected 48h later and assessed for the presence of cytokines using a sandwich 
ELISA. Data represent mean concentration values extrapolated from ELISA standard curves. Detection 
limits from the cytokine ELISA were as follows: IL-2 and IL-4 = 7.8 pglml, IL-10 = 15.6 pglml, and IFN-y 
= 62.5 pg/ml. 
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Table 4.6 Inhibition ofhTSHR438-449-specific LNC proliferation by various mAb in 
vitro 
Blocking mAb 
None 
Anti-IAk 
Anti-IEk 
Anti- influenza A NP 
In vitro proliferation ( cpm ± 
SDt 
6158 ± 1167 
2921 ± 575 
2812 ± 544 
5707 ± 755 
% Inhibition of 
Proliferation b 
0 
53 
54 
7 
3LNCs from AKR/J mice primed in vivo with 200 runol of the indicated peptide in CFA and 9 days later 
were cultured in vitro with 13.3 11M of the immunizing peptide and 10 11g/ml of the indicated mAb. 
Background cpm did not exceed 1200. 
bPercent inhibition of proliferation was calculated as described in Materials and Methods. 
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experiments were performed with the hTSHR716-731 peptide, however, complications 
with the TopCount NXT™ following the inhibition assay precluded data analysis. 
4.3.4 hTSHR peptides induce strong lgG responses in AKR/J mice but not thyroid 
lymphocytic infiltration 
An alkaline-phosphatase based ELISA was used to assess peptide-specific IgG in 
pooled sera (day 35) from 5-6 AKR/J mice primed (day 0) with hTSHR438-449 or 
h TSHR 716-731 peptide in CF A and boosted on day 21 with the same Ag in IF A. Both 
peptides induced moderate levels of peptide-specific IgG after 5 weeks (Table 4.7). Thus 
at the serological level, both hTSHR peptides are clearly immunogenic. To determine 
peptide pathogenicity, thyroids from the same mice were removed and histologically 
examined for mononuclear cell infiltration. Despite proliferative T -cell responses 
(Section 4.3.2) and antibody production, no lymphocytic infiltration was observed in any 
of the mice from either group (Table 4.7). 
4.4 DISCUSSION 
Although autoantibodies specific for the TSHR are the direct cause of 
hyperthyroidism in GD1' the initiation and/or the amplification of autoantibody 
production is largely T-cell dependent. In addition, thyroid glands ofGD patients contain 
infiltrating activated T lymphocytes. Thus, identifying the epitopes recognized by these T 
cells would not only improve our understanding of the pathogenesis of autoimmune GD, 
but would facilitate development of specific immunosuppressive therapies. Several 
diverse strategies have been used to map T -cell epitopes of various autoantigens. 
Computerized algorithms, for example, have helped identify two pathogenic Tg epitopes 
by selecting 
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Table 4.7 EAT and serum IgG responses in AKR/J mice challenged with hTSHR 
peptides 
Peptide• 
hTSHR 
438-449 
Infiltration Index 
0 1 2 3 4 5 
5 0 0 0 0 0 
hTSHR 6 0 0 0 0 0 
716-731 
Mice with 
EATb 
015 
0/6 
Serum IgG response (OD 405 nm) toe 
hTSHR hTSHR Murine 
438-449 716-731 lysozyme 
1:80 1:160 1:80 1:160 1:80 1:160 
0.576 0.428 ND ND 0.167 0.127 
NDd ND 0.941 0.504 0.245 0.133 
8AKR/J mice were primed and boosted with the indicated peptide as described in Materials and Methods. 
bDirect EAT induction was assessed by scoring thyroid mononuclear cell infiltration as described in 
Materials and Methods. 
cSpecific IgG was assessed by an alkaline-phosphatase based ELISA in pooled sera (collected 5 weeks 
from initial challenge) from each group, tested at the dilutions shown. Results are expressed as mean OD 
~ 405 nm) of triplicate wells. 
NO = not determined 
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peptides with physico-chemical and structural properties that enable their binding to 
MHC class II molecules151 ;156;178. Using an algorithm that predicts Ak and Ek-binding 
potential157, we have identified 2 immunogenic hTSHR peptides: hTSHR438-449 and 
hTSHR716-731. 
The 764 a.a. of the TSHR molecule is organized into three distinct regions, an 
extracellular domain of 398 amino acids, followed by the 264 amino acid transmembrane 
spanning domain, and an 82 amino acid intracellular carboxyl-terminal domain179. The 
two peptides used in this study, hTSHR438-449 and hTSHR716-731, corresponded to the 
transmembrane and intracellular domains respectively. Both peptides contained 
completely overlapping A and B motifs, and in the 16-mer (hTSHR716-731), more than 
one A and B motif were found (Table 4.3). 
The moderate peptide-specific in vitro proliferative response ofhTSHR438-449-
primed LNCs from AKR/J mice (Figure 4.2A), was inhibited in the presence of anti-A k 
monoclonal Ab (Table 4.6). These results indicate that this peptide is recognized by A k_ 
restricted T -cells and therefore highlight the value of this computer algorithm in 
identifying A k-binding peptides. Interestingly, the Ek -specific mAb similarly inhibited 
hTSHR438-449-specific LNC proliferation (Table 4.6), perhaps because this peptide can 
also be presented in the context of I-Ek. It is not uncommon for the same peptide to bind 
to both I-A and I-E molecules. For example, Balasa, et al. 178, blocked peptide-specific 
proliferative responses of rat LNC in vitro with mAbs specific for RTl-B (I-A 
equivalent) and RTl-D (I-E equivalent) antigens. Our result, however, was not expected 
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since the hTSHR438-449 peptide was not identified as a potential Ek-binder by the same 
computer algorithm of Altuvia, et al.157 (results not shown). 
Although both hTSHR peptides yielded stimulation indices (S.I.) > 3 when 
primed LNCs from AKR/J mice were incubated with 15 f.!M ofthe immunizing peptide 
(Figure 4.2A & B), only low levels of IL-2 were detected in the culture supernatants 
(Table 4.5). Thus, these results do not support the induction ofThl cells.during the 
immunization period despite the fact that CF A is known to elicit Thl cells. 
Despite the induction of proliferative T -cell responses (Figure 4.2) and specific 
IgG responses (Table 4.7), neither peptide induced thyroid lymphocytic infiltration 
(Table 4.7). This is not surprising since proliferative LNC responses do not always 
correlate with peptide pathogenicity. CBA mice, for example, mount strong proliferative 
T-cell responses to bTg, but bTg is not pathogenic in this strain180. In contrast, some Tg 
peptides, such as rTg (2499-2507), directly elicit weak EAT but appear nonimmunogenic 
by proliferation assays152. Also, peptides that do not directly induce proliferative LNC 
responses or thyroid pathology are nevertheless known to mediate EAT by adoptive 
transfer of peptide-specific LNC into naive hosts181 . This protocol usually leads to 
consistent EAT induction and a more severe lymphocytic infiltration of the thyroid than 
direct challenge of mice with peptide in adjuvant. Thus, the lack of EAT induction after 
direct challenge of mice with either hTSHR peptides does not exclude their pathogenic 
potential. Unfortunately, time constraints prevented us from testing EAT induction by the 
adoptive transfer method. 
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Other factors such as the genetic environment of the host and the heterologous 
nature of the hTSHR peptides may have also contributed to the lack of peptide 
pathogenicity. Ideally, peptide screening should be simultaneously tested in mice of 
several MHC haplotypes. Besides the fact that the algorithm used in this experiment 
selects A k-binding peptides, we chose AKR/J mice because the H-2k haplotype is known 
to be susceptible to EAT induction182• Moreover, TSAb have been induced in AKR mice 
following immunization with fibroblasts stably expressing hTSHR and MHC class II 
molecules, which correlated with elevated T 4 levels, indicating this strain is also 
susceptible to hyperthyroidism. Nevertheless, we cannot exclude the possibility that these 
peptides could be pathogenic in other H-2k mouse strains (i.e. C3H, CBA, or BALB/K), 
or in mice of other MHC haplotypes. Similarly, a.a. differences between heterologous 
hTSHR peptide sequences and corresponding mTSHR sequence may have abolished the 
peptides pathogenic properties. Evidence supporting this idea was shown when human T g 
peptides, highly homologous to rat pathogenic fragments were unable to induce EAT in 
mice 183• Amino acid differences between homologous and heterologous proteins may 
also prevent the detection of pathogenic peptides by an algorithmic approach or, 
conversely, identify peptides that are not pathogenic. 
In conclusion, the computer algorithm used in this experiment has been successful 
in identifying 2 immunogenic T -cell epitopes, one of which was shown to bind to A k and 
Ek molecules. Further experimentation with these peptides in different mouse strains and 
by adoptive transfer assays is required to properly assess their pathogenicity. 
103 
CHAPTER FIVE 
PROGRESS TOWARD IDENTIFICATION OF PATHOGENIC T CELL 
EPITOPES USING DNA IMMUNIZATION 
5.1 ABSTRACT 
EAT, an analogue of Hashimoto's thyroiditis in humans, is experimentally 
induced in mice by injection ofTg or Tg peptides emulsified in adjuvant. To date, five 
immunopathogenic Tg peptides have been identified. Diverse strategies have been 
employed to help identify other pathogenic Tg epitopes, all of which require the synthesis 
of peptides, which can be quite expensive. Immunization of mice with plasmid DNA 
encoding Tg gene segments can, in theory, induce EAT and identify larger pathogenic 
regions. If practical, this method would obviate the need for synthetic peptides as 
immunogens. Here, we designed DNA vectors encoding mTg fragments known to 
harbour one or several pathogenic T-cell epitopes. These vectors were used to transiently 
transfect APCs (T A3 and LS 1 02.9) that were subsequently tested for their capacity to 
present MHC class Il/peptide complexes to appropriate peptide-specific T cell 
hybridomas. None of the T cell hybridomas were activated when incubated with TA3 or 
LS 102.9 cells transiently transfected with pcDNA3.lzeo +encoding p2494 and p2694 
mTg peptides, or when transfected with plasmid DNA encoding the carboxyl terminus of 
mTg encompassing both pathogenic peptides. T cell hybridomas were, however, 
activated when transfected APCs were pulsed with the appropriate exogenous peptide. 
These results suggested that either the synthesis of peptides in the cytosol was inefficient, 
or that the peptides could not be targeted to the MHC class II pathway. 
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5.2 INTRODUCTION 
Murine EAT, an analogue of Hashimoto's thyroiditis in humans, is aT-cell-
mediated autoimmune disease that can be experimentally induced in mice by injection of 
Tg and adjuvant184. The evidence that Tg-mediated EAT is under H-2 control 185 and that 
Tg-specific T cells are responsible for disease suggests that the large Tg molecule harbors 
only a limited number ofthyroiditogenic peptides that can be recognized by MHC-
restricted T cells. To date, five immunopathogenic Tg peptides have been identified, none 
ofwhich appears to be immunodominant (reviewed in Carayanniotis et al. 175). Epitope 
mapping methodologies including the use of overlapping synthetic peptides or 
immunoenzymatic techniques are laborious, expensive and impractical when applied to 
autoantigens of high molecular mass, such as Tg (homodimeric mass= 660 kDa). 
Alternative mapping approaches based on computer algorithms have helped in the 
selection of peptides with physico-chemical and structural properties that enable their 
binding to MHC class II molecules. Although this approach has been successful on 
several occasions151 ;156;178, it still requires synthesis ofpeptides that can be quite 
expensive. Avoiding peptide synthesis altogether by immunizing mice with DNA 
encoding potential pathogenic peptides rather than the peptides themselves would not 
only cut the cost associated with peptide synthesis, but could identify larger pathogenic 
regions for further analysis. Several studies have prevented or suppressed experimental or 
spontaneous autoimmune disease induction in mice following immunization with DNA 
encoding the appropriate self-antigen97-101 • However, it has not been tested whether 
vaccination with DNA encoding a self-peptide will abrogate self-tolerance and lead to an 
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autoimmune response. If so, there will be important implications for mapping of disease-
causing T -cell epitopes in large self-proteins. This chapter describes the initial progress 
toward developing DNA vectors encoding murine Tg (mTg) fragments known to harbor 
one or several pathogenic T -cell epitopes, which will eventually be used for future mouse 
immunizations. 
5.3 RESULTS 
5.3.1 Sequencing of eDNA segments encoding murine p2494 and p2694 Tg 
peptides and the carboxyl terminus of murine Tg 
Murine Tg eDNA segments encoding pathogenic T cell epitopes were amplified 
using RT-PCR and subcloned into the multicloning site ofpcDNA3.lzeo+ mammalian 
expression vector as described in Materials and Methods (Section 2.5). The 
dideoxynucleotide chain termination method was used to sequence the eDNA inserts 
encoding murine p2494 (a.a. 2494-2510) and p2694 (a.a. 2694-2711) Tg peptides, and 
the carboxyl terminus of murine Tg. The nucleotide and derived amino acid sequence of 
each minigene are shown in Figure 5.1 (A, B, & C). Sequences were identical to the 
published mTg sequence153 with the exception of one nucleotide substitution from 
thymine (T) to cytosine (C) at position 8110 ofp2694 and mTg-carboxyl terminal 
nucleotide sequences (Figure 58 and 5C respectively). The nucleotide substitution did 
not result in an amino acid substitution. Artificial start and stop codons, as well as 
restriction enzyme sites remained intact. 
5.3.2 Transfection Efficiency ofTA3 and LS 102.9 APC Cells: Luciferase Assay 
The transfection efficiency of both TA3 and LS 102.9 antigen-presenting cell 
lines was determined using the luciferase reporter gene system. Celllysates ofT A3 or 
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Figure 5.1 Nucleotide and derived amino acid sequences of the eDNA encoding 
murine p2494 (A) and p2694 (B) Tg peptides and the carboxyl terminus ofmTg (C). 
Note the artificial start and stop codons (double underlined), as well as the Kpnl and Xbal 
restriction enzyme sites (underlined) introduced at the 5' and 3' ends of each eDNA 
insert to facilitate peptide transcription and translation and subcloning into 
peON A3 .1 zeo + mammalian expression vector respectively. Sequences were identical to 
the published murine thyroglobulin sequence with the exception of one nucleotide 
substitution from thymine (T) to cytosine (C) at position 8110 (*) ofp2694 and mTg-
carboxyl terminus nucleotide sequences. Sequence coordinates correspond to the 
published mTg sequence without the leader sequence. 
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(A) p2494 7480 
I 5'ggt ace gee ~ ggg ctt ate aat agg gca aag get gtg aag caa ttt gaa gag age caa 
G L I N R A K A V K Q F E E 5 Q 
7530 
ggt ~ tct aga 3' 
G 
(B) p2694 
* 5' ggt ace 
7480 
I 
gee~ tgc tee ttc tgg tee aag tac ate cag act ctg aag gat gca gat gga 
c 5 F W 5 K Y I Q T L K D A D G 
7530 
I 3' gee aag gat gca ~ tct aga 
A K D A 
(C) mTg-carboxyl terminus 
7480 
I S'ggt ace gee atg ggg ctt ate aat agg gca aag get gtg aag caa ttt gaa gag age caa 
G L I N R A K A V K Q F E E 5 Q 
ggc ega ace aac age aaa aca gee ttt tac cag gca ctg cag aat tea etc ggt ggt gag 
G R T N 5 K T A F Y Q A L Q N 5 L G G E 
gac tea gat gee cgc ate ctt get get get gta tgg tat tac tee ttg gag cac tee aca 
D 5 D A R I L A A A V W Y Y 5 L E H 5 T 
gac gac tat gee tee ttc tct egg gca ctg gag aat gee ace egg gac tac ttt ate ate 
D D Y A S F S R A L E N A T R D Y F I I 
tgt ccc atg gtc aac atg gee age etc tgg gca agg aga ace cgt gga aat gtc ttc atg 
C P M V N M A S L W A R R T R G N V F M 
tac cat gtc ccc gaa age tat ggc cat ggc age eta gaa ttg ctg gca gat gtt caa tat 
Y H V P E S Y G H G 5 L E L L A D V Q Y 
get ttt gga ctg ccc ttc tac tct gee tac cag ggc cag ttt tea acg gag gag cag age 
A F G L P F Y S A Y Q G Q F S T E E Q S 
ctg tee ctg aaa gtc atg cag tat tte tee aac ttc ate aga tea gga aat cct aac tac 
L 5 L K V M Q Y F S N F I R S G N P N Y 
cca cat gag ttc tea agg aag gca get gag ttt gee aca cct tgg cca gac ttt att cct 
P H E F S R K A A E F A T P W P D F I P 
gga get gga gga gag age tac 
G A G G E 5 Y 
gac tgc tee ttc 
D C S F 
aag 
K 
tgg 
w 
gag etc age gee cag ctt 
E L 5 A Q L 
tee aag 
S K 
tac 
y 
aaa caa 
K Q 
gee aag 
A K 
get 
A 
gat 
D 
gca cag tta ace aag agt gaa gag 
E 
ate cag 
I Q 
gaa gac 
E D 
act 
T 
ttg 
L A Q L T K S E 
CCC 
*p 
ctg 
L 
aat egg cag ggc etc 
N R Q G L 
aag gat gca gat gga 
K D A D G 
gaa gtt gga 
E V G 
gaa gaa gac etc tea ggc tea ctg gag cct gtc ccc aag age tac age aaa 
E E D L S G S L E P V P K S Y S K 
cct gga tta 
P G L 
tga U,g, .til 
z I 
.E.&.a 3' 8241 
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LS 102.9 cells transiently transfected with varying amounts of either pGL3-Basic or 
pGL3-Control vectors were mixed with luciferase assay reagent (substrate) and light 
intensity was measured using a luminometer. As shown in Figure 5.2 (A & B), cell 
lysates from both cell lines transiently transfected pGL3-Control, but not pGL3-Basic 
vectors contain the luciferase product based on its ability to produce light following the 
addition of luciferin substrate. The inability of pGL3-Basic transfected APCs to produce 
light following substrate addition was expected due to the lack of eukaryotic promoter 
and enhancer sequences that would allow luciferase expression in mammalian cells. A 
steady increase in light production (RLU) following the addition of substrate to T A3 cell 
lysates previously transfected with pGL3-Control was observed and corresponded to the 
increasing amounts ofDNA used to transfect the cells. These results confirm that TA3 
and LS 102.9 cells can be efficiently transfected with plasmid DNA. 
5.3.3 T Cell Activation Assay: Transiently transfected APC are unable to present 
peptide and activate peptide-specific T cell hybridomas 
The TA3 (1-A kid; 1-Ekld) or LS 102.9 (H-2A dis and H-Ed) APCs were transiently 
transfected with pcDNA3.lzeo +constructs containing eDNA inserts encoding the 
pathogenic T cell epitopes p2494 (a.a. 2494-2510) or p2694 (a.a. 2694-2711). The 
transfected cells were then examined for their capacity to synthesize and present these 
peptides in the context ofi-A k' 1-Ek, or l-As MHC class II molecules and activate 
appropriate peptide-specific T cell hybridomas. As shown in Figure 5.3 (A & B), all four 
T-cell hybridomas (4A2, 4A12, 5E8, and 6E10) were activated and produced IL-2 when 
incubated with non-transfected APCs (TA3 or LS 102.9) pulsed with their respective 
peptide. 4A2, 4Al2, and 5E8 T cells are 1-Ek, 1-Ak, and l-As-restricted T cell hybridomas 
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Figure 5.2 Luciferase gene expression in TA3 (A) and LS 102.9 (B) 
cells. Celllysates (20 J.l.l) from TA3 and LS 102.9 cells transiently 
transfected with either pGL3-Basic or pGL3-Control vectors (1, 2, or 3 
J.lg) were mixed with luciferin substrate, and light produced following the 
reaction between luciferase and luciferin was measured using a 
Monolight® 2010 luminometer. Results are expressed as means of 
duplicate± SD. 
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Figure 5.3 Transfected APCs are unable to activate peptide-specific T -cell 
hybridomas. TA3 (A) and LS 102.9 (B) cells (t05) transiently transfected with 
pcDNA3.lzeo+ containing minigenes encoding murine Tg peptides (p2494 and 
p2694) or the carboxyl-terminus of mTg were incubated with 1 o5 peptide-specific 
T-cell hybridomas (4A2, 4Al 2, 5E8, and 6El0). After 24 h, supernatants (1 00 f.!l) 
were tested for IL-2 production using a CTLL-2 bioassay (Section 2.9.4). 
Untransfected APCs and APCs transfected with pcDNA3.lzeo+ alone pulsed 
with specific and non-specific peptide were used as controls. Results are expressed 
as means of triplicates ± SD. 
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respectively, specific for p2494, whereas 6E10 is an l-As-restricted T cell hybridoma 
specific for p2694 peptide. Activation was not observed after pulsing of APC with the 
control peptide (p2694 for 4A2, 4Al2, and 5E8; p2494 for 6E10). The antigen presenting 
machinery ofboth TA3 and LS 102.9 cells remained intact following the 48-hour 
transfection period, since APCs transfected with the empty vector (pcDNA3.1zeo +)and 
pulsed with exogenous peptide could activate the T cell hybridomas. None of the T cell 
hybridomas were activated when incubated with TA3 or LS 102.9 cells transiently 
transfected with pcDNA3.1zeo +encoding p2494 and p2694 peptides, or when transfected 
with plasmid DNA encoding the carboxyl terminus of mTg encompassing both 
pathogenic peptides. These results suggested that either the synthesis of peptides in the 
cytosol was inefficient, or that the peptides could not be targeted to the MHC class II 
pathway. 
5.4 DISCUSSION 
DNA vaccination with a plasmid encoding dominant pathogenic peptides from 
various autoantigens including myelin and proteolipid proteins, and the P-chain of insulin 
have been shown to suppress and/or prevent the onset of spontaneous and experimentally 
induced autoimmune diseases97-101. No studies, however, have attempted to abrogate self-
tolerance and experimentally generate autoimmune diseases using DNA immunization. If 
this novel approach is able to induce disease analogous to the disease induced using 
conventional immunization regimes, it could have profound implications in the mapping 
of disease-causing T -cell epitopes of large self-proteins. We have taken the initial steps 
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toward developing DNA vectors encoding known EAT-inducing T-cell epitopes in the 
hope to induce thyroiditis in mice following DNA immunization. 
Despite complete identity between the published mTg sequence153 and eDNA 
insert sequences (Figure 5.1A, B, & C), as well as the good transfection efficiency of 
both APCs (Figure 5.2A & B), transiently transfected TA3 and LS 102.9 cells were 
unable to present MHC class Illpeptide complexes to activate peptide-specific T cell 
hybridomas (Figure 5.3A & B). It is well established that the immune system uses two 
different antigen-presenting pathways to process exogenous and endogenous proteins. 
Exogenous antigens are processed in the endocytic pathway and presented on the 
membrane with class II MHC molecules, while endogenous antigens are processed in the 
cytosolic pathway and presented on the membrane with class I MHC molecules167• It 
remains unclear, however, how antigen encoded by plasmid DNA is processed and 
presented through the MHC class II pathway following DNA immunization. Evidence 
suggests that soluble protein is released from transfected cells (i.e. APC or somatic cells) 
and is taken up by professional APCs, which process and present peptide similar to other 
exogenous proteins (reviewed by Cohen et al. 102). Our DNA vector lacked a leader or 
signal sequence that would allow secretion of the translated peptide from the transfected 
cell, and therefore the peptide probably remained in the cytosol. Recent studies indicate 
that some APC can introduce endogenous antigen directly into the MHC class II pathway 
without the protein first having to be relea~ed in soluble form 186-190• In most instances, 
this process applies only to proteins with natural access to the endoplasmic reticulum (i.e. 
cell membrane proteins). A study performed by Brooks et al. 187 demonstrated that class 
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II-positive B-lymphoma cells (Ml2.C3) transfected with plasmid DNA encoding hen egg 
lysozyme (HEL) peptide (a.a. 46-61) could form HEL(46-61)/I-Ak complexes and 
activate a peptide-specific T -cell hybridoma (3A9) provided the carboxyl-terminal 
sequence of the HEL minigene included KDEL residues or, alternatively, the complete 
HEL-coding sequence was joined in frame with H-2Kb eDNA. The KDEL sequence is a 
retention sequence that allows the retrieval of soluble proteins from salvage 
compartments into the endoplasmic reticulum oftransfected cells191 • The H-2Kb eDNA, 
on the other hand, encodes the transmembrane and cytoplasmic domains of the MHC 
class I molecule promoting chimeric membrane expression of the HEL peptide. 
Designing plasmid vectors encoding pathogenic mTg epitopes together with sequences 
that promote peptide translocation to the ER or membrane would be another approach 
that could be used to encourage peptide MHC class II processing and presentation that 
may lead to peptide-specific T -cell hybridoma activation. 
Secretion or translocation of peptide to the ER or cell membrane may have 
yielded positive results; however, we cannot exclude the possibility that the inability of 
both transiently transfected APCs to activate peptide-specific T cell hybridomas was 
caused by the lack of transcription and translation of the eDNA insert. Transcription may 
have been detected by RT-PCR using mRNA isolated from transfected cells and primers 
specific for the mTg minigenes. This technique used by Ruiz, et al.99, however, does not 
confirm peptide translation. Alternatively, both transcription and translation of the eDNA 
inserts may be confirmed either by immunoblotting celllysates from transfected cells 
using peptide-specific mAb or in vitro translation. The small size of the translated 
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peptides would still make detection difficult using either approach. Moreover, even if 
these methods were able to confirm peptide expression, they do not provide any 
information regarding peptide presentation, in particular MHC class II presentation. 
None of the studies that claimed to suppress or prevent experimental or 
spontaneous autoimmune disease induction when immunizing mice with DNA encoding 
immunodominant self-peptides confirmed peptide expression on APC before injecting 
mice with DNA97-101. Ruiz, et al.99, for example, immunized SJLIJ mice with plasmid 
DNA encoding the encephalitogenic residues of myelin proteolipid protein (PLP139-Jsl) 
and observed a delayed onset of disease, reduced mean peak disease severity, and 
reduced mean disease score compared to control mice following subsequent induction of 
EAE with PLP139_151 and CFA. In addition, proliferative responses and production ofThl 
cytokines (IL-2 and IFN-y) were reduced in LNCs taken from mice injected with DNA 
encoding for the PLPI39-15l peptide when restimulated in vitro. Similar suppression of 
EAE clinical signs and reduced IFN-y production were found by another group that 
immunized Lewis rats with DNA encoding a different encephalitogenic T cell epitope, 
guinea pig myelin basic protein peptide 68-85 (pZZ/MBP6s-ss)98. However, unlike Ruiz, 
et al.99, proliferative responses to MBP6s-ss ofT cells derived from the regional lymph 
nodes of pZZ/MBP 6s-s5-treated rats was not significantly different from that of controls. 
Another study was able to reduce the incidence of insulin-dependent diabetes mellitus 
(IDDM) in the well-established transgenic RIP-LCMV-NP 25-3 H-2d mouse line if the 
mice were immunized with plasmid expressing the porcine insulin B chain after, but not 
before disease induction97. Reduction in the incidence ofiDDM was also observed in 
I 15 
NOD mice following i.m. injection with plasmid encoding insulin B peptide (9-23), 
which appeared to be mediated by insulin B (9-23)-specific down-regulation of IFN-y 
production by T cells. Suggested explanations for the protection afforded by DNA 
vaccination include the generation of antigen-specific regulatory cells97;170 and induction 
of anergy in autoreactive T cells99. Exactly how these regulatory cells were induced or 
how autoreactive T cells were anergized remains unclear. The lack of evidence 
supporting peptide expression further complicates the interpretation of these results. Ruiz 
et a1.99 did detect low titers ofPLPt39-ISI peptide-specific antibodies in the sera of mice 
immunized with DNA encoding PLP139.15 , peptide suggesting that the peptide was 
expressed and specific serological immune responses against that peptide occurred. 
However a non-specific peptide control was not used, nor were sera from mice 
immunized with the empty vector tested. Thus it cannot be concluded that the humoral 
immune response observed in these mice was peptide-specific since it might have 
resulted from the immunization regime itself. 
Confirmation of peptide expression on APC in vitro prior to the initiation of in 
vivo immunization is a parameter that we feel should not be overlooked. Once expression 
of p2494 and p2694 is confirmed in our model, we will proceed to immunize EAT-
susceptible murine strains (SJL, C3H, and B 1 O.BR). It will be interesting to see whether 
EAT can be induced following DNA immunization encoding self-peptide or, like 
previous studies, ameliorates or prevents disease induction. 
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CHAPTER SIX 
FUTURE DIRECTIONS 
6.1 FUTURE EFFORTS TOWARD EST ABLISIDNG A MOUSE MODEL FOR 
GRAVES' HYPERTHYROIDISM 
Before a mouse model of GD is deemed successful, a number of criteria must first 
be met. For instance, the experimental protocol should, reproducibly, induce most of the 
clinical signs and symptoms of GD including i) elevated thyroid hormone and/or reduced 
TSH; ii) TSAb activity; iii) changes in thyroid architecture; and iv) lymphocytic 
thyroiditis in experimental mice. Using intradermal DNA immunization with 
pcDNA3.lzeo +/hTSHR, we were able to induce 2 of the 4 criteria (i.e. elevated TT4 and 
goiter) in a small proportion (37.5%) ofBALB/cJ mice (Chapter 3). Unfortunately, 
elevated TT4levels and enlarged thyroids in these hyperthyroid mice did not correlate 
with TSAb activity or lymphocytic thyroiditis. As discussed in Section 3.4, TSBAb may 
have masked TSAb activity in vitro. Before this assumption can be made, however, 
TSBAb activity must be confirmed. This could be accomplished by seeing whether the 
thyrotoxic mouse serum inhibits bTSH-induced cAMP response in JP09 cells. 
Alternatively, use of a different cell line (i.e. JP26) expressing comparable numbers of 
TSHR molecules to normal thyroid epithelial cells may have increased the sensitivity of 
this assay to detect TSAb by decreasing the nonspecific stimulation by normal sera. 
Although most protocols aimed at establishing an animal model of Graves' 
hyperthyroidism induced TSHR-specific autoantibodies, very few, including ours, were 
able to induce lymphocytic thyroiditis. Costagliola et al.83, however were able to induce 
severe lymphocytic infiltration in 14 BALB/c mice following i.m. immunization with 
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hTSHR eDNA. Notably, these thyroids were collected 6 and sometimes 8 weeks later 
than our thyroid collection time points (10 or 12 weeks postpriming). Thus, it is possible 
that lymphocytic thyroiditis may have developed in our hyperthyroid mice and/or mice 
positive for TSHR-specific Abs at a later time point. 
With the exception of Kaithamana et al. 80 who was able to induce 
hyperthyroidism in almost 1 00% of experimental mice, we and others have not been able 
to exceed 40% disease induction regardless ofTSHR-specific Ab production. As 
discussed in Section 3.4, this inability to induce 100% hyperthyroidism most likely 
reflects the delicate balance between different TSHR autoantibodies in vivo (i.e. TSAb, 
TSBAb, and neutral TSHR Ab ), an obstacle that will be difficult to overcome in future 
studies. Isolating TSAb from the heterogeneous TSHR Ab population or generating a B 
cell hybridoma that secretes monoclonal TSAbs would greatly enhance our understanding 
of the interaction between the TSHR and TSAbs. Currently, only mAbs specific for 
linear147 or conformational TSHR epitopes exist83, all of which lack stimulatory activity. 
Thus, future research should aim toward generating thyroid stimulating mAbs. 
6.2 ASSESSMENT OF hTSHR PEPTIDE PATHOGENICITY 
In Chapter 4, an algorithm-based approach was described that helped identify 2 
immunogenic hTSHR peptides (i.e. induced peptide-specific proliferative secondary LNC 
responses in vitro and specific serum IgG Abs following in vivo priming of AKR/J mice) 
that lacked pathogenicity (i.e. unable to induce thyroid lymphocytic infiltration). As 
discussed in Section 4.4, it is not uncommon for peptides to be immunogenic, but not 
pathogenic180. However, before this assumption can be made for our peptides, they need 
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to be simultaneously tested in other H-2k mouse strains (i.e. C3H, CBA, or BALBI K), or 
in mice of other MHC haplotypes. In addition, adoptive transfer experiments using 
peptide-specific LNC should be carried out before the pathogenic potential of these 
peptides is ruled out since this protocol usually leads to consistent EAT induction and 
more severe lymphocytic infiltration than direct challenge of mice with peptide and 
adjuvant. 
The lack of correlation between hTSHR peptide immunogenicity and 
pathogenicity may also be due to the heterologous nature of the peptides. Amino acid 
differences between hTSHR peptide sequences and corresponding mTSHR sequences 
may have abolished its pathogenic properties similar to that observed with human Tg 
peptides and highly homologous pathogenic rat peptides183. For this reason, murine 
TSHR peptides with A k -binding potential ( 4.4A & B) should also be synthesized and 
tested for immunogenic and pathogenic potential in various H-2k mouse strains. 
Finally, additional attempts to synthesize the hTSHR peptide corresponding to 
residues 79-94 should be made since 2 different algorithms157;177 identified the same 
region of the hTSHR as a potential Ak-binding peptide, and that scanning the mTSHR 
sequence identified the same sequence coordinates (Table 4.4A & B). 
6.3 REENGINEERING PLASMID MINIGENES MAY PROMOTE MHC 
CLASS II PROCESSING AND PRESENTATION 
In Chapter 5 the initial progress toward identifying pathogenic mTg T cell 
epitopes using genetic immunization was described. DNA vectors encoding mTg 
fragments known to harbour one or several pathogenic T -cell epitopes were designed and 
used to transiently transfect APCs that were subsequently tested for their capacity to 
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present MHC class 11/peptide complexes and activate peptide-specific T cell hybridomas. 
The lack of transcription and translation of the eDNA insert, or the inability of APCs to 
process and present endogenously produced Ag through the endocytic (MHC class II) 
pathway may have contributed to the lack ofT cell activation. As discussed in Section 
5.4, reengineering the eDNA insert that will allow the mig peptide to be secreted (i.e. 
introduction of an IgG signal sequence) may promote classical MHC class II processing 
and presentation of exogenous Ag that will ultimately lead to T cell activation. 
Alternatively, redesigning plasmid vectors to include sequences that promote peptide 
translocation to the endoplasmic reticulum (ER) or cell membrane may also result in 
expression ofmTg peptide/MHC class II complexes. This idea stems from the numerous 
studies192"197 that demonstrated nonclassical MHC class II presentation ofpeptides 
derived from endogenous proteins that have natural access to the ER (i.e. cell membrane 
proteins). A study performed by Brooks et al. 187, for example demonstrated that the 
addition ofKDEL residues to the carboxyl-terminus of a minigene encoding the hen egg 
lysozyme peptide (a.a. 46-61) leads to retention of this peptide in the ER ofB-lymphoma 
cells (Ml2.C3) transfected with this vector. The same study designed a plasmid construct 
that linked the complete HEL coding sequence to a portion of the H-2Kb eDNA, which, 
following transfection ofM12.C3 cells, resulted in chimeric membrane expression of the 
HEL peptide. In both cases, Ml2.C3 cells were able to activate 1-Ak-restricted, HEL(46-
61 )-specific T cell hybridomas. It is hoped through reengineering our plasmid vectors 
using one or all of these strategies, we can confirm peptide expression and proceed to 
immunize EAT susceptible mouse strains. 
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